European Association of Hospital Pharmacists | making the difference in medication use

Vertical Tabs

General Information

Abstract submission is open. Click here! *

The poster exhibition and the oral poster communication session are the mainstay of the annual European Association of Hospital Pharmacists (EAHP) Congress and only the best are selected!

The EAHP Scientific Committee (SC) encourages all hospital pharmacists, other health care professionals and scientists to submit their work for consideration leading to possible acceptance and display at the annual EAHP congress. The SC strives to receive submissions of hospital pharmacy related initiatives from applicants in Europe and all over the world. All potential contributors are requested to carefully read and comply with the guidelines presented in this document. Abstracts/posters which have already been published at the international level may only be submitted if new data is included, the work is presented from the hospital pharmacy perspective or in a new context giving new inspirations for colleagues. Data, which have been published in international, peer-reviewed journals, should not be submitted.

IMPORTANT: When submitting your abstract, please be sure that your hospital server will accept emails from abstract[at]eahp[dot]eu . Otherwise, you will not receive the emails from our system. Alternatively, you may use a personal email address such as gmail, hotmail, etc.

DEADLINE	ACTION
Tuesday, 15 October 2020	Deadline for abstract submissions. Abstracts submitted after the deadline will not be accepted
Wednesday, 10 November 2020	Authors will be advised of their abstract status after the first review
Thursday, 19 November 2020	Modifications due from abstract authors who were requested to make changes
Tuesday, 03 December 2020	Authors will be advised of their abstract status after review of modifications

The SC accepts two types of abstracts: scientific abstracts and "Good Practice Initiatives" (GPIs). GPIs comprise hospital pharmacy practice or education initiatives, which may inspire colleagues internationally, but do not necessarily comply with the traditional abstract demands. For further information regarding definition of a GPI, please go here. For authors interested in submitting a GPI, please go here.

If you want to submit a scientific abstract, please go here. (abstract submission opens 1st August, 2020)

If you have any questions concerning the abstract submission process, please send an email to abstract[at]eahp[dot]eu

*If your abstract was accepted for the 2020 EAHP Congress in Gothenburg, you do not need to resubmit it again. Your abstract will be automatically transferred as an "accepted" abstract for the 25th Anniversary EAHP Congress in Vienna. Resubmitting your abstract will result in automatic withdrawal of your abstract and poster. If you want to submit a new abstract, please use the link above.

Abstract Submissions and guidelines

Important announcement

If your abstract was accepted for the 2020 EAHP Congress in Gothenburg, you do not need to resubmit it again. Your abstract will be automatically transferred as an "accepted" abstract for the 2021 EAHP Congress in Vienna. Resubmitting your abstract will result in automatic withdrawal of your abstract and poster.

To check if your abstract meets the eligibility criteria for being a GPI or an abstract, answer all the following questions:

Table 1: The eligibility criteria for being a GPI or an abstract.

QUESTION	DEFINITION
1. Is your abstract relevant for hospital pharmacists?	Yes: Your abstract may be a scientific abstract or a GPI
1. Is your abstract relevant for hospital pharmacists?	No: Please do not submit your work to EAHP
2. Does your abstract describe a protocol or plan for a project not yet conducted?	Yes: Please do not submit your work to EAHP
	No: Your abstract may be a scientific abstract or a GPI
3. Is your abstract about the development and implementation of a pharmacy practice or a program in pharmacy education?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
4. Can other colleagues use your experience as the basis to introduce the same type of improvement in their settings by e.g. observing what you did in your setting?	Yes: Your abstract may be a GPI
	No: Your abstract may be a scientific abstract
5. Does your abstract describe a project conducted as a scientific study using e.g. robust methodology?	Yes: Your abstract may be a scientific abstract
	No: Your abstract may be a GPI

For authors interested in submitting a GPI, please go here.

If you want to submit a scientific abstract, please check the instructions below and submit your abstract here.

ABSTRACT SUBMISSIONS AND GUIDELINES

The EAHP Scientific Committee (SC) is looking for contributions with:

A high grade of relevance and/or innovation to the European community of Hospital Pharmacists,
A high impact on the future of hospital pharmacy practice, or
A high relevance regarding practice changes due to the investigated intervention.

SCOPE OF ABSTRACTS AND TOPIC GROUPS

We encourage the submission of abstracts from all disciplines of hospital pharmacy or related areas. The major categories and examples of topics are illustrated in the table below. The topics are not meant to represent a complete and exclusive list, but examples only that guide authors to select the most appropriate topic groups during the submission process.

Table 2: Categories for abstract submission with examples.

CATEGORY	EXAMPLES OF TOPICS
Section 1: Introductory Statements and Governance	Management theories, human resources, training requirements, financing, resource optimization, staffing, organisation, working environment, medicines management policies, drug & therapeutics committees, communication technology (telepharmacy, eHealth), national standards of hospital pharmacy services, pharmacoeconomics, health technology assessment
Section 2: Selection, Procurement and Distribution	Procurement processes, logistics, storage conditions, ordering systems, drug distribution technology (e.g., bar code scanning, electronic cabinets, dose dispensing), home delivery, supply chain management, medicines shortages, policy for medicines brought into the hospital by patients, preparation conditions, dispensing conditions, distribution conditions, disposal of medicines, medicines formulary systems, drug use evaluations
Section 3: Production and Compounding	Production technology, use of suitable commercially available pharmaceutical equivalents, risk assessment prior to production, formulation, quality control, best practice quality requirements, procedures for reconstitution or mixing of medicines, stability studies
Section 4: Clinical Pharmacy Services	Multidisciplinary therapeutic decision-making, quality improvement interventions, adherence, seamless care between and within healthcare settings, monitoring medication changes, service evaluation, service implementation, outcome evaluation, medicines reconciliation, medication history, prescription review, medication management review, medication appropriateness, drug-related problems, patient education, career education, health care professional education, patient knowledge, therapeutic drug monitoring, interactions, clinical pharmacokinetics, drug information and pharmacotherapy, nutrition support
Section 5: Patient Safety and Quality Assurance	Medication errors, adverse drug events, pharmacovigilance, medication error reporting, root cause analysis, high-risk medicines, patient safety programmes, risk minimization procedures, computerised decision support, safe transcription steps, accurate recording of allergy etc., quality and safety procedures, safe medicines use (preparation and administration), labelling, quality assurance, traceability, drug efficacy/safety evaluations
Section 6: Education and Research	Development of curricula, participation in European-wide competency frameworks (e.g., for initial post graduate education and training in hospital pharmacy), research methods, publication skills, pharmacy practice research, pharmacoepidemiology, protocols

IMPORTANT ITEMS TO CONSIDER BEFORE WRITING YOUR ABSTRACT

We kindly invite all applicants to carefully consider the following before submitting your abstract:

The prerequisite for a good abstract is a well-conducted study with clear study aims and methodology.
The purpose of the study should be understandable and should allow the reader to follow what has been done at a glance.
The interventions and relevant outcomes should be clearly defined.
The authors are strongly requested, prior to submission, to see what is published in their relevant field and reflect on the added value of their work (e.g. if they present data of national or even local peculiarities).
Before writing the abstract, clarify for yourself what is the new evidence you want to present and consider why colleagues should be interested in your study.

ABSTRACT STRUCTURE

Abstracts must be structured and written in five paragraphs: (1) Background and importance, (2) Aim and objectives, (3) Materials and methods, (4) Results, (5) Conclusion and relevance.

This structure of an EAHP congress abstract has to be strictly adhered to. The online abstract submission will guide you through this process. Abstracts are limited to no more than 350 words (or less if you use graphs or tables) and must be typed in English. The online submission system does not allow you to enter abstracts above this limit.

A blinded approach is used during the abstract review process, so it is recommended that the institution name and/or country name are NOT indicated in the abstract title and text. Contact data will not be displayed during the review process. This process is meant to ensure that the reviews are conducted in the most ethical and professional way possible.

Title: The title of the abstract must be strictly coherent with the data included in the abstract. Do not use abbreviations. If you are submitting a case report, the area of focus and "case report" should appear in the title.
Contact data: The name of every author, preceded by initials, and the name of the presenting author underlined and entered as instructed via the online submission process. Omit degrees, titles or institutional appointments. Then, insert the institution, city, country where the study took place or the case occurred, as well as the email address of the presenting author.
(1) Background and importance: The background sets the frame of your study. To set the scene you must answer the following questions: What is already known about this topic? what are the unmet needs which brought you to conduct this study? To answer those questions, you have to do a literature search to identify whether other observations in this field are already published. You should present the problem you want to focus on and highlight why the answer to the problem is important. For case reports briefly summarize why this case is unique with medical literature references.
(2) Aim and objectives: State the aim of the study. This very clear and concise text should state: What did you investigate and among whom? If you present a case report give patient information regarding the main concerns and symptoms of the patient in this section. Add medical, family, and psychosocial history including genetic information if applicable and needed. Relevant past interventions and their outcomes should also be reported here.
(3) Materials and methods: Describe the method, facilities (e.g. equipment/statistics, models), design, setting and participants and interventions being used. Please describe the intervention and which outcome measures were used, when applicable. If you do a literature review or a meta-analysis you have to give information regarding the data sources and the study selection criteria. For case reports relevant physical examination (PE) and other clinical findings should be reported in this section. Also the timeline of the case with relevant data from this episode of care organized as a timeline could be important. In some cases diagnostics and prognostic characteristics should be given when applicable. Please present therapeutic Interventions in this section.
(4) Results: Present the necessary data in a way that it is easy to understand. There is no discussion of the results in this part. For case reports clinician- and patient-assessed outcomes when appropriate should be given here. Please refer also to important follow-up diagnostic and other test results. Intervention adherence and tolerability (how was this assessed?) besides adverse and unanticipated events should be reported.
(5) Conclusion and relevance: Discuss your results and compare to literature data if available. Are other observations in this field already published and relevant to be mentioned? Based on your results, what are the answers to the problem you focused on? What are the new findings? What are the implications for practice and research? For case reports, please present strengths and limitations in your approach to this case. Please discuss the relevant medical literature and the rationale for your conclusions. You must present the primary "take-away" lessons from this case report.
References and/or acknowledgements: These may be given at the end of the abstract.

Please click here to download the abstract structure template which can give you an idea of an abstract structure before the online submission. Please note that only submitted online abstracts will be reviewed.

We advise authors to use scientifically common principles in abstract writing.

Abbreviations may be used only if they are defined (spelled out in full text at first mention, followed by abbreviation in parentheses). Only general standard abbreviations for e.g. millilitres, seconds, and moles may be used without explanation.
Don't use excessive decimals e.g. a person might weigh 70,237 kg at a given moment, but only 70 kg should be mentioned.
References should be limited to a minimum, unless they are important for understanding methods, background or conclusions drawn. References should be added in a special field during the abstract submission, which is optional for use and not mandatory. Comprehensive bibliography can be displayed on the poster.
The authors are encouraged to submit well-edited abstracts and avoid submission of negligent work.

THE SUBMISSION PROCESS

Please consider the selection of the appropriate topic group before submission and compare with the examples prior to submission (Table 2). The topics are directly related to the EAHP statements.
For every abstract there must be 3-5 keywords selected by the authors. These are used for indexing purposes and have to be strictly in line with the content of the abstract.
You can only add 1 presenting author and up to 10 co-authors.

THE REVIEW PROCESS

Each abstract is read, assessed and scored independently by two members of the SC and considered from two perspectives: the scientific content and the practical value of the submission.
In case of divergence between the two reviewers, the full SC discusses the submission in plenum and comes to a view whether to accept the abstract or not.
You will be notified in a timely manner as to the outcomes of the review process. You may be asked to revise your abstract and re-submit it.
All accepted abstracts will be allocated a spot for display at the congress.
The SC selects outstanding abstracts for poster walks and poster prize competition. Only those abstracts that are considered to have a high grade of relevance, innovation and added value in a well-written form are eligible for winning the poster prize.

SPECIFICS REGARDING STUDY TYPES AND METHODOLOGY

Particular attention is given to those abstracts that report scientifically valid results with appropriate study methodology giving the type of study design, interventions and outcomes. Outcomes could comprise either direct patient benefit, economical or clinical outcomes, or a combination of these.
Quantitative studies should include at least 30 patients.
Case Reports of a single or of a few patients will be accepted only if they include original and new data, that is not as yet published in literature. Please find below more information.
Case reports of ADRs will only be accepted if they present some kind of causality or probability assessment (e.g. Naranjo algorithm)
Everyday clinical practice studies are of interest if effectiveness is reported in an adequately chosen size of study population, which is in line with the prevalence of the disease studied.
New drug interactions not already described in the literature are encouraged to be reported but should come with a possible mechanism or explanation.If interventions of improvements processes are reported, please always report baseline values or data regarding the situation prior to the intervention as well. Otherwise comparison is not scientifically valid and therefore of limited value and validity.
Abstracts reporting purely lab sciences or associated sciences to pharmacy (e.g. microbiology, biology, chemistry etc.) are only accepted if the implications of these basic study findings to hospital pharmacy practice are made clear by the authors.
Drug Usage Evaluation (DUE) will only be considered if data of at least 30 patients are reported.
Authors planning to perform and report the results of a DUE are referred to relevant guidelines (e.g. those from American Society of Health-system Pharmacists).

EAHP welcomes well-described reports of cases that include the following:
• Unreported or unusual side effects or adverse interactions involving medications.
• Unexpected or unusual presentations of a disease.
• New associations or variations in disease processes.
• Presentations, diagnoses and/or management of new and emerging diseases.
• An unexpected association between diseases or symptoms.
• An unexpected event in the course of observing or treating a patient.
• Findings that shed new light on the possible pathogenesis of a disease or an adverse effect.

Abstracts of case reports submited to the SC of EAHP with the aim to present a poster at the EAHP Congress should make a contribution to medical knowledge and must have educational value or highlight the need for a change in clinical practice or diagnostic/prognostic approaches. EAHP will not consider case reports describing preventive or therapeutic interventions, as these generally require stronger evidence.

Case reports should be writen in the same way like the other abstracts, meaning you have to use the same template.

REASONS FOR REJECTION

This practice is well established in many countries.
This abstract is not relevant to Hospital Pharmacy.
The committee did not understand the abstract either due to English use or other reasons.
Quantitative studies should usually include at least 30 participants.
The abstract does not follow the given structure.
The conclusion does not cover the aim of the study.
Insufficient data was included to support your conclusions.
An inappropriate or weak study methodology was used.
The abstract is not presenting a study with a defined aim, a described method to obtain results, presentation of the obtained results and/or a conclusion based on these findings.
The abstract may be better suited as a GPI. Please resubmit using the appropriate format.
This topic has already been studied and published several times.

If a same author or a same group of authors has submitted the same abstract several times by mistake, they should send an email to the EAHP office to inform them and delete the duplicated abstracts. Otherwise, the judges will reject all abstracts.
If a same abstract has been submitted by its author(s) both as a Good Practice Initiative and as an abstract, the judges will reject both abstracts.
Other

RECCOMENDATIONS

Prior to conducting your study, reflect on the appropriate methodology and the number of patients (e.g. power analysis) that is necessary for this study design. Your study must include at least 30 patients to be accepted.
Ask other colleagues who are not involved in the study if the abstract is understandable and your proposed message is conveyed.
Consider the coherence of the abstract. If not coherent, please strongly consider rewriting your abstract.
The conclusion should be limited to statements that directly arise from the results presented. General statements without reflection of results or not in line with the aim of the study have to be avoided, as this is a common reason for abstract rejection.
The word count has to be adhered to. Be aware, that this is an abstract. The purpose of an abstract is to report clear, concise and relevant scientific results. Additional data, which are not ultimately needed for understanding, can be shown in the final poster.
Please avoid formatting of abstracts, don't use bold type, and ensure that at the final checking stage that any special characters or symbols used are displayed correctly.
Abstracts reporting vague or unclear interventions and/or irrelevant outcomes will be rejected.

DISCLAIMER

While every effort is made by publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned.

Accordingly, the publishers and the European Association of Hospital Pharmacists (EAHP), the editorial committee and their respective employees, officers and agents, accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure that drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage, described within this Journal, should only be followed in conjunction with the drug manufacturer's own published literature.

The author is responsible for obtaining the permission and licenses used to complete his/her study. Please note that EAHP cannot be held responsible in case an author disrespects his/her obligation to obtain the permission and licenses.

Please click here to read the author licence from BMJ.

IMPORTANT: The abstracts that were rejected last year CANNOT BE RESUBMITTED again unless major modifications have been made. Should the authors not follow this rule, they will be banned from the submission process for the following EAHP congresses.

Good luck to all!

The EAHP Scientific Committee

Poster guidelines

POSTER GUIDELINES

SIZE

841 mm wide x 1189 mm high (A0) - portrait format (posters may not be smaller or larger than this size).

1. ASSISTANCE PROVIDED AT CONGRESS CENTRE

1.1. A poster panel on which to hang posters
1.2. A number for each poster board: this number indicates your assigned display station and also corresponds to the abstract number
1.3. Mounting materials, including double sided adhesive tape. Note that the use of drawing pins will NOT be allowed
1.4. Staff to advise during poster mounting

2. THE FOLLOWING COMPONENTS SHOULD BE INCLUDED AND USED AS HEADING WHERE APPROPRIATE

2.1. Title
2.2. Contact data
2.3. Background and Importance
2.4. Aim and Objectives
2.5. Materials and Methods
2.6. Results
2.7. Conclusion and Relevance
2.8. References and/or Acknowledgements

3. IT IS OFTEN USEFUL TO HAVE A SUMMARISED VERSION OF THE POSTER TO HAND TO INTERESTED READERS

You should also provide a notepad so that interested readers can leave their contact addresses, and a drop-box in which they can leave business cards or envelopes.

4. DESIGNING THE POSTER

4.1. Remember that viewers should be able to grasp the meaning of the poster without listening to an explanation or reading a report. To assist in this:
4.1.1. Communicate the message simply
4.1.2. Do not clutter the poster with too much detail
4.1.3. Only use materials that can be mounted on the poster board (plus handouts)
4.1.4. Use title lettering at least 2.5 cm high with text lettering at least 8 mm high and 0.7 mm thick. Test readability from 1 m or more away.
4.1.5. Use pie charts, histograms, graphs, tables, clip art, drawings, symbols and photos to illustrate key points. Use colour effectively in these and make them simple, rather than complex.
4.1.6. Design the poster to be read from left to right and top to bottom
4.1.7. Where possible, use one-line statements or bullet phrases to highlight key points, rather than full sentences (this list is set off by bullet points)
4.1.8. Use bold face type for headings and sub-headings
4.1.9. Proof-read the poster carefully. Ask a person independent of the project to review the text for clarity, organisation and brevity
4.1.10. Bring white correction tape or fluid and black felt tip pen to the meeting to correct errors or scratches

5. POSTER CERTIFICATES

Poster certificates for the presented posters will be sent to the authors by email within 15 days after the Congress. The duplicates can be provided by the author's request within 60 days after the last Congress. Please note that in case of loss of your poster certificates, the certificate duplicates of the last EAHP congress as well as any other previous EAHP congresses certificates will not be provided after the deadline of 60 days.

6. POSTER PDFs FOR WEB SITE

Authors should send a pdf of their poster to abstract[at]eahp[dot]eu for inclusion on the EAHP web site following the congress. Deadline for receipt of your poster pdf is 15 March 2021.

7. DISCIPLINARY ACTION

If an author is unable to present his poster during the congress, he absolutely needs to notify the EAHP by sending an email to abstract[at]eahp[dot]eu. If same situation happens 3 years in a row, the EAHP reserves the right to reject any other abstracts submitted by the same author for future congresses. In addition, should the author not insure that their poster is hunger during the congress either by the author or a colleague, the abstract will be removed from the online version of the abstract book.

Poster prize winners

ENCOURAGEMENT PRIZE FOR INVESTIGATORS

The best abstracts/posters (up to 12 award nominees) – with regards to aspects like originality, scientific quality and practical applicability – will be awarded with 3 prizes amounting EURO 750, EURO 500 and EURO 250.

Please be aware that the judges reserve the right not to award prizes if there are no clear winners.

Poster nominees will be requested to give an oral presentation on Wednesday, 24 March 2021. Oral presentations are to consist of 5 minutes for presentation and 2 minutes for questions and answers. Poster prize nominees should disclose whether their work or comparable/similar work was submitted at an earlier International conference or somewhere else. More details will be sent at a later date when the poster prize nominees are selected. Judging will take place on Thursday, 26 March and the winners will be announced at the closing ceremony on 26 March 2021. You must be present to win!

Check the posters of last year's winners in Barcelona here!

IMPORTANT NOTE: the presence of at least one poster's author is mandatory under disciplinary sanction.

The Scientific Committee will also choose up to 18 abstracts for the Poster walk. The authors of these abstracts will not have to give a 1-minute oral presentation during the Poster Walk on Wednesday, 24 March 2021. The posters will be hung in the "Award nominees and Poster walk" section and marked with special rosettes.

Online abstract poster walks

Please find below the online abstract Poster Walks of the last EAHP Congresses.

Please select the desired annual Congress to view the posters presented in the different topic categories.

25th Anniversary EAHP Congress - Hospital Pharmacy 5.0 - the future of patient care

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	IMPACT OF AN ORAL NUTRITION PROTOCOL IN PATIENTS TREATED WITH ELECTIVE RADICAL CYSTECTOMY: A LONG TERM FOLLOW-UP
	NP-002	MEDICATION SAFETY IN PATIENTS TREATED WITH ORAL ANTITUMOR AGENTS: A PROSPECTIVE, RANDOMIZED INVESTIGATION TO IMPROVE PATIENT SAFETY AND WELL-BEING BY INTENSIFIED CLINICAL PHARMACEUTICAL/ PHARMACOLOGICAL CARE
	NP-003	STEADY-STATE PHARMACOKINETICS AND EARLY SAFETY DATA IN HIV-INFECTED AFRICAN CHILDREN WEIGHING ≥25KG AFTER SWITCHING TO 50MG FILM-COATED DOLUTEGRAVIR TABLETS IN THE ODYSSEY TRIAL
	NP-004	INITIATION OF A CLINICAL PHARMACIST LED, PROSPECTIVE AUDIT ON ANTIBIOTIC PRESCRIBING
	NP-005	IMPLEMENTING MEDICATION RECONCILIATION ON HOSPITAL ADMISSION: A MULTICENTER PILOT STUDY IN ESTONIA AND FINLAND
	NP-006	A PAIR OF PHARMACY TECHNICIAN / NURSE TO TRAIN ON THE ANTI-RETURN VALVES
	NP-007	A MIXED METHODS EVALUATION OF THE CROSS-SECTOR PHARMACIST VOCATIONAL TRAINING FOUNDATION PROGRAMME: IS THE TRAINING PROGRAMME FIT FOR PURPOSE?
	NP-008	MONITORING OF PRESCRIPTIONS ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN BEATRIZ ÂNGELO HOSPITAL
	NP-009	THE IMPACT OF TNFa INHIBITORS ON GLUCOCORTICOIDS USE AMONG PATIENTS WITH ARTHRITIDES
	NP-010	CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE
	NP-011	MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE
	NP-012	COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE’ DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST’POINT OF VIEW
	NP-013	THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY
	NP-014	MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	CAN RIVAROXABAN BECOME COST SAVING COMPARED WITH VITAMIN K ANTAGONISTS IN THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE?
	1ISG-002	BIOLOGICAL DRUGS FOR THE TREATMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS: A COST ANALYSIS AND AN APPLICATION OF A CORRELATION ANALYSIS TO INVESTIGATE COST EFFECTIVENESS
	1ISG-003	STUDY OF THE USE OF INTRAVENOUS IMMUNOGLOBULINS DURING THE FOURTH QUARTER OF 2018 AND ANALYSIS OF ITS OFF-LABEL USE
	1ISG-004	ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE OF TREATMENT MULTIPLE MYELOMA
	1ISG-005	ABC-VEN CROSSTAB ANALYSIS: A DECISION MAKING SYSTEM APPLIED FOR ANTICANCER MEDICINES
	1ISG-006	EFFECTIVENESS EVALUATION OF HIGHCOST DRUGS FOR ADVANCED NON-SMALL-CELL LUNG CANCER: REAL WORLD EVIDENCE, COMPLIANCE WITH CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION
	1ISG-007	NEW CANCER DRUGS APPROVALS IN PORTUGAL
	1ISG-008	COST EFFICACY ANALYSIS OF ABIRATERONE IN NEWLY DIAGNOSED HIGH RISK METASTATIC CASTRATION SENSITIVE PROSTATE CANCER
	1ISG-009	BUDGET IMPACT ANALYSIS OF A NATALIZUMAB EXTENDED INTERVAL DOSING REGIMEN
	1ISG-010	INTRODUCTION OF RITUXIMAB BIOSIMILAR: AN OPPORTUNITY TO IMPROVE HEALTH SYSTEM EFFICIENCY?
	1ISG-011	ASSESSMENT OF ASTHMA DIAGNOSED POPULATION ELIGIBLE FOR NEW MONOCLONAL ANTIBODY THERAPY AND RELATED COST IN THE VENETO REGION
	1ISG-012	NATIONAL REPORTING SYSTEM FOR DRUG SHORTAGES : CLASSIFICATION AND TRENDS IN REPORTED CAUSES FROM 2015 TO 2018
	1ISG-013	SMARTPHONE APPLICATIONS FOR PATIENTS DIAGNOSED WITH GENITOURINARY TUMOURS: ANALYSIS OF THE QUALITY USING THE MOBILE APPLICATION RATING SCALE
	1ISG-014	COST EFFECTIVENESS ANALYSIS OF PATIENTS' SELF-ADMINISTRATION OF MEDICATION (SAM) DURING HOSPITALISATION IN A CARDIOLOGY UNIT
	1ISG-015	EVALUATION OF BISPECTRAL INDEX MONITORING IN GENERAL ANAESTHESIA THROUGH A HEALTH TECHNOLOGY ASSESSMENT METHOD: A POSSIBLE INTRODUCTION IN CLINICAL PRACTICE IN AN ITALIAN HOSPITAL?
	1ISG-016	ENVISIONING SUSTAINABILITY IN PERSONALISED MEDICINE: FONDO AIFA 5% AND THE ITALIAN EXAMPLE
	1ISG-017	IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE
	1ISG-018	APPLICATION OF A TIME SLOT MODEL IN ONCOLOGY: DELIVERY PLANNING AND PROCESS OPTIMISATION
	1ISG-019	HOSPITAL PHARMACISTS AGED <45 YEARS: AN EMPLOYMENT STATUS AND JOB SATISFACTION SURVEY IN ITALY

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	IMPLEMENTATION OF HOME DELIVERY AND TELEPHARMACY SYSTEMS IN A THIRD LEVEL HOSPITAL
	2SPD-002	IMPROVEMENT IN AN ANTIMICROBIAL STEWARDSHIP PROGRAMME AFTER IMPLEMENTING A SCREENING ALERT SYSTEM
	2SPD-003	ECONOMIC IMPACT OF THE INTRODUCTION OF LAMIVUDINE PLUS DOLUTEGRAVIR BITHERAPY IN HIV NAIVE PATIENTS
	2SPD-004	EFFICIENCY OF PRECISION DOSING WITH INTRAVENOUS IMMUNOGLOBULINS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES
	2SPD-005	ECONOMIC ANALYSIS OF OSIMERTINIB IN PREVIOUSLY UNTREATED EGFR MUTANT ADVANCED NON-SMALL CELL LUNG CANCER
	2SPD-006	ASSESSMENT OF REGORAFENIB, RAMUCIRUMAB AND CABOZANTINIB AS SECONDLINE THERAPY IN HEPATOCARCINOMA AND ALFA-FETOPROTEIN VALUE ≥400 NG/ML
	2SPD-007	OUT OF SUPPLY OF CHEMOTHERAPY INJECTABLE MEDICINES OVER 9 MONTHS: PATIENT IMPACT
	2SPD-008	IMPACT OF FRENCH EXPERIMENT FOR INCENTIVISING ETANERCEPT BIOSIMILAR USE AFTER 10 MONTHS
	2SPD-009	COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB
	2SPD-010	ECONOMIC IMPACT OF SWITCHING THE ADMINISTRATION ROUTE OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS
	2SPD-011	TRANS-INTERFACE GAIN SHARE PROGRAMME FOR BIOSSIMILAR INFLIXIMAB
	2SPD-012	COST MINIMISATION STUDY IN SEVERE ASTHMA TREATMENT
	2SPD-013	APPLICATION OF THE ABC ANALYSIS METHOD FOR OPTIMIZING THE STOCK MANAGEMENT OF MEDICAL DEVICES IN COMMON USE
	2SPD-014	EVALUATING THE METHODOLOGICAL QUALITY OF PIVOTAL CLINICAL TRIALS´S PUBLICATIONS FOR ORPHAN DRUGS AUTHORISED IN 2018. ARE THEY RELIABLE?
	2SPD-015	COST OF STOCKOUT. A GROWING PROBLEM
	2SPD-016	FUTURE DISTRIBUTION MODELTS FOR PAID PHARMACEUTICALS: THE PATIENT'S PERSPECTIVE
	2SPD-017	IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE AT THE LISBON PORTUGUESE INSTITUTE OF ONCOLOGY (FG, EPE)
	2SPD-018	FOUR YEAR STUDY OF DRUGS SHORTAGES IN TWO PUBLIC HOSPITALS
	2SPD-019	FOUR YEARS OF SHORTAGES REGARDING THE ANATOMIC, THERAPEUTIC AND CHEMICAL CLASSIFICATION
	2SPD-020	IMPACT OF MEDICINE SHORTAGES ON AN OUTPATIENT CLINIC OF A GENERAL HOSPITAL
	2SPD-021	SURVEY OF DRUG SHORTAGES IN HUNGARIAN HOSPITALS
	2SPD-022	DRUG SHORTAGES AND DRUG UNAVAILABILITY: ANALYSIS FROM AN ITALIAN HOSPITAL
	2SPD-023	HOW MUCH DOES FALSIFIED MEDICINES DIRECTIVE ACTUALLY COSTS? DETAILED COST EVALUATION OF SERIALISATION IN A REPRESENTATIVE SAMPLE OF HUNGARIAN HOSPITAL PHARMACIES
	2SPD-024	SHORTAGES OF MEDICINES IN HOSPITAL: RESULTS OF A SURVEY ON THE PERCEPTION OF HEALTH WORKERS IN THE WARDS VSV REAL WORLD
	2SPD-025	APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE THE RISK LEVEL OF MEDICINE SHORTAGES
	2SPD-026	MANAGEMENT OF DRUG SHORTAGES
	2SPD-027	ECONOMIC IMPACT OF DRUG SHORTAGES
	2SPD-028	REFERENCING A MIDLINE: HOW TO MAKE A CHOICE?

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	COMPATIBILITY AND STABILITY ASSESSMENT OF A SODIUM GLYCEROPHOSPHATE FORMULATION MIXED IN BAGS FOR NEONATAL TOTAL PARENTERAL NUTRITION
	3PC-002	MICROBIOLOGICAL STABILITY TEST OF 15% TOPICAL RESORCINOL FOR QUALITY CONTROL
	3PC-003	TERLIPRESSIN PH STABILITY FOR CONTINUOUS INFUSION
	3PC-004	PHYSICOCHEMICAL STABILITY OF CEFEPIME IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES.
	3PC-005	PHYSICOCHEMICAL STABILITY OF CEFAZOLIN IN POLYPROPYLENE SYRINGES AND IN ELASTOMERIC DEVICES.
	3PC-006	PHYSICOCHEMICAL STABILITY OF AZTREONAM IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATION FOR INTENSIVE CARE UNITS.
	3PC-007	LEVOFLOXACIN 0.05 % EYEDROPS ELABORATION: A CASE OF STUDY
	3PC-008	INTRAVENOUS PERFUSION OF CEFTOLOZANE-TAZOBACTAM USING ELASTOMERIC INFUSION PUMPS
	3PC-009	TREATMENT OF RECURRENT OTOMYCOSIS WITH LOCAL APPLICATION OF A COMPOUNDED FORMULATION OF VORICONAZOLE EAR DROPS: CASE SERIES
	3PC-010	EVALUATION OF THE PRODUCTION ACCURACY AND ERROR RATE IN THE AUTOMATED COMPOUNDING OF CYTOTOXIC PREPARATIONS BY A ROBOT
	3PC-011	CLOSED SYSTEM TRANSFER DEVICE BASED ON AIR FILTRATION: THE DRUG VAPOUR CHALLENGE
	3PC-012	MANAGEMENT OF NON-ADMINISTERED CHEMOTHERAPY PREPARATION: AN OPPORTUNITY TO MINIMISE DRUG WASTE IN ONCOLOGY PHARMACY
	3PC-013	COMPARATIVE BIOPHYSICAL STABILITY STUDY OF ZIV-AFLIBERCEPT (ZALTRAP, OPENED VIALS) STORED AT 4ºC AND ROOM TEMPERATURE FOR 2 WEEKS
	3PC-014	USE OF CABAZITAXEL AND REDUCTION OF WASTE: THE POTENTIAL OF DRUG-DAY.
	3PC-015	SHORT TERM STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY DARATUMUMAB
	3PC-016	STABILITY OF COMPOUNDED NIVOLUMAB SOLUTION AFTER PNEUMATIC SYSTEM TRANSPORTATION
	3PC-017	INCREASING PHARMACY PRODUCTIVITY BY EXPANDING THE ROLE OF THE INTRAVENOUS COMPOUNDING ROBOT IN A COMPREHENSIVE CANCER CENTRE
	3PC-018	MITOMYCIN C STABILITY ACCORDING TO PH AND TEMPERATURE CONDITIONS
	3PC-019	IN USE PHYSICOCHEMICAL AND MICROBIOLOGICAL STABILITY OF DILUTED SOLUTIONS OF THE MONOCLONAL ANTIBODY NIVOLUMAB
	3PC-020	PHYSICOCHEMICAL STABILITY OF 25 MG/ML PEMETREXED DIARGININE IN PARTIALLY-USED VIALS AND 3 AND 12 MG/ML DILUTED IN DEXTROSE 5% IN POLYOLEFIN BAG.
	3PC-021	STORAGE OF NIVOLUMAB, PEMBROLIZUMAB AND DARATUMUMAB FOR 14 DAYS AFTER COMPOUNDING IN THE HOSPITAL PHARMACY: A MICROBIOLOGICAL STABILITY STUDY
	3PC-022	PARTICULATE QUALITY OF A CONTROLLED ATMOSPHERE AREA. COMPLIANCE WITH GOOD MANUFACTURING PRACTICES AT REST AND DURING ACTIVITY, HIGHLIGHTING OF FACTORS IMPACTING ON CONTAMINATION
	3PC-023	DEVELOPMENT AND VALIDATION OF A DISCRIMINATIVE METHOD FOR ANTHRACYCLINES DRUGS USED IN ONCOLOGY BY VISIBLE SPECTROMETER
	3PC-024	THE EFFECTS OF FREEZE-THAW CYCLING ON THE STABILITY OF THE ADALIMUMAB BIOSIMILAR SB5
	3PC-025	MAGISTRAL FORMULATION FOR A PATIENT WITH MULTIPLE FOOD ALLERGY
	3PC-026	FORMULATION AND GALENIC CHARACTERISATION OF A TACROLIMUS ADHESIVE GEL FOR TREATMENT OF ULCERATIVE PROCTITIS
	3PC-027	LONG TERM STABILITY OF A READY TO USE TOPICAL ANAESTHETIC GEL KIT
	3PC-028	COMPOUNDING AN ORAL LIQUID FORMULATION OF DIAZEPAM ALCOHOL FREE
	3PC-029	PAEDIATRIC DRUG RESISTANT EPILEPSY: NITRAZEPAM 1MG/ML SOLUTIONS TO AVOID CLINICAL THERAPEUTIC ERROR
	3PC-030	ANALYTICAL METHOD VALIDATION TO CARRY OUT PHYSICOCHEMICAL STABILITY STUDIES OF METHADONE ORAL SOLUTIONS.
	3PC-031	CURRENT STATE OF THE ANTI-INFECTIVE OPHTHALMIC COMPOUNDING FORMULATION IN PHARMACY SERVICES: A NATIONAL SURVEY
	3PC-032	AUTOLOGOUS TISSUE ADHESIVE IN OPHTHALMOLOGICAL SURGERY
	3PC-033	INTRACAMERAL AND INTRASTROMAL VORICONAZOLE ADMINISTRATION IN FUSARIUM KERATITIS
	3PC-034	CONTENT UNIFORMITY OF EXTEMPORANEOUS COMPOUNDED SUSPENSIONS
	3PC-035	93% OXYGEN SELF-PRODUCTION: EXPERIENCE IN NA ITALIAN HOSPITAL
	3PC-036	CASE STUDY: DEVELOPMENT OF AN OINTMENT ACCORDING TO THE PHARMACEUTICAL INSPECTION CONVENTION GUIDELINE
	3PC-037	STERILITY OF SINGLE USE VIALS WHEN ACCESSED USING A CLOSED SYSTEM TRANSFER DEVICE
	3PC-038	PHYSICOCHEMICAL STABILITY OF THE BEVACIZUMAB BIOSIMILAR, ABP 215, IN INTRAVENOUS BAGS AFTER PREPARATION AND STORAGE
	3PC-039	OPTIMISATION OF MIXING AN ORAL POWDER MIXTURE OF CODEINE PREPARED IN THE HOSPITAL PHARMACY FOR FILLING INTO HARD CAPSULES
	3PC-040	GALENIC VALIDATION OF A DEXAMETHASONE 0.01% MOUTHWASH SOLUTION TO PREVENT EVEROLIMUS RELATED STOMATITIS
	3PC-041	SURFACE CONTAMINATION WITH CYTOTOXIC DRUGS IN EUROPEAN HOSPITAL WARDS
	3PC-042	THE SIGNIFICANCE OF PHARMACY PREPARATION IN PAEDIATRICS: MAKING INDIVIDUAL THERAPIES FOR CRITICALLY ILL CHILDREN POSSIBLE
	3PC-043	HAZARDOUS DRUGS: IMPACT OF MEASURES FOR SAFE HANDLING
	3PC-044	IN USE PHYSICOCHEMICAL STABILITY OF PEMBROLIZUMAB UNDER THE DILUTION CONDITION REQUIRED FOR USE IN A DAY HOSPITAL
	3PC-045	IMPACT OF THE PREPARATION OF A CLINICAL SOLUTION OF RITUXIMAB 1.0 MG/ML ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: SODIUM CHLORIDE AND GLUCOSE CONCENTRATION, AND AGITATION EFFECT
	3PC-046	PARENTERAL NUTRITION ADMIXTURES: REVIEW OF THE MICROBIOLOGICAL SAMPLING PLAN
	3PC-047	STUDY OF THE TRIGON DEPOT ALLERGY TEST (TRIAMCINOLONE AND EXCIPIENTS: CARBOXYMETHYLCELLULOSE, POLYSORBATE 80) DEVELOPED IN THE PHARMACY DEPARTMENT
	3PC-048	IMPORTANCE OF NON-STERILE FORMULATION IN A PAEDIATRIC HOSPITAL
	3PC-049	IMIPENEM-CILASTATIN FORTIFIED EYE DROPS FOR THE TREATMENT OF CORNEAL ULCERS CAUSED BY: CONTACT LENSES. DEVELOPMENT AND CHARACTERISATION
	3PC-050	IMPORTANCE OF COMPOUNDING IN THE PAEDIATRIC HOSPITAL PHARMACY
	3PC-051	CIRCUIT TO PREPARE AND CONDITION ORAL HAZARDOUS MEDICINES
	3PC-052	HAZARDOUS MEDICINES IN A PAEDIATRIC HOSPITAL
	3PC-053	IMPACT OF SERIALISATION ON RECEPTION OF MEDICINES AND ACTIVITY SMOOTHING
	3PC-054	SODIUM BENZOATE SUSPENSION IN NON-KETOTIC HYPERGLYCINAEMIA: A CASE REPORT

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	EXPERIENCE WITH THE NEW DIRECT ACTING ANTIVIRAL AGENTS IN A THIRD LEVEL HOSPITAL IN 2018
	4CPS-002	ANTICHOLINERGIC BURDEN IN CONSTIPATED PATIENT ADMITTED TO AN EMERGENCY DEPARTMENT
	4CPS-003	LIRAGLUTIDE IN CHRONIC INTESTINAL FAILURE: OVERVIEW AND CASE REPORT
	4CPS-004	EVALUATION OF THE USE OF HYDROCORTISONE, VITAMIN C AND THIAMINE FOR THE TREATMENT OF SEPTIC SHOCK
	4CPS-005	RISK FACTORS FOR PERSISTENCE AND TOLERANCE OF COW'S MILK ALLERGY
	4CPS-006	USE OF AMMONIUM TETRATHIOMOLYBDATE IN WILSON DISEASE
	4CPS-007	PHARMACEUTICAL CARE AS A MEANS OF PREVENTION AGAINST DRUG IATROGENESIS: CASE OF ORAL ANTICOAGULANTS
	4CPS-008	RISK FACTORS ASSOCIATED WITH RE-ADMISSION TO THE EMERGENCY DEPARTMENT, IN PATIENTS WITH PREVIOUS GASTROINTESTINAL HAEMORRHAGE SECONDARY TO ORAL ANTICOAGULANT THERAPY
	4CPS-009	DURATION OF DUAL ANTIPLATELET THERAPY IN CORONARY ARTERY DISEASE: IS PHARMACIST INTERVENTION NECESSARY TO IMPROVE PATIENT SAFETY?
	4CPS-010	SAFETY AND EFFICACY OF LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS WITH PORTAL VEIN THROMBOSIS
	4CPS-011	PRESCRIPTION ANALYSIS OF DIRECT ACTING ORAL ANTICOAGULANTS
	4CPS-012	AUDIT OF ORAL ANTICOAGULANT PRESCRIBING; WHAT HAS CHANGED IN 4 YEARS?
	4CPS-013	EFFECT OF 2MG INTRAVENOUS PHYTONADIONE TREATMENT ON INTERNATIONAL NORMALISED RATIO IN THE HOSPITALISED ADULT
	4CPS-014	CLINICAL AND ASSISTED IMPACT OF ISCHAEMICAL ICTUS IN PATIENTS TREATED WITH ORAL ANTICOAGULANTS
	4CPS-015	SITUATIONAL ANALYSIS OF POSTOPERATIVE IRON SUPPLEMENTATION PRESCRIPTIONS IN A PLASTIC SURGERY DEPARTMENT
	4CPS-016	INAPPROPRIATE USE OF HUMAN ALBUMIN IN A TEACHING HOSPITAL
	4CPS-017	EFFICACY AND SAFETY OF TOLVAPTAN IN THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE
	4CPS-018	EFFICACY OF UREA IN THE TREATMENT OF HYPONATRAEMIA IN SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION
	4CPS-019	ALIROCUMAB AND EVOLOCUMAB: EFFECTIVENESS AFTER 3 YEARS OF FOLLOW-UP IN A REAL WORLD SETTING
	4CPS-020	USE, EFFICACY AND ADHERENCE TO TREATMENT WITH PCKS9 INHIBITORS IN REAL CLINICAL PRACTICE
	4CPS-021	ALIROCUMAB AND EVOLOCUMAB: RESULTS IN CLINICAL PRACTICE.
	4CPS-022	PCSK9 INHIBITORS: EVALUATION OF EFFECTIVENESS IN OUR CENTRE IN RELATION TO THE OFFICIAL CLINICAL ENDPOINTS
	4CPS-023	LONG-TERM EFFICACY, SAFETY AND ADHERENCE TO ALIROCUMAB IN PATIENTS WITH DYSLIPIDAEMIA FROM A TERTIARY HOSPITAL COHORT
	4CPS-024	EFFECTIVENESS OF ANTI-INTERLEUKIN-17 DRUGS IN PSORIASIS IN CLINICAL PRACTICE
	4CPS-025	DUPILUMAB IN THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS: CASE REPORTS
	4CPS-026	DALBAVANCIN OFF-LABEL USE: EFFECTIVENESS AND SAFETY
	4CPS-027	ANTIBIOTIC THERAPY REASSESSMENT AND ITS DOCUMENTATION: CAN VIRTUAL TOOLS IMPROVE PRACTICES?
	4CPS-028	EXPERIENCE OF CEFTAROLINE USE IN A THIRD LEVEL HOSPITAL
	4CPS-029	PRELIMINARY RESULTS OF AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN ONCOLOGY DEPARTMENT
	4CPS-030	INCIDENCE AND RISK FACTORS FOR PROSTHETIC JOINT INFECTION WITHIN 90 DAYS AFTER HEMIARTHROPLASTY FOR FEMORAL NECK FRACTURES IN THE ELDERLY
	4CPS-031	AUDIT OF ANTIBIOTIC PROPHYLAXIS PRACTICE IN VISCERAL SURGERY IN AN AFRICAN COUNTRY
	4CPS-032	ANTIBIOTIC PRESCRIPTION THROUGH MOTIVATED REQUEST: CLINICAL PHARMACY TOOL TO IMPROVE APPROPRIATENESS AND LIMIT RESISTANT BACTERIAl STRAINS. A FOLLOW-UP AFTER A YEAR OF MONITORING IN A LOCAL HOSPITAL
	4CPS-033	OFF-LABEL USE OF NEBULISED AZTREONAM LYSINE IN PATIENTS WITH CHRONIC GRAM-NEGATIVE BACTERIAL LUNG COLONISATION
	4CPS-034	IS IT POSSIBLE TO RATIONALISE THE ANTIBIOTIC USE AMONG HOSPITALISED PATIENTS BY CLINICAL PHARMACISTS’ ACTIVITY?
	4CPS-035	CLINICAL PHARMACOKINETICS OF VANCOMYCIN IN NEUTROPENIC PATIENTS
	4CPS-036	PHARMACEUTICAL INTERVENTIONS IN A SMALL HOSPITAL
	4CPS-037	CLINICAL OUTCOME IN PAEDIATRIC INTENSIVE CARE UNIT PATIENTS TREATED WITH VANCOMYCIN
	4CPS-038	STABILITY TO HIGH TEMPERATURES OF THE ANTIMICROBIALS USED IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY PROGRAMMES
	4CPS-039	NOSOCOMIAL INFECTION BY MULTIRESISTANT PATHOGENS IN KIDNEY TRANSPLANTED PATIENTS
	4CPS-040	ADEQUACY OF ANTIBIOTIC PRESCRIPTIONS IN A NURSING HOME
	4CPS-041	PHARMACIST LED ANTIMICROBIAL STEWARDSHIP PROGRAMME
	4CPS-042	PHARMACIST'S MISSION IN INFECTION MANAGEMENT : EVALUATION OF IMPROVEMENT ACTIONS
	4CPS-043	EFFECTIVENESS OF A NEW INTERNAL PROTOCOL FOR DOSAGE OF VANCOMYCIN IN NEONATES
	4CPS-044	THE ROUTINE USE OF ANTIBIOTICS AFTER INSERTION OF A CARDIAC IMPLANTABLE ELECTRONIC DEVICE (CIED): EVIDENCE AND CURRENT PRACTICE
	4CPS-045	COST EFFECTIVENESS ANALYSIS OF MEROPENEM DOSE OPTIMISATION IN CRITICAL PATIENTS
	4CPS-046	MONITORING THE PRESCRIPTION OF NEW ANTIBIOTICS: THE WORK OF THE ANTIMICROBIAL STEWARDSHIP TEAM IN A THIRD LEVEL HOSPITAL
	4CPS-047	ASSESSING THE IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN HOSPITALS: ROLE OF HOSPITAL PHARMACISTS.
	4CPS-048	BETA-LACTAM ANTIBIOTICS IN CRITICAL ILL PATIENTS: ARE WE DOSING CORRECTLY OUR PATIENTS CORRECTLY?
	4CPS-049	UNDERDOSING WITH HIGH DOSE PIPERACILLIN/TAZOBACTAM ADMINISTERED VIA CONTINUOUS INFUSION IN OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY: A STABILITY OR VISCOSITY PROBLEM?
	4CPS-050	CONFORMITY OF ANTIBIOTIC THERAPY DURATION IN PATIENTS WITH FEBRILE NEUTROPENIA, HOSPITALISED IN THE HAEMATOLOGY DEPARTMENT OF A UNIVERSITY HOSPITAL
	4CPS-051	ANTIBIOTICS IN THE EMERGENCY DEPARTMENT: IS IT POSSIBLE TO IMPROVE THE PRESCRIPTIONS FOR INFECTIOUS RESPIRATORY DISEASES IN AMBULATORY PATIENTS?
	4CPS-052	EVALUATION OF PIPERACILIN/TAZOBACTAM DOSAGE IN SEPTIC PATIENTS ATTENDING THE EMERGENCY DEPARTMENT
	4CPS-053	ANTIMICROBIAL STEWARDSHIP PROGRAMME IN AN INTENSIVE CARE UNIT
	4CPS-054	A MULTIDISCIPLINARY AND EDUCATIONAL APPROACH TO ANTIMICROBIAL STEWARDSHIP PROGRAMMES IN THE EMERGENCY DEPARTMENT
	4CPS-055	EVALUATION OF USE, EFFECTIVENESS AND SAFETY OF ISAVUCONAZOL
	4CPS-056	PROPER USE OF ANTIFUNGALS: IMPLEMENTATION OF OPERATIONAL MULTIDISCIPLINARY TEAMS DEDICATED TO ANTIFUNGALS
	4CPS-057	THERAPEUTIC DRUG MONITORING OF VORICONAZOLE
	4CPS-058	MANAGEMENT OF THE HOSPITALISED PATIENT WITH FLU
	4CPS-059	STRATEGY FOR CHANGE IN ANTIRETROVIRAL THERAPY: LOOKING FOR BETTER RESULTS
	4CPS-060	PRESCRIPTION ANALYSIS OF TENOFOVIR DISPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE FUMARATE IN A THIRD LEVEL HOSPITAL
	4CPS-061	ADHERENCE TO ANTIRETROVIRAL TREATMENT AS A FUNCTION OF THE COMPLEXITY OF THE TREATMENT
	4CPS-062	PATIENTS WITH DARUNAVIR/COBICISTAT/EMTRICITABINE/TENOFOVIR ALAFENAMIDE TREATMENT IN A THIRD LEVEL HOSPITAL
	4CPS-063	USE OF OSELTAMIVIR IN THE TREATMENT OF INFLUENZA A
	4CPS-064	ADHERENCE TO ANTIRETROVIRAL TREATMENT IN PATIENTS WITH HIV
	4CPS-065	SWITCHING TO EQUIVALENT ALTERNATIVES: ANTIRETROVIRAL OPTIMISATION STRATEGY
	4CPS-066	CHANGING FROM COBICISTAT TO A RITONAVIR BOOSTED REGIMEN IN HIV POSITIVE PATIENTS
	4CPS-067	ANALYSIS OF USAGE OF DIRECT ACTIN ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C.
	4CPS-068	EFFECTIVENESS OF DOLUTEGRAVIR AND LAMIVUDINE THERAPY IN A TWO DRUG REGIMEN IN A THIRD LEVEL HOSPITAL.
	4CPS-069	EVALUATION OF PALIVIZUMAB AS PROPHYLAXIS AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION
	4CPS-070	ANALYSIS OF THE USE OF NON-SPECIFIC INTRAVENOUS IMMUNOGLOBULINS IN A TERTIARY HOSPITAL.
	4CPS-071	ANALYSIS OF EFFECTIVENESS: USE OF PERTUZUMAB AND TRASTUZUMAB IN NEOADJUVANT TREATMENT IN PATIENTS WITH HER2 POSITIVE BREAST CANCER AND ITS CORRELATION WITH PLASMA LEVELS OF TRASTUZUMAB
	4CPS-072	COMPARISON OF IMMUNE CHECKPOINT INHIBITORS (NIVOLUMAB, PEMBROLIZUMAB, ATÉZOLIZUMAB AND DURVALUMAB) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: TOLERANCE AND FINANCIAL IMPACT
	4CPS-073	EFFECTIVENESS AND SAFETY OF PLATIN/PERMETREXED COMBINATION IN NON-SMALL CELL LUNG CANCER.
	4CPS-074	CYCLIN DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER: POTENTIAL DRUG INTERACTIONS
	4CPS-075	IBRUTINIB ASSOCIATED ATRIAL FIBRILLATION: INCIDENCE AND MANAGEMENT IN THE REAL LIFE CLINICAL SETTING
	4CPS-076	INDIRECT COMPARISON BETWEEN PEMBROLIZUMAB MONOTHERAPY AND PEMBROLIZUMAB CHEMOTHERAPY REGIMENE IN SQUAMOUS LUNG CANCER
	4CPS-077	DETECTION AND COMMUNICATION OF CONCOMITANT USE OF CAPECITABINE AND PROTON PUMP INHIBITORS
	4CPS-078	EFFECTIVENESS AND SAFETY OF ERIBULIN FOR ADVANCED BREAST CANCER TREATMENT
	4CPS-079	SEQUENCING OF IBRUTINIB, IDELALISIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL
	4CPS-080	REAL LIFE TYROSINE KINASE INHIBITOR DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
	4CPS-081	GEFITINIB IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY.
	4CPS-082	RISK OF MYELOTOXICITY IN NON-CANCER PATIENTS TREATED WITH CHEMOTHERAPY
	4CPS-083	SAFETY AND TOLERABILITY OF PALBOCICLIB IN CLINICAL PRACTICE IN A TERTIARY HOSPITAL
	4CPS-084	ANTHRACYCLINES DOSAGE IN PAEDIATRIC OBESE PATIENTS
	4CPS-085	IMPROVED ACCESS TO CHEMOTHERAPEUTIC TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA
	4CPS-086	IMATINIB DOSE OPTIMISATION THROUGH THERAPEUTIC MONITORING IN CHRONIC MYELOID LEUKAEMIA AS PART OF PHARMACEUTICAL CARE
	4CPS-087	OPTIMISATION OF RESOURCES IN THE USE OF IMUNOTHERAPY: NIVOLUMAB AND PEMBROLIZUMAB IN WEIGHT-BASED DOSING INSTEAD OF FLAT DOSE.
	4CPS-088	CHECKPOINT INHIBITORS IN NON-MICROCYTIC LUNG CANCER: RESULTS IN COMMON CLINICAL PRACTICE
	4CPS-089	COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER
	4CPS-090	EFFICACY AND SAFETY OF ERLOTINIB IN NON-SMALL CELL LUNG CANCER
	4CPS-091	EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH PANCREATIC CANCER
	4CPS-092	EVALUATION OF AGGRESSIVENESS OF CANCER CARE NEAR THE END OF LIFE IN PATIENTS WITH METASTATIC NON-MICROCYTIC LUNG CANCER
	4CPS-093	EFFECTIVENESS OF DEXAMETHASONE MOUTHWASH 0.1MG/ML FOR PREVENTION OF EVEROLIMUS RELATED STOMATITIS
	4CPS-094	CHARACTERISATION OF POTENTIAL DRUG-DRUG INTERACTIONS IN ONCOLOGICAL PATIENTS TREATED WITH ORAL ANTICANCER DRUGS
	4CPS-095	REVIEWING THE LATEST CLINICAL RESEARCH FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER: SELECTION OF RANDOMISED CONTROLLED TRIALS PUBLISHED IN 2018
	4CPS-096	EVALUATION OF CLINICAL PHARMACY SERVICES IN A HAEMATOLOGY OUTPATIENT SETTING.
	4CPS-097	SECOND LINE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS
	4CPS-098	INDIRECT TREATMENT COMPARISONS OF IBRUTINIB-OBINOTUZUMAB VERSUS VENETOCLAX-OBINOTUZUMAB IN NAIVE CHRONIC LYMPHOCYTIC LEUKAEMIA
	4CPS-099	REAL WORLD EVIDENCE OF PEMBROLIZUMAB AS MONOTHERAPY IN NON-SMALL CELL LUNG CANCER: EFFECTIVENESS AND SAFETY STUDY
	4CPS-100	ANTHRACYCLINE DOSING IN OBESE ADULT PATIENTS: A SYSTEMATIC REVIEW
	4CPS-101	TRIFLURIDINE-TIPIRACIL FOR METASTATIC COLORECTAL CANCER: REAL WORLD DATA EXPERIENCE
	4CPS-102	INFLUENCE OF PALBOCICLIB TOXICITY IN THE REAL WORLD CLINICAL PRACTICE
	4CPS-103	IS THERE A ROLE FOR THE PHARMACIST IN SCREENING FOR METABOLIC SYNDROME?
	4CPS-104	SWITCHING ORAL ANTIANDROGENIC TREATMENT IN PATIENTS WITH CASTRATE METASTATIC PROSTATE CANCER: AN ANALYSIS.
	4CPS-105	TOLERANCE PROFILE TO ANTI-THYMOCYTE IMMUNOGLOBULIN TREATMENT AND ITS RELATION TO INFECTIOUS PARAMETERS IN PAEDIATRIC PATIENTS
	4CPS-106	ANALYSIS OF THE PRESCRIPTION AND SAFE DRUG ADMINISTRATION OF OCRELIZUMAB
	4CPS-107	IMPACT OF A TOOL IN THE ELECTRONIC CLINICAL HISTORY FOR THE OPTIMISATION OF BIOLOGIC DRUGS IN RHEUMATOLOGY
	4CPS-108	A REVIEW OF INFLIXIMAB BIOSIMILAR TO BIOSIMILAR SWITCH: REMSIMA TO FLIXABI
	4CPS-109	ANALYSIS OF CHANGES IN DISEASE MODIFYING TREATMENT IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE SCLEROSIS
	4CPS-110	VEDOLIZUMAB: OUTCOMES AND THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE
	4CPS-111	CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB BIOSIMILAR INFLECTRA IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHROPATHY AND ANKYLOSING SPONDYLITIS NAÏVE AND SWITCHED PATIENTS: AFTER 5 YEARS OF FOLLOW-UP
	4CPS-112	ADHERENCE TO ADALIMUMAB, GOLIMUMAB AND USTEKINUMAB THERAPY IN INFLAMMATORY BOWEL DISEASE
	4CPS-113	INOTUZUMAB OZOGAMIZIN FOR THE TREATMENT OF THE RELAPSE B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA IN AN ADULT PATIENT: A CASE REPORT.
	4CPS-114	BELIEFS ABOUT MEDICATION AND QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB
	4CPS-115	THERAPEUTIC DRUG MONITORING OF ETANERCEPT BIOSIMILAR IN PSORIATIC PATIENTS
	4CPS-116	TEN YEARS OF EXPERTISE IN USTEKINUMAB USE FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS
	4CPS-117	CASE REPORT: USEFULNESS OF THERAPEUTIC DRUG MONITORING OF VEDOLIZUMAB IN MANAGING ACUTE GRAFT VERSUS HOST DISEASE
	4CPS-118	REAL CLINICAL IMPACT OF DRUG-DRUG INTERACTIONS OF IMMUNOSUPPRESSANTS IN TRANSPLANT PATIENTS.
	4CPS-119	“REAL WORLD” EXPERIENCE OF TOFACITINIB AND BARICITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: EFFECTIVENESS AND SAFETY EVALUATION
	4CPS-120	TEN YEAR ANALYSIS OF THE USE OF INFLIXIMAB IN ULCERATIVE COLITIS
	4CPS-121	EVALUATION OF COST AND EFFICACY OF ECULIZUMAB IN COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY IN THE CLINICAL SETTING
	4CPS-122	POTENTIAL OPTIMISATION OF TREATMENT WITH USTEKINUMAB IN CROHN'S DISEASE
	4CPS-123	EVALUATION OF ADHERENCE TO ORAL DISEASE MODIFYING THERAPIES (ORAL-DMT) IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
	4CPS-124	ADHERENCE TO SELECTIVE IMUNOSUPPRESSIVE DRUGS TREATMENTS IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES
	4CPS-125	ACCEPTANCE OF PHARMACOKINETIC RECOMMENDATIONS FOR EVEROLIMUS IN RENAL TRANSPLANT PATIENTS
	4CPS-126	A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN A COHORT OF PAEDIATRIC PATIENTS WITH INFLAMMATORY BOWOL DISEASE: A PRELIMINARY ANALYSIS
	4CPS-127	ECONOMIC IMPACT OF INTENSIFICATION REGIMENS IN INFLAMMATORY BOWEL DISEASE
	4CPS-128	LIVER TRANSPLANT AND DIABETES MELLITUS
	4CPS-129	PILOT STUDY TO SURVEY THE ATTITUDE, SUPPLEMENT USE AND STORAGE CONDITIONS OF DRUG PRODUCTS AMONG PATIENTS RECEIVING BIOLOGICAL THERAPY
	4CPS-130	ONE IN A MILLION: A TNF RECEPTOR-1 ASSOCIATED SYNDROME RESISTANT TO ANTI-TNF-ALPHA THERAPY.
	4CPS-131	EFFECTIVENESS OF NUSINERSEN IN PAEDIATRIC PATIENTS SMA1 AND SMA2
	4CPS-132	INDIRECT TREATMENT COMPARISON OF ANTICALCITONIN GENE RELATED PEPTIDE PATHWAY ANTIBODIES IN CHRONIC MIGRAINE
	4CPS-133	IS PARACETAMOL A REAL ALTERNATIVE IN THE MANAGEMENT OF PATENT DUCTUS ARTERIOSUS IN PRETERM INFANTS?
	4CPS-134	PREVALENCE ANALYSIS OF PATIENTS TREATED WITH TRIPTANS AT RISK OF DEVELOPING MEDICATION OVERUSE HEADACHE AND DEVELOPMENT OF A PRESCRIPTION OPTIMISATION STRATEGY.
	4CPS-135	PERPHENAZINE AND PROPRANOLOL POISONING: A CASE REPORT.
	4CPS-136	DEXMEDETOMIDINE TREATMENT FOR THE SEDATION OF PRETERM NEONATES
	4CPS-137	REVIEW OF 3 MONTH PRESCRIPTIONS CONTAINING DRUGS INDUCING QT PROLONGATION AND TORSADE DE POINTE
	4CPS-138	AN OBSERVATIONAL RETROSPECTIVE STUDY ON TREATMENT ADHERENCE OF LONG ACTING INJECTABLE ANTIPSYCHOTICS
	4CPS-139	PSYCHOTROPIC DRUG USAGE IN OCTOGENARIAN AND NONAGENARIAN COMPLEX CHRONIC PATIENTS
	4CPS-140	CURRENT STATUS OF CLINICAL TRIALS FOR ALZHEIMER’S DISEASE
	4CPS-141	EFFECTIVENESS OF IMMUNOTHERAPY IN SEVERE UNCONTROLLED ASTHMA
	4CPS-142	EFFECTIVENESS AND SAFETY OF ANTI-IL-5 BIOLOGIC AGENTS IN SEVERE EOSINOPHILIC ASTHMA
	4CPS-143	TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTION PULMONARY DISEASE: ARE OUR HOSPITAL NURSES AND PHYSICIANS READY TO TREAT AND EDUCATE IN-PATIENTS?
	4CPS-144	SAFETY AND EFFECTIVENESS OF REDUCED DOSE OF OMALIZUMAB FOR CHRONIC IDIOPATHIC URTICARIA
	4CPS-145	EVALUATION OF A PHARMACEUTICAL CARE PROGRAMME FOR PATIENTS BEING TREATED WITH OMALIZUMAB
	4CPS-146	EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN THE TREATMENT OF SEVERE UNCONTROLLED ASTHMA
	4CPS-147	THERAPEUTIC POSITIONING AND USE OF INTRAVITREAL RANIBIZUMAB AND AFLIBERCEPT
	4CPS-148	CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (PLASMA RICH IN GROWTH FACTORS)
	4CPS-149	INITIAL THERAPY FOR NEOVASCULAR AGE RELATED MACULAR DEGENERATION: ARE THE GUIDELINES MET IN CLINICAL PRACTICE?
	4CPS-150	ASSESSMENT OF BURDEN OF DISEASE IN TERMS OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
	4CPS-151	THE IMPACT OF AN INTEGRATED ELECTRONIC MEDICAL RECORD ON THERAPEUTIC DRUG MONITORING
	4CPS-152	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN THE EXCHANGE OF THERAPEUTIC EQUIVALENTS
	4CPS-153	INTENSIFICATION IN BIOLOGICAL TREATMENT IN ULCERATIVE COLITIS
	4CPS-154	POTENTIALLY INAPPROPRIATE MEDICATION FOR ELDERLY HOSPITALISED PATIENTS IN A TRAUMA AND ORTHOPAEDIC SURGERY DEPARTMENT
	4CPS-155	REAL LIFE EXPERIENCE OF HOME CARE ADMINISTRATION OF 5-AZACITIDINE AND DOMICILIARY MANAGEMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROME
	4CPS-156	ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
	4CPS-157	INTRAVENOUS BIOSIMILAR PRESCRIBING TRENDS IN A THIRD LEVEL SPANISH HOSPITAL
	4CPS-158	PRESCRIBING TRENDS OF ADALIMUMAB AND ETANERCEPT BIOSIMILAR DRUGS IN A THIRD LEVEL HOSPITAL
	4CPS-159	MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA AT A TERTIARY CARE TEACHING HOSPITAL
	4CPS-160	MANAGEMENT OF DRUGS IN PATIENTS WITH SWALLOWING DIFFICULTIES IN A PUBLIC RESIDENTIAL CARE HOME: ROLE OF THE HOSPITAL PHARMACIST
	4CPS-161	PHARMACIST INTERVENTIONS IN A HOSPITAL AT HOME UNIT
	4CPS-162	PHARMACEUTICAL INTERVENTIONS IN DRUGS PROVIDED TO THE OUTPATIENT HOSPITAL PHARMACY
	4CPS-163	CLINICAL PHARMACIST RESIDENCE IN AN INTENSIVE CARE UNIT: SCOPE AND RELEVANCE
	4CPS-164	A SAFE HANDLING HAZARDOUS DRUGS STRATEGY TO IMPROVE THE SAFETY OF HEALTH PROFESSIONALS: REDUCING EXPOSURE BY MEDICAL PRESCRIPTION REVIEW IN NURSING HOMES
	4CPS-165	ANALYSIS OF ANTIBIOTIC CONSUMPTION IN A NURSING HOME
	4CPS-166	ANALYSIS OF THE MAINTENANCE RATE OF LONG ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT IN OUTPATIENTS
	4CPS-167	EVALUATION OF PHARMACEUTICAL INTERVENTIONS: IMPROVEMENT PLANS
	4CPS-168	DEVELOPMENT OF A BELGIAN CLASSIFICATION SYSTEM FOR CLINICAL PHARMACY ACTIVITIES
	4CPS-169	EFFECT OF ABIRATERONE VERSUS ENZALUTAMIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
	4CPS-170	ANALYSIS AND EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL
	4CPS-171	PHARMACISTS AT THE HEALTH CENTRE
	4CPS-172	OFF-LABEL USE OF INTRALESIONAL CIDOFOVIR IN RECURRENT RESPIRATORY PAPILLOMATOSIS: A CASE REPORT.
	4CPS-173	ROLE OF THE PHARMACIST IN THE MULTIDISCIPLINARY MANAGEMENT OF OSTEOMYELITIS: FROM MEDICATION RECONCILIATION TO SUPPORT IN CLINICAL DECISION MAKING.
	4CPS-174	FACILITATORS AND BARRIERS TO PERFORMING COMPREHENSIVE MEDICATION REVIEWS AND FOLLOW-UP IN OLDER HOSPITALISED PATIENTS BY MULTIPROFESSIONAL WARD TEAMS INCLUDING A CLINICAL PHARMACIST
	4CPS-175	EVOLUTION OF ANTIMICROBIAL CONSUMPTION IN A TRAUMA INTENSIVE CARE UNIT USING DEFINED DAILY DOSES PER 100 OCCUPIED BED DAYS
	4CPS-176	ELECTROLYTE DISTURBANCES IN PREMATURE INFANTS WITH INTRAUTERINE GROWTH RESTRICTION RECEIVING PARENTERAL NUTRITION
	4CPS-177	COMPARATIVE STUDY OF PATIENT PROFILES AND INITIAL ANTIRETROVIRAL TREATMENT IN 2014 VERSUS 2018
	4CPS-178	TRANSCRIPTION OF SUPPORTIVE MEDICATION FOR INPATIENT CHEMOTHERAPY BY DESIGNATED ONCOLOGY WARD PHARMACISTS
	4CPS-179	THE WIDE REVIEW OF POLYPHARMACY IN THE FRAIL OLDER PERSON
	4CPS-180	FROM EVIDENCE BASED MEDICINE TO PRACTICE: GUM CHEWING FOR POSTOPERATIVE RECOVERY OF GASTROINTESTINAL FUNCTION AFTER COLORECTAL SURGERY WITH INTERPROFESSIONAL TEAMWORK
	4CPS-181	BUDGETARY IMPACT OF BIOSIMILAR PRESCRIPTION IN THE TREATMENT OF RHEUMATIC DISEASES
	4CPS-182	PRELIMINARY DESIGN OF HOSPITAL TELEPHARMACY
	4CPS-183	SELECTION OF A POPULATION PHARMACOKINETIC MODEL OF ADALIMUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SUITABLE FOR THERAPEUTIC DRUG MONITORING
	4CPS-184	EVALUATION OF A CLINICAL PHARMACY SERVUCE ON AN INPATIENT WARD IN AN ACUTE HOSPITAL
	4CPS-185	ADMINISTRATION OF ORAL ANTICANCER DRUGS FOR PATIENTS WITH SWALLOWING DIFFICULTIES
	4CPS-186	DESCRIPTION OF PHARMACEUTICAL INTERVENTIONS IN AN INTENSIVE CARE UNIT
	4CPS-187	PROGNOSTIC VALUE OF HAEMATOLOGICAL INFLAMMATORY MARKERS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER TREATED WITH PEMBROLIZUMAB
	4CPS-188	PHARMACEUTICAL INTERVENTION TO REDUCE THE ANTICHOLINERGIC BURDEN IN OLDER HOSPITALISED PATIENTS
	4CPS-189	FALL INCIDENTS IN NURSING HOME PATIENTS: DEVELOPMENT OF A PREDICTIVE CLINICAL RULE (FINDER)
	4CPS-190	EVALUATION OF A NEW CLINICAL PHARMACY SERVICE WITHIN A NEWLY LAUNCHED SURGICAL ADMISSION PROCESS
	4CPS-191	PHARMACEUTICAL INTERVENTIONS IN A MEDICATION RECONCILIATION PROGRAMME UPON ADMISSION IN SURGICAL PATIENTS
	4CPS-192	ESTIMATING THE SURVIVAL PROGNOSIS OF PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCY ON HOME PARENTERAL NUTRITION: A RETROSPECTIVE, MONOCENTRE STUDY
	4CPS-193	MEASURING THE IMPACT OF HOSPITAL PHARMACIST PRESCRITION REVIEWING IN AN ONCOLOGY SETTING ON THE PHARMACOVIGILANCE REPORTING IN A COMPREHENSIVE CANCER CENTRE
	4CPS-194	THE UNDERREPORTING RATE AS A PHARMACOVIGILANCE PROCESS INDICATOR IN A COMPREHENSIVE CANCER CENTRE
	4CPS-195	PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION FOR CRITICALLY ILL PATIENTS
	4CPS-196	STABILITY OF LIPID EMULSION IN PAEDIATRIC PARENTERAL NUTRITION WITH HIGH ELECTROLYTIC LOAD
	4CPS-197	MONITORING OF OFF-LABEL USE: ANALYSIS OF PRESCRIPTIONS IN THE PHARMACY'S ANTIBLASTIC DRUGS UNIT
	4CPS-198	RESULTS OF A MEDICATION RECONCILIATION PROGRAMME IN COMPLEX CHRONIC PATIENTS AT HOSPITAL DISCHARGE
	4CPS-199	PHARMACEUTICAL INTERVENTIONS IN HAEMODIALYSIS PATIENTS: A 2 YEAR OVERVIEW
	4CPS-200	DIFFERENCES IN ALLELIC FREQUENCIES OF RELEVANT PHARMACOGENETIC POLYMORPHISMS MAY LEAD TO LOCAL GENE PANEL DEVELOPMENT
	4CPS-201	IDENTIFICATION OF HAZARDOUS DRUGS AND PROCESS IN A UNIVERSITY HOSPITAL
	4CPS-202	NUTRITIONAL RISK EVALUATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A PUBLIC NURSING HOME
	4CPS-203	NURSES: WHAT DO YOU THINK ABOUT A PHARMACEUTICAL PRESENCE IN THE EMERGENCY WARD?
	4CPS-204	MEDICINE RECONCILIATION AT HOSPITAL DISCHARGE
	4CPS-205	ASSESSMENT OF THE PALATABILITY OF ANTIBIOTIC ORAL SUSPENSIONS: A LITERATURE REVIEW.
	4CPS-206	IMPACT OF MEDICATION RECONCILIATION IN COMPLEX CHRONIC PATIENTS
	4CPS-207	TREATMENT ADEQUACY IN DOMICILIARY CARE PROGRAMME PATIENTS
	4CPS-208	NUTRITIONAL SUPPORT IN ONCOLOGY: A CROSS SECTIONAL STUDY AMONG CANCER PATIENTS
	4CPS-209	AN EXPLORATION INTO A PHARMACIST-LED MEDICINES RECONCILIATION SERVICE IN AN ACUTE HOSPITAL SETTING.
	4CPS-210	PHARMACISTS’ COMMUNICATION WITH FOREIGN LANGUAGE SPEAKING PATIENTS IN A FOREIGNER SETTLEMENT AREA, JAPAN
	4CPS-211	ADHERENCE AND INTERACTIONS IN PATIENTS TREATED WITH ABIRATERONE AND ENZALUTAMIDE
	4CPS-212	HEALTHCARE PROVIDERS' VIEWS OF PHARMACY TEAM INVOLVEMENT IN THE PREPARATION AND ADMINISTRATION OF MEDICINES ON INPATIENTS WARDS: AN EXPLORATORY STUDY
	4CPS-213	PATIENT PERCEPTIONS OF GENERIC MEDICINES 20 YEARS AFTER THE RIGHT OF SUBSTITUTION BY PHARMACISTS
	4CPS-214	IMPROVING INTRAVENOUS TO ORAL SWITCH BY IDENTIFYING AND TACKLING BARRIERS PERCEIVED BY PHYSICIANS AND NURSES
	4CPS-215	THE IMPACT OF CLINICAL PHARMACIST DRIVEN INTERVENTIONS ON PATIENT SAFETY IN HOSPITALISED PATIENTS: PRELIMINARY RESULTS OF A POINT PREVALENCE STUDY
	4CPS-216	PROMOTION OF THE QUALITY OF DRUG EDUCATION FOR THE PATIENTS USING NASOGASTRIC TUBE FEEDING BEFORE DISCHARGE

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	PHARMACIST INTERVENTION TO IMPROVE THE SAFETY OF PATIENTS TREATED WITH PROTON PUMP INHIBITORS
	5PSQ-002	HYPOMAGNESAEMIA ALERT! MONITOR CLOSELY THE PROTON PUMP INHIBITORS FOR CHRONIC TREATMENT IN ELDERLY PATIENTS
	5PSQ-003	EFFECTIVENESS OF ANTIEMETIC THERAPY DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL
	5PSQ-004	ADEQUACY OF ANTIEMETIC TREATMENT DURING CHEMOTHERAPY IN A REGIONAL HOSPITAL
	5PSQ-005	ANALYSIS OF THE ADEQUACY OF VITAMIN D PRESCRIPTIONS
	5PSQ-006	PARENTERAL NUTRITION IN A NEONATOLOGY INTENSIVE CARE UNIT: DURATION AND COMPLICATIONS
	5PSQ-007	THE PHARMACEUTICAL GOVERNANCE OF LOW MOLECULAR WEIGHT HEPARINS: APPROPRIATENESS ANALYSIS
	5PSQ-008	RESISTANCE TO SODIUM HEPARIN TREATMENT OR TREATMENT FAILURE TO THE EQUIVALENT ANALOGUE?
	5PSQ-009	EVALUATION OF DIRECT ORAL ANTICOAGULANT USE IN PATIENTS ADMITTED FOR UPPER GASTROINTESTINAL AND INTRACRANIAL HAEMORRHAGES IN THE EMERGENCY SERVICE
	5PSQ-010	BENEFITS PROVIDED BY RECOMBINANT LONG HALF-LIFE COAGULATION FACTORS IN PATIENTS WITH SEVERE HAEMOPHILIA “A” IN PROPHYLAXIS
	5PSQ-011	COMPLICATIONS OF DRUG CONTAINING PARENTERAL NUTRITION: A COHORT STUDY.
	5PSQ-012	DRUG INTERACTIONS AND POLYPHARMACY IN A COHORT OF HIV POSITIVE HAEMOPHILIAC PATIENTS
	5PSQ-013	ANALYSIS OF THE RISK OF QT INTERVAL PROLONGATION IN INSTITUTIONALISED ELDERLY PATIENTS IN A NURSING HOME
	5PSQ-014	RETROSPECTIVE EVALUATION OF RESUSCITATION MEDICATION UTILISATION IN HOSPITALISED ADULT PATIENTS WITH CARDIAC ARREST
	5PSQ-015	COMPARING THREE CRITERIA FOR ASSESSMENT OF WHAT MEDICINES INCLUDED IN NATIONAL HOSPITAL FORMULARY ARE CLASSIFIED AS POTENTIALLY INAPPROPRIATE MEDICATIONS FOR OLDER PATIENTS
	5PSQ-016	TOLVAPTAN ASSOCIATED CREATINE KINASE ELEVATION IN TWO PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
	5PSQ-017	PCSK-9 INHIBITORS: REAL WORLD EFFECTIVENESS
	5PSQ-018	ADALIMUMAB IN PALMOPLANTAR PUSTULOSIS
	5PSQ-019	EFFICACY OF SECUKINUMAB IN MODERATE-SEVERE PSORIASIS WITH A REDUCED TREATMENT REGIMEN
	5PSQ-020	ANALYSIS OF THE EFFECTIVENESS OF SECUKINUMAB AND IXEKIZUMAB IN THE TREATMENT OF MODERATE-SEVERE PSORIASIS
	5PSQ-021	TRANSVAGINAL MESH IN PELVIC ORGAN PROLAPSES: 2017-2019 RETROSPECTIVE ANALYSIS
	5PSQ-022	ANALYSIS OF INFECTIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS USED FOR ADMINISTRATION OF PARENTERAL NUTRITION IN A THIRD LEVEL HOSPITAL
	5PSQ-023	EFFECTIVENESS OF CEFTAZIDIME-AVIBACTAM IN INFECTIONS BY MULTIRESISTANT MICROORGANISMS.
	5PSQ-024	PHARMACOLOGIC INTERVENTION BY HOSPITAL PHARMCIST FOR LEUCOPENIA DUE TO TAZOBACTAM/PIPERACILLIN IN THE POSTPARTUM PERIOD: A CASE REPORT
	5PSQ-025	PHARMACEUTICAL INTERVENTION FOR THE OPTIMISATION THE USE OF ANTIBIOTICS IN A TERTIARY HOSPITAL
	5PSQ-026	IMPACT OF THE EARLY SWITCHING FROM INTRAVENOUS TO ORAL ANTIBIOTICS IN A TERTIARY HOSPITAL
	5PSQ-027	OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY WORKING GROUP IN A HOSPITAL AT HOME UNIT: THE ESSENTIAL ROLE OF PHARMACISTS
	5PSQ-028	Clone of PRESCRIPTION PROFILE OF ISAVUCONAZOLE IN THE REAL WORLD CLINICAL PRACTICE
	5PSQ-028	PRESCRIPTION PROFILE OF ISAVUCONAZOLE IN THE REAL-WORLD CLINICAL PRACTICE
	5PSQ-029	SAFE ADMINISTRATION OF SOFOSBUVIR/VELPATASVIR IN A PATIENT WITH PERCUTANEOUS ENDOSCOPIC GASTROSTOMY
	5PSQ-030	ADVERSE DRUG REACTIONS DUE TO INTERACTION WITH COBICISTAT OR RITONAVIR IN HIV POSITIVE PATIENTS: A CASE SERIES
	5PSQ-031	CLINICAL AND ECONOMIC IMPACT AFTER BREAKING THE SINGLE TABLET ABACAVIR/LAMIVUDINE/DOLUTEGRAVIR COMBO TREATMENT INTO TWO DRUG REGIMENES
	5PSQ-032	SUCCESSFUL TREATMENT OF CHRONIC HEPATITIS C INFECTION WITH CRUSHED SOFOSBUVIR/VELPATASVIR
	5PSQ-033	GLECAPREVIR/PIBRENTASVIR USE IN CHRONIC HEPATITIS C: EFFECTIVENESS AND SAFETY
	5PSQ-034	EVALUATION OF OSELTAMIVIR USE IN CLINICAL PRACTICE IN A SECOND LEVEL HOSPITAL.
	5PSQ-035	DUAL THERAPY WITH DOLUTEGRAVIR AND LAMIVUDINE: EFFICACY AND SAFETY.
	5PSQ-036	STOPP/START CRITERIA IN PATIENTS WITH HIV
	5PSQ-037	DOCETAXEL INDUCED NEUTROPENIC ENTEROCOLITIS: A CASE REPORT
	5PSQ-038	SAFETY OF CYCLIN DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF BREAST CANCER WITH POSITIVE HORMONAL RECEPTORS AND NEGATIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2.
	5PSQ-039	PANCREATITIS INDUCED BY IMMUNOTHERAPY? TWO CASE REPORTS
	5PSQ-040	SECURITY PROFILE OF IBRUTINIB AS MONOTHERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: EXPERIENCE IN A TERTIARY HOSPITAL
	5PSQ-041	CONSUMPTION OF HERBAL MEDICINE IN PATIENTS ON ORAL ANTICANCER DRUGS: STILL A LONG WAY TO GO!
	5PSQ-042	EVALUATION OF AN INFORMATION CHECKLIST FOR VALIDATION OF ANTINEOPLASTIC PRESCRIPTIONS
	5PSQ-043	IMPLEMENTATION OF A PREPARATION PROTOCOL FOR CHEMOTHERAPY ADMIXTURES OF HIGH ECONOMIC IMPACT
	5PSQ-044	IMPACT OF DRUG INTERACTIONS IN HIGH DOSE METHOTREXATE ELIMINATION
	5PSQ-045	OLARATUMAB: WHAT IS THE ECONOMIC IMPACT ON THE NATIONAL HEALTH SYSTEM?
	5PSQ-046	PREVALENCE OF NIVOLUMAB ADVERSE EVENTS IN ROUTINE CLINICAL PRACTICE
	5PSQ-047	RIBOCICLIB SAFETY IN METASTATIC BREAST CANCER
	5PSQ-048	ANALYSIS OF DRUG INTERACTIONS BETWEEN ORAL ANTINEOPLASTIC AGENTS AND CONCURRENT MEDICATIONS
	5PSQ-049	PALBOCICLIB IN METASTATIC BREAST CANCER TREATMENT: REAL LIFE TOXICITY AND FREQUENCY OF DOSE REDUCTION OR PERMANENT DISCONTINUATION.
	5PSQ-050	SUCCESSFUL DESENSITISATION IN A PATIENT WITH DASATINIB HYPERSENSITIVITY
	5PSQ-051	IMMUNE RELATED ADVERSE EVENTS IN CANCER PATIENTS TREATED WITH CONTROL POINT INHIBITORS
	5PSQ-052	EARLY RESULTS FROM THE EFFECTIVENESS AND SAFETY EVALUATION OF BIOSIMILAR RITUXIMAB AND BRAND-RITUXIMAB IN GLOMERULAR INFLAMMATORY DISEASE
	5PSQ-053	OFF-LABEL USE OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES
	5PSQ-054	EXAMINATION OF A NEW METHOD FOR ANALYSING IDENTITY AND CONCENTRATION OF DRUGS IN READY TO USE PREPARATIONS: PROOF OF CONCEPTS OF THE DRUGLOG SYSTEM
	5PSQ-055	FILGRASTIM IN EARLY STAGE BREAST CANCER: DIFFERENCES BETWEEN TWO SMALL HOSPITALS
	5PSQ-056	EXPERIENCE WITH TOFACINITIB AND BARICITINIB IN RHEUMATOID ARTHRITIS
	5PSQ-057	ANALYSIS OF INCIDENCE OF HEPATOTOXICITY ASSOCIATED WITH THE USE OF TOCILIZUMAB
	5PSQ-058	THE IMPORTANCE OF MONITORING ADVERSE DRUG REACTIONS: DATA FROM THE TREATMENT OF A RARE DISEASE
	5PSQ-059	PHARMACIST-LED OBSERVATIONAL STUDY ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: EVIDENCES FROM THE QOSMOS STUDY
	5PSQ-060	EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN CLINICAL PRACTICE FOR CROHN'S DISEASE
	5PSQ-061	ALEMTUZUMAB FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS: EFFECTIVENESS AND SAFETY
	5PSQ-062	EFFECTIVENESS OF ADALIMUMAB IN INFLAMMATORY BOWEL DISEASE AND INFLUENCE OF RESPONSE TO FIRSTLINE TREATMENT
	5PSQ-063	SERIOUS CELLULITIS IN A PATIENT WITH ATOPIC DERMATITIS TREATED WITH BARICITINIB: A CASE REPORT
	5PSQ-064	RELATED RISK OF BIOLOGIC DRUGS FOR CROHN’S DISEASE IN PREGNANCY: A CASE REPORT AND REVISION OF THE LITERATURE
	5PSQ-065	PREDICTION OF TOXICITY OF METHOTREXATE BY MEANS OF GENETIC TESTS IN PATIENTS DIAGNOSED WITH MODERATE-SEVERE PSORIASIS
	5PSQ-066	ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN ELDERLY ONCOLOGIC PATIENTS BY THE CHECK THE MEDS APP
	5PSQ-067	SAFETY PROFILE OF PIRFENIDONE AND NINTEDANIB IN A REAL LIFE SETTING: ASSESSMENT OF SUSPECTED ADVERSE DRUG REACTIONS IN THE EMILIA ROMAGNA REGION, ITALY
	5PSQ-068	INCIDENCE OF FUNGAL INFECTIONS IN PATIENTS TREATED WITH IXEKIZUMAB
	5PSQ-069	CONCOMITANT PRESCRIPTION OF DRUGS FOR OSTEOPOROSIS AND MEDICATION THAT INCREASE THE OF RISK FALLS
	5PSQ-070	SAFETY STRATEGIES TO IMPROVE DRUG LABELLING IN OPERATING ROOMS
	5PSQ-071	AN ADVERSE DRUG REACTION IN A PAEDIATRIC PATIENT WITH DRAVET SYNDROME: CANNABIDIOL AND VALPROATE DRUG-DRUG INTERACTION
	5PSQ-072	ADEQUACY OF ANTIDEPRESSANT MEDICATION IN ELDERLY PATIENTS
	5PSQ-073	USEFULNESS OF SALIVA IN THERAPEUTIC DRUG MONITORING OF CAFFEINE IN PRETERM INFANTS
	5PSQ-074	FAMPRIDINE RELATED ATRIAL FIBRILLATION: TWO CASE REPORTS
	5PSQ-075	SAFETY PROFILE OF FINGOLIMOD IN REAL WORLD CLINICAL PRACTICE: A PRELIMINARY STUDY
	5PSQ-076	PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A CROSS-SECTIONAL SURVEY STUDY.
	5PSQ-077	PERCEPTIONS ABOUT PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A QUALITATIVE STUDY.
	5PSQ-078	HEALTHCARE PROVIDERS' PERCEPTIONS OF PRESCRIPTION MEDICATION SHARING AMONG ADULTS IN SAUDI ARABIA: A QUALITATIVE STUDY.
	5PSQ-079	IMMUNOTHERAPY IN METASTATIC MELANOMA: A MIRACLE OR POISON
	5PSQ-080	ASSESSMENT OF DOSE PREPARATION PRACTICES FROM LIQUID ORAL FORMS BY MOTHERS OF CHILDREN HOSPITALISED IN OUR PAEDIATRIC DEPARTMENT
	5PSQ-081	THE BENEFITS-RISKS BALANCE OF LEECH THERAPY IN ONE HOSPITAL : A RETROSPECTIVE STUDY
	5PSQ-082	EVALUATING AN ELECTRONIC CLINICAL DECISION SUPPORT SYSTEM FOR DRUG-DRUG INTERACTIONS IN A LARGE ACUTE TEACHING HOSPITAL
	5PSQ-083	A SYSTEMATIC RISK ANALYSIS METHOD APPLIED TO STEAM STERILISATION PROCESS IN A TEACHING HOSPITAL
	5PSQ-084	POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN GERIATRIC HIV PATIENTS
	5PSQ-085	MEDICATION ERRORS AND PHARMACEUTICAL INTERVENTIONS FOR DRUGS ADMINISTERED BY FEEDING TUBE
	5PSQ-086	MANAGEMENT OF A CONTAMINATION EPISODE IN A PARENTERAL NUTRIENT MIXTURE PREPARATION UNIT
	5PSQ-087	SEVERE MALARIA: 3 YEAR REVIEW OF INTRAVENOUS ARTESUNATE USE IN A UNIVERSITY HOSPITAL
	5PSQ-088	MONITORING OF THE INTRODUCTION OF CHLORHEXIDINE RELEASING POLYURETHANE MEDICATION IN PILOT WARDS OF A LARGE CITY HOSPITAL
	5PSQ-089	CYTOKINE RELEASE SYNDROME REACTION: THE CLINICAL PHARMACIST IN THE CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY TEAM
	5PSQ-090	PHARMACIST'S CONTRIBUTION TO IMPROVING CUSTOMERS SATISFACTION AT HOSPITALS CARE UNITS
	5PSQ-091	ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATIONS IN CHRONIC COMPLEX PATIENTS AND IN PATIENTS WITH ADVANCED CHRONIC DISEASE IN THE EMERGENCY DEPARTMENT
	5PSQ-092	HOW DOES THE ON-SCREEN DESIGN OF ELECTRONIC PRESCRIBING SYSTEMS AFFECT SAFE PRESCRIBING? A QUALITATIVE STUDY USING A THINK ALOUD APPROACH.
	5PSQ-093	EXPLORING EYE TRACKING AS A METHOD TO STUDY USERS’ INTERACTIONS WITH A HOSPITAL ELECTRONIC PRESCRIBING SYSTEM: A DESCRIPTIVE STUDY
	5PSQ-094	HOW CAN PATIENT HELD INFORMATION ABOUT MEDICATION IMPROVE PATIENT SAFETY?
	5PSQ-095	ANALYSIS OF THE TOXICITIES ASSOCIATED WITH TYROSINE KINASE INHINITORS IN PATIENTS WITH CHRINIC MYELOID LEUKAEMIA
	5PSQ-096	HAZARD VULNERABILITY ANALYSIS TO EVALUATE RISK OF DRUG SHORTAGES ACCORDING TO THE THERAPEUTIC CLASS
	5PSQ-097	POTENTIALLY HARMFUL EXCIPIENTS IN NEONATAL AND PAEDIATRIC PATIENTS
	5PSQ-098	ALLERGIES AND INTOLERANCES: AN OPPORTUNITY FOR IMPROVEMENT
	5PSQ-099	POTENTIALLY INADEQUATE MEDICATION– DETECTED DIFFERENTLY BY PRISCUS, FORTA OR EU(7)-PIM – IS ASSOCIATED WITH REDUCED COGNITIVE FUNCTION IN MULTIMORBID ELDERLY PATIENTS
	5PSQ-100	COMPARATIVE ANALYSIS OF THE SAFETY AND TOLERABILITY PROFILE OF PIRFENIDONE AND NINTEDANIB IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
	5PSQ-101	DRUG-DRUG INTERACTIONS AND POTENTIALLY RELATED ADVERSE CLINICAL EVENTS IN PATIENTS WITH CARDIOVASCULAR DISEASES
	5PSQ-102	AMBULATORY SUBCUTANEOUS BIOLOGIC THERAPY OPTIMISATION IN RHEUMATOLOGY: IMPLEMENTATION OVER TIME
	5PSQ-103	EXPERIENCE OF ANTIFIBROTIC AGENTS IN THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS
	5PSQ-104	DESCRIPTION OF A PHARMACOVIGILANCE PROGRAMME IN A TERTIARY HOSPITAL
	5PSQ-105	PREVENTING FALLS IN ORTHOGERIATRIC PATIENTS BY MANAGING THEIR THERAPEUTIC PROFILES
	5PSQ-106	ANALYSIS OF HANDLING OF HAZARDOUS DRUGS IN A NURSING HOME
	5PSQ-107	ACTIVE PHARMACOVIGILANCE AND DEDICATED PHARMACIST: THE EXPERIENCE OF A TERRITORIAL HEALTHCARE HOSPITAL
	5PSQ-108	INFECTION WITH CLOSTRIDIUM DIFFICILE: RISK FACTORS AND PHARMACOTHERAPEUTIC MANAGEMENT
	5PSQ-109	READMISSIONS OF OLDER PATIENTS PRESENTING TO HOSPITAL WITH A FALL (RELIEF): A SYSTEMATIC REVIEW
	5PSQ-110	NUTRITIONAL ASSESSMENT IN A LONG TERM CARE FACILITY
	5PSQ-111	ADVERSE DRUG REACTIONS DUE TO MEDICINES UNDER ADDITIONAL MONITORING
	5PSQ-112	IMPACT OF HIGH TEMPERATURE AND SHAKING ON CHARGE VARIANTS OF ADALIMUMAB (HUMIRA) ASSESSED BY LIQUID CHROMATOGRAPHY COUPLED MASS SPECTROMETRY
	5PSQ-113	COMPATIBILITY AND STABILITY OF ONDANSETRON AND MIDAZOLAM MIXTURES USED IN PALLIATIVE CARE
	5PSQ-114	IMPROVING MEDICATION ADMINISTRATION FOR PATIENTS WITH DYSPHAGIA
	5PSQ-115	NEAR MISS DISPENSING ERRORS DURING WORKING HOURS IN INPATIENT DISPENSARIES AT A LARGE UK TEACHING HOSPITAL
	5PSQ-116	SAFER HANDLING OF ORAL HAZARDOUS DRUGS IN HOSPITAL UNITS
	5PSQ-117	ANALYSIS OF MEDICATION ERRORS AN ONCOLOGY SETTING USING AN INTERNAL REPORTING SYSTEMS
	5PSQ-118	DESCRIPTIVE COMPARATIVE SAFETY ANALYSIS OF PALBOCICLIB AND RIBOCICLIB IN METASTATIC BREAST CANCER HER2 NEGATIVE WITH POSITIVE HORMONAL RECEPTORS

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	PCSK9 INHIBITORS: VARIATION IN THE LIPID PROFILE IN A REAL WORLD SETTING
	6ER-002	A COMPARATIVE REVIEW OF THE IMPACT OF THE INTRODUCTION OF ON-SITE MOLECULAR TESTING ON THE MANAGEMENT OF ADULT PATIENTS HOSPITALISED WITH SUSPECTED INFLUENZA VIRUS INFECTION
	6ER-003	EFFECTIVENESS OF NEOADJUVANT TREATMENT IN LOCALLY ADVANCED BREAST CANCER
	6ER-004	PRELIMINARY CLINICAL RESPONSE OF RIBOCICLIB AS A SINGLE AGENT IN ADVANCED BREAST CANCER: IN SEARCH OF NEW THERAPEUTIC INDICATIONS
	6ER-005	EFFECTIVENESS OF OMALIZUMAB AND BEE VENOM IMMUNOTHERAPY COMBINATION: CASE REPORT
	6ER-006	DIGITAL LITERACY IN MULTIPLE SCLEROSIS
	6ER-007	PERSISTENCE AND SAFETY OF ADALIMUMAB IN PSORIASIS
	6ER-008	STUDY OF THE USE OF DIMETHYL FUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN A THIRD LEVEL HOSPITAL
	6ER-009	TREATMENT PATTERNS IN MULTIPLE SCLEROSIS WITH DISEASE MODIFYING DRUGS
	6ER-010	THERAPEUTIC DRUG MONITORING OF TUMOUR NECROSIS FACTOR a INHIBITORS IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM A REAL WORLD SETTING
	6ER-011	REAL WORLD ADHERENCE TO MULTIPLE SCLEROSIS THERAPY
	6ER-012	PERSISTENCE FOR DISEASE MODIFYING DRUGS FOR MULTIPLE SCLEROSIS
	6ER-013	ENRICHED DEVELOPMENTAL BIOLOGY MOLECULAR PATHWAYS: IMPACT ON ANTIPSYCHOTIC INDUCED WEIGHT GAIN
	6ER-014	EDUCATION OF PATIENTS RECEIVING OXYGEN THERAPY
	6ER-015	RISKS OF PHARMACIST RECOMMENDED ANTIBIOTIC USE: GENERAL PUBLIC PERCEPTION
	6ER-016	ECONOMIC VALUE OF UNUSED HIGH COST EXPERIMENTAL INFUSION DRUGS: A POTENTIAL SAVING FOR THE NATIONAL HEALTH SYSTEM
	6ER-017	DIGITAL LITERACY OF PATIENTS IN A DAY HOSPITAL ONCOLOGY UNIT
	6ER-018	THE IMPACT OF HOSPITAL PHARMACY SPECIALISATION ON THE PATIENTS’ OUTCOME: A LITERATURE REVIEW
	6ER-019	TEACHING AND LEARNING EFFECT ANALYSIS OF AN INTERPROFESSIONAL TRAINING PROGRAMME FOR UNDERGRADUATE PHARMACY INTERNS
	6ER-020	STANDARDISATION OF PROCESSES BY ELECTRONIC ASSISTED PRESCRIPTION PROGRAMME IN A UNIVERSITY PAEDIATRIC HOSPITAL
	6ER-021	DEGREE OF BURNOUT AMONG PHARMACISTS IN ISRAEL
	6ER-022	PERCEPTION OF RARE DISEASES AND ORPHAN MEDICINES
	6ER-023	THE ROLE OF INSTITUTIONAL REVIEW BOARDS, AND HOSPITAL PHARMACISTS AS MEMBERS, IN THE INFORMED CONSENT PROCESS IN CLINICAL RESEARCH: A RETROSPECTIVE OBSERVATIONAL STUDY

24th Congress of the EAHP

National Poster Prize Winners
PDF document	Poster number	Poster Title
	NP-001	PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH HIGH DOSES OF BIOTIN: PREVENTION OF SIGNIFICANT BIOLOGICAL EXAMINATION DISTURBANCES BY HOSPITAL PHARMACISTS
	NP-002	MEDICATION RECONCILIATION AND MEDICATION REVIEW IN THE UROLOGICAL-ONCOLOGICAL OUTPATIENT CLINIC
	NP-003	ANTIBIOTIC RESISTANCE IN COMMUNITY-ACQUIRED PNEUMONIA: A ROMANIAN EXPERIENCE
	NP-004	IMPLEMENTATION OF CLINICAL PHARMACY SERVICES IN LONG-TERM CARE WARDS
	NP-005	ESTIMATING RENAL FUNCTION FOR DRUG DOSING: EQUATIONS MATTER
	NP-006	EARLY DETECTION OF RETINOPATHY IN PREMATURE INFANTS USING MIXTURE OF EYE DROPS WITH 2.5% PHENYLEPHRINE HYDROCHLORIDE AND 0.5% TROPICAMIDE
	NP-007	MEDICATION ANALYSIS FOR HOSPITAL PATIENTS WITH RENAL INSUFFICIENCY: FROM DEVELOPMENT PHASE TO STANDARD PRACTICE
	NP-008	STABILITY OF CEFTOLOZANE/TAZOBACTAM IN SOLUTION AS INFUSION FOR PROLONGED OR CONTINUOUS APPLICATION
	NP-009	PATIENTS’ PERSONAL TREATMENT MANAGEMENT IN A UNIVERSITY HOSPITAL
	NP-010	WHAT IS THE EFFECT OF INTERPROFESSIONAL STUDENT PLACEMENTS IN PRIMARY CARE? A RETROSPECTIVE PRE-POST STUDY
	NP-011	MEDISCREEN: IMPLEMENTATION OF A TOOL FOR DETECTING PATIENTS AT RISK OF ADVERSE DRUG EVENTS VIA THE ELECTRONIC MEDICAL RECORD
	NP-012	STANDARDISATION OF ANALGESIA AND SEDATION INFUSION SOLUTIONS IN PAEDIATRIC PALLIATIVE PATIENTS RECEIVING END-OF-LIFE CARE AT HOME
	NP-013	IMPLEMENTING THE EUROPEAN STATEMENTS OF HOSPITAL PHARMACY IN ITALY: RESULTS OF A WORKING GROUP
	NP-014	DEVELOPMENT OF NEW PRODUCTION WHEN NEITHER PACKAGING NOR SOME OF THE RAW MATERIALS CONFORM TO EUROPEAN STANDARDS

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-001	HEALTH UTILITIES IN CHRONIC HEPATITIS C PATIENTS ONE YEAR AFTER SUCCESSFUL TREATMENT WITH DIRECT-ACTING ANTIVIRALS
	1ISG-002	BUDGETARY IMPACT OF ALIROCUMAB REPACKAGING IN A THIRD-LEVEL HOSPITAL
	1ISG-003	BIOSIMILAR GROWTH HORMONE: DEFINED DAILY DOSE IN AN ITALIAN DISTRICT AFTER THE REGIONAL TENDER
	1ISG-004	ABSTRACT WITHDRAWN
	1ISG-005	A COST EFFECTIVE STRATEGY: SWITCHING FROM ONE TO TWO TABLETS, IN A ONCE-DAILY REGIMEN IN HIV PATIENTS
	1ISG-006	HEPATITIS C TREATMENT: COST AND EFFECTIVENESS
	1ISG-007	PEMETREXED´S LESSON
	1ISG-008	FLAT DOSES OF ANTI-PD1: WHAT IS THE ECONOMIC IMPACT?
	1ISG-009	AVOIDED COST STUDY OF DRUGS IN CLINICAL TRIALS AT A TERTIARY HOSPITAL
	1ISG-010	REAL-WORLD EVIDENCE OF HIGH-COST DRUGS FOR METASTATIC MELANOMA: EFFECTIVENESS, COMPLIANCE TO CLINICAL PRACTICE GUIDELINES AND ECONOMIC EVALUATION
	1ISG-011	REDUCTION OF THE PATIENT WAITING TIME: WHAT COST FOR THE CHEMOTHERAPIES PREPARATION UNIT?
	1ISG-012	COST-EFFECTIVENESS OF AZACITIDINE IN THE REAL-WORLD: ANALYSIS IN HIGH-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM THE PERSPECTIVE OF A EUROPEAN PUBLIC HOSPITAL
	1ISG-013	BUDGET IMPACT ANALYSIS OF LUNG CANCER IMMUNOTHERAPY: A HOSPITAL PERSPECTIVE
	1ISG-014	RHEUMATOID ARTHRITIS: BIOLOGICAL DRUGS PHARMACEUTILISATION ANALISYS IN AN ITALIAN DISTRICT
	1ISG-015	OPTIMISATION OF BIOLOGICAL THERAPIES IN THE TREATMENT OF PSORIASIS
	1ISG-016	COST-EFFECTIVENESS OF MORPHINE VERSUS FENTANYL IN MANAGING VENTILATED NEONATES WITH RESPIRATORY DISTRESS SYNDROME IN THE INTENSIVE CARE SETTING
	1ISG-017	CLINICAL AND ECONOMIC EVALUATIONS OF MORPHINE AND FENTANYL WITH MECHANICAL VENTILATION IN INTENSIVE CARE SETTINGS: A SYSTEMATIC REVIEW OF METHODOLOGICAL TRENDS, AND REPORTING QUALITY
	1ISG-018	ORGANISATIONAL COMMITMENT OF HOSPITAL PHARMACISTS, RELATING TO THE SUPPORTIVE ORGANISATIONAL ENVIRONMENT
	1ISG-019	INSIGHT INTO PHARMACY AND THERAPEUTICS COMMITTEES' STRUCTURE AND ACTIVITIES AMONG HOSPITALS IN X: MIXED-METHODS APPROACH
	1ISG-020	CHEMICAL RISK ASSESSEMENT IN A QUALITY CONTROL LABORATORY BY A TOOL USING ACTIVITY ANALYSIS
	1ISG-021	A COMPREHENSIVE REGIONAL STRATEGY ADDRESSING GUIDANCE ON SAFE HANDLING OF HAZARDOUS DRUGS
	1ISG-022	FINANCIAL IMPACT OF THIRD-GENERATION CEPHALOSPORINES RESISTANCE IN HOSPITAL SETTINGS – AN EXAMPLE WITH CEFTRIAXONE
	1ISG-023	CYSTIC FIBROSIS OUTPATIENT TREATMENT COSTS: A RETROSPECTIVE ANALYSIS
	1ISG-024	BIOSIMILARS SWITCH: DO DOCTORS AND PATIENTS REVERT BACK AFTER SWITCHING?
	1ISG-025	A CONNECTED APPLICATION FOR BETTER FORMATION
	1ISG-026	ABSTRACT WITHDRAWN
	1ISG-027	INTRODUCTION OF SELF-MANAGEMENT IN A HOSPITAL PHARMACY
	1ISG-028	AN ASSESSMENT OF HOSPITAL PHARMACISTS' JOB SATISFACTION: APPLICATION OF THE JOB SATISFACTION SURVEY
	1ISG-029	IMPACT OF THE IMPLEMENTATION OF THE ENFIT SYSTEM ON THE ADMINISTRATION OF ENTERAL MEDICATION
	1ISG-030	BIOLOGICS UTILISATION AND ITS EFFICIENCY THROUGH A HOSPITAL PHARMACY CENTRALISED MANAGEMENT SYSTEM
	1ISG-031	ABSTRACT WITHDRAWN
	1ISG-032	SURGICAL SUTURE TO REDUCE NEEDLE-HOLE LEAKAGE: COMPARISON OF TWO SUTURES
	1ISG-033	INFLAMMATORY BOWEL DISEASE: BIOLOGICAL PRESCRIBING TRENDS IN AN ITALIAN HOSPITAL
	1ISG-034	A CRITICAL LOOK AT ERRONEOUS INCENTIVES AND LACKING LEGAL FRAMEWORK AS DRIVERS OF MEDICINES SHORTAGES AND OBJECTORS TO PROBLEM-SOLVING APPROACHES
	1ISG-035	URETERAL MAGNETIC CATHETER: AN EASY AND ECONOMICAL WAY TO REMOVE THE DEVICE
	1ISG-036	THE IMPACT OF HOSPITAL PHARMACY INFRASTRUCTURE AND HUMAN RESOURCES ON MEDICINES OPTIMISATION AND INTEGRATED CARE
	1ISG-037	HEALTH-RELATED QUALITY OF LIFE IN HEPATITIS C PATIENTS WHO ACHIEVE SUSTAINED VIROLOGICAL RESPONSE TO DIRECT-ACTING ANTIVIRALS: A COMPARISON WITH THE GENERAL POPULATION
	1ISG-038	CRITICAL ANALYSIS OF THE INFORMATION AND COMMUNICATION TECHNOLOGIES’ TOOLS MOST USED IN CLINICAL PRACTICE BY THE PHARMACIST
	1ISG-039	THE COST-SAVINGS POTENTIAL OF BIOSIMILAR DRUGS: A BUDGET IMPACT ANALYSIS
	1ISG-040	EMERGENCY AND DISASTER SITUATIONS : HOW ARE HOSPITAL PHARMACIES PREPARED IN EUROPE?

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-001	DESCRIBING A THICKENER HOME DELIVERY PROTOCOL AND THE BENEFITS OF ITS IMPLEMENTATION
	2SPD-002	COMPARATIVE EFFICACY OF DIMETHYLFUMARATE AND OTHER TREATMENTS FOR MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
	2SPD-003	MONITORING THE USE OF LINEZOLID IN A THIRD-LEVEL HOSPITAL
	2SPD-004	DRUG CONSUMPTION DATA FOR GUIDING ANTIBIOTIC USE RATIONALISATION IN A SURGICAL DEPARTMENT
	2SPD-005	ECONOMICAL ANALYSIS OF TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR-DISOPROXIL FURAMATE
	2SPD-006	ECONOMIC IMPACT OF INLFLIXIMAB BIOSIMILAR REFERENCING IN THE HOSPITAL
	2SPD-007	COST-MINIMISATION ANALYSIS OF LUNG CANCER PD-L1 POSITIVE TREATMENT
	2SPD-008	RISK ANALYSIS ON CYTOTOXIC CIRCUIT IN A CENTRAL PHARMACY
	2SPD-009	ANALYSIS OF OLAPARIB AND TALAZOPARIB AS POSSIBLE THERAPEUTIC ALTERNATIVES IN ADVANCED BREAST CANCER AND A GERMLINE BRCA MUTATION
	2SPD-010	INDIRECT COMPARISON OF PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN LUNG CANCER
	2SPD-011	NETWORK META-ANALYSIS OF FIRST-LINE ANTIANGIOGENIC DRUGS IN ADVANCED RENAL CELL CARCINOMA
	2SPD-012	RELATIVE VALUE UNITS AS A PRODUCTIVITY SCORE OF MANAGEMENT OF ONCOLOGY MEDICATION IN SPECIAL SITUATIONS
	2SPD-013	ECONOMIC IMPACT OF THE USE OF FLAT DOSE VS PERSONALISED DOSE OF PEMBROLIZUMAB
	2SPD-014	MULTIDISCIPLINARY STOCK MANAGEMENT AND REDUCED DISTRIBUTION OF MEDICINE UP TO A DRUG PATENT EXPIRY REDUCED EXPENSES WITHOUT COMPROMISING MEDICINE SUPPLY IN A HOSPITAL SETTING
	2SPD-015	RISK-ADAPTED MANAGEMENT OF DRUG SHORTAGES TO ENSURE PROPER CARE FOR PATIENTS IN MEDICAL NEED
	2SPD-016	BIOSIMILARS OF INFLIXIMAB AND RITUXIMAB: DOES THE INITIAL STRATEGY OF SELECTION HELP THEIR PRESCRIPTIONS?
	2SPD-017	ECHO-ENDOSCOPY : FOR A SOURCING AS SHARP AS A NEEDLE
	2SPD-018	AUDIT ON THE MANAGEMENT OF PERSONAL TREATMENT OF PATIENTS AT THE HOSPITAL
	2SPD-019	EVALUATION OF THE INTRODUCTION OF A MEDICAL DEVICE FOR MECHANICAL INDUCTION OF LABOUR IN WOMEN WITH UNFAVOURABLE CERVIX
	2SPD-020	EXPIRED MEDICINES AND MEDICAL DEVICES, AN ACROBATIC MANAGEMENT
	2SPD-021	NONCOMPLIANCE OF DATAMATRIX CODES, AN OBSTACLE TO IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE
	2SPD-022	ON THE ROAD TO SERIALISATION: A PRATICAL APPLICATION
	2SPD-023	INTEREST IN CONSIGNMENT INVENTORY MANAGEMENT OF ARTICULAR PROSTHESES AT A UNIVERSITY HOSPITAL
	2SPD-024	IMPLEMENTED STRATEGIES TO SOLVE MEDICINES SHORTAGES
	2SPD-025	OPTIMISING OF PLANNED DRUGS ORDERS AND RECEPTION PLATFORM ACTIVITY
	2SPD-026	AUTOMATED UNIT DOSE-DISPENSING DEVICE: ASSESSMENT OF THE CONTROL METHOD
	2SPD-027	MULTI-CRITERIA DECISION ANALYSIS FOR EVALUATING NEW MEDICINES IN HEALTH TECHNOLOGY ASSESSMENT FRAMEWORK ANALYSIS
	2SPD-028	OPTIMISATION OF SURGICAL PROCEDURAL-KIT SETTING
	2SPD-029	MEDICAL DEVICES MANAGEMENT: CONSUMPTION IN SURGICAL PRACTICE WITH RADIO FREQUENCY IDENTIFICATION SYSTEM
	2SPD-030	OPTIMISING INVENTORY MANAGEMENT IN A HOSPITAL PHARMACY
	2SPD-031	MANAGEMENT OF DRUG SHORTAGES IN A TERTIARY HOSPITAL
	2SPD-032	PHARMACY, CLINICAL SERVICES: COMMUNICATE WELL TO SERVE BETTER! EXAMPLE OF THE CARDIOLOGY CENTRE OF A UNIVERSITY HOSPITAL
	2SPD-033	IMPACT OF SUPPLY PROBLEMS IN A HOSPITAL PHARMACY SERVICE
	2SPD-034	DRUG SHORTAGES. ANALYSIS OF THE ECONOMIC IMPACT
	2SPD-035	MEDICINE SHORTAGES: IMPACT ON A THIRD-LEVEL HOSPITAL PHARMACY DEPARTMENT ACTIVITY
	2SPD-036	STORAGE AND DISPENSING OF SOLID ORAL DOSAGE FORMS FROM MULTIPLE UNIT CONTAINERS
	2SPD-037	OVER 5 YEARS OF MEDICINES SHORTAGES IN A UNIVERSITY HOSPITAL
	2SPD-038	HOW LONG DO HOSPITAL PHARMACISTS SPEND IN MANAGING MEDICINES SHORTAGES?
	2SPD-039	MEDICINE SHORTAGES IN A GENERAL COUNTY HOSPITAL: EVALUATION AND ESSENTIAL QUALITY
	2SPD-040	IS PNEUMATIC TUBE DELIVERY SAFE FOR MEDICINES?
	2SPD-041	DRUG SHORTAGES ANALYSIS FROM AN ITALIAN HOSPITAL PHARMACY PERSPECTIVE

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-001	MAGISTRAL FORMULATION OF 10% SUCRALFATE ENEMAS IN PROCTITIS
	3PC-002	PRELIMINARY RESULTS ON THE USE OF ORAL REHYDRATION SOLUTION IN THE FORM OF GELATO FOR REHYDRATION OF CHILDREN WITH ACUTE GASTROENTERITIS
	3PC-003	WEIGHT-LOWERING PSEUDOEPHEDRINE-BASED PRESCRIPTIONS: MONITORING PATIENT FEEDBACK AFTER UPDATE OF NATIONAL PRICE LIST OF MEDICINES AND MAGISTRAL PREPARATION
	3PC-004	WHAT HAPPENS WHEN INSULIN ASPART IS DILUTED IN DEXTROSE?
	3PC-005	STABILITY STUDY OF A 10% SODIUM BENZOATE ORAL SOLUTION
	3PC-006	ANALYSIS OF THE REGIMENS ESTABLISHED AT THE PHARMACY SERVICE FOR TOTAL PARENTERAL NUTRITION AND THE USE OF GLUTAMINE AS SOURCE OF NITROGEN
	3PC-007	IMPLEMENTATION AND QUALITY CONTROL OF A 5% FRUCTOSE AND 10% GLYCEROL STERILE SOLUTION FOR DIGESTIVE ENDOSCOPY
	3PC-008	PHYSICOCHEMICAL STABILITY OF NOREPINEPHRINE BITARTRATE IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS
	3PC-009	SUCCESSFUL TREATMENT OF HAMARTOMA IN CHILD SYNDROME AFTER 30 MONTHS WITH TOPICAL ADMINISTRATION OF SIMVASTATIN/CHOLESTEROL CREAM: A CASE REPORT
	3PC-010	STABILITY OF CHLORHEXIDINE 0.05% EYE DROPS COMPOUNDING DRUG
	3PC-011	EFFECTIVENESS OF 3% TOPICAL IMIQUIMOD IN OFF-LABEL USE FOR ORAL FLORIDA PAPILLOMATOSIS: A CASE REPORT
	3PC-012	TOPICAL CIDOFOVIR COMPOUNDING CREAM FOR THE TREATMENT OF DISSEMINATED INFECTION BY MOLLUSCUM CONTAGIOSUM
	3PC-013	FEEDBACK FROM A FEASIBILITY STUDY OF ALLERGY TEST PREPARATIONS IN DAY HOSPITALISATION
	3PC-014	STABILITY OF 1 MG/ML AND 4 MG/ML HYDROCORTISONE SOLIUM SUCCINATE SOLUTIONS IN 0.9% SODIUM CHLORIDE AND 5% GLUCOSE
	3PC-015	PHYSICOCHEMICAL STABILITY OF CEFOTAXIME IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS
	3PC-016	PHYSICOCHEMICAL STABILITY OF VANCOMYCIN HYDROCHLORIDE IN POLYPROPYLENE SYRINGES AT HIGH CONCENTRATIONS FOR INTENSIVE CARE UNITS
	3PC-017	PHYSICAL COMPATIBILITY OF INTRAVENOUS ANTI-INFECTIVE DRUGS WITH MEDICATIONS COMMONLY USED IN INTENSIVE CARE UNITS
	3PC-018	IMPLEMENTATION OF QUALITY CONTROL OF PAEDIATRIC CYTOTOXIC DRUG PREPARATIONS: PILOT TRIAL WITH ETOPOSIDE.
	3PC-019	RISK MANAGEMENT OF CROSS-CONTAMINATION OF PAEDIATRIC ANTI-CANCER PREPARATIONS USING FAILURE MODE AND EFFECTS CRITICALITY ANALYSIS
	3PC-020	NIVOLUMAB WEIGHT-BASED DOSING VS FLAT DOSE ECONOMIC ANALYSIS
	3PC-021	IMPACT OF A CENTRALISED INTRAVENOUS ADDITIVE SERVICE IN PATIENTS AND HEALTHCARE WORKERS RISK REDUCTION
	3PC-022	PRELIMINARY MICROBIOLOGICAL STUDY OF INJECTABLE CHEMOTHERAPY DOSE-BANDING
	3PC-023	A RISK ANALYSIS METHOD TO EVALUATE THE IMPACT OF A CHEMOTHERAPY COMPOUNDING WORKFLOW MANAGEMENT SYSTEM ON CANCER PATIENTS' SAFETY
	3PC-024	THE VALIDATION OF CONTROL METHOD : THE GRAVIMETRIC ANALYSIS IN CYTOTOXIC DRUG PREPARATION
	3PC-025	OPTIMISATION OF COMPOUNDING ORGANISATION AFTER IMPLEMENTING A ROBOTIC SYSTEM FOR AUTOMATED PREPARATION OF ONCOLOGIC DRUGS
	3PC-026	WHAT IS THE BEST CHEMICAL DECONTAMINATION SOLUTION FOR CONVENTIONAL ANTI-NEOPLASTIC DRUGS IN A HOSPITAL COMPOUNDING UNIT?
	3PC-027	PRODUCTIVITY ANALYSIS OF AN AUTOMATED COMPOUNDING SYSTEM FOR INTRAVENOUS CHEMOTHERAPY
	3PC-028	DOSE-BANDING GEMCITABINE AND STANDARDISATION OF CHEMOTHERAPY PROTOCOLS PRODUCTION
	3PC-029	QUALITY OF GEMCITABINE READY TO ADMINISTER PREPARATIONS
	3PC-030	PHYSICAL, CHEMICAL AND MICROBIOLOGICAL STABILITY OF SIROLIMUS 0.4% IN TOPICAL FORMULATIONS
	3PC-031	THE TRANSITION FROM THE USE OF BUPIVACAINE TO ROPIVACAINE IN THE DELIVERY ROOM, IN ORDER TO ACHIEVE A BETTER ANALGESIC EFFECT
	3PC-032	LOW-DOSE MORPHINE SOLUTION FOR SPINAL ANAESTHESIA - READY TO USE TO IMPROVE PATIENT SAFETY IN DRUG THERAPY
	3PC-033	LABELLING WITHOUT STRENGTH FOR A PHARMACEUTICAL PREPARATION USED IN A BLINDED DOSAGE ADJUSTMENT OF CLOZAPINE
	3PC-034	IMIPENEM-FORTIFIED EYE DROPS FOR THE TREATMENT OF BACTERIAL KERATITIS: DEVELOPMENT AND CHARACTERISATION
	3PC-035	GALENIC FORMULATIONS FOR OPHTALMOLOGISTS: NEW FORMULATIONS, PRESCRIBING PATHWAYS AND PATIENT INFORMATION
	3PC-036	COMPARISON OF METABOLITE LEVELS IN SERUM AND TEARS: IMPLICATIONS FOR THE DILUTION OF AUTOLOGOUS-SERUM-EYE-DROPS
	3PC-037	DEVELOPMENT OF VIRTUAL DRUG INFORMATION CENTRE FOR PHARMACY COMPOUNDING AREA
	3PC-038	ABSTRACT WITHDRAWN
	3PC-039	STABILITY STUDY OF (99MTC)DOTATOC AND (68GA)DOTATOC IN SYRINGES
	3PC-040	HEALTH HAZARDS OF RAW MATERIALS USED IN THE COMPOUNDING OF PHARMACEUTICALS FORMULATIONS
	3PC-041	AUTOMATION OF PARENTERAL NUTRITION COMPOUNDING: RESULTS OF GRAVIMETRIC QUALITY CONTROL BEFORE AND AFTER ITS IMPLEMENTATION
	3PC-042	A SCIENCE- AND RISK-BASED STRATEGY TO QUALIFY STERILISED PREFILLED SYRINGES AS PRIMARY PACKAGING MATERIAL IN A HOSPITAL PHARMACY
	3PC-043	NEW FORMULATION OF NOREPINEPHRINE SOLUTION IN PREFILLED CYCLIC OLEFIN STERILISED SYRINGES
	3PC-044	PARAFFIN OIL-BASED EMULSION: INFLUENCE OF GUM ARABIC AND THE MIXING RATE ON EMULSION STABILITY
	3PC-045	FORMULATION AND STABILITY STUDY OF EXTEMPORANEOUS ORAL LIQUID DOSAGE FORMS CONTAINING FLECAINIDE ACETATE 2MG/ML FOR PAEDIATRIC USE
	3PC-046	STUDY OF STABILITY OF TWO LIQUID FORMULATIONS OF OMEPRAZOLE ELABORATED IN THE PHARMACEUTICAL SERVICE
	3PC-047	EVALUATION OF THE EFFECTIVENESS AND SATISFACTION OF THE MASTER SUSPENSION FORMULA FOR MUCOSITIS ELABORATED IN A TERTIARY HOSPITAL
	3PC-048	ORAL MUCOADHESIVE DEXAMETHASONE 0.1% (M / M) GEL: A STRATEGY FOR MOTOR INHIBITORS MUCOSITIS
	3PC-049	MOBILE APPLICATIONS RELATED TO PARENTERAL NUTRITION: QUALITATIVE AND QUANTITATIVE ANALYSIS
	3PC-050	APPLICATION OF HAZARD VULNERABILITY ANALYSIS TO EVALUATE POTENTIAL RISKS OF PHARMACY COMPOUNDING
	3PC-051	IMPACT OF OPHTHALMOLOGICAL PREPARATIONS IN THE PHARMACY SERVICE OF A REFERENCE HOSPITAL
	3PC-052	CHEMICAL DISINFECTANTS VS STERILE WATER AND COMPOSITE FIBRE: THE EFFECT OF CLEANING METHODS ON MICROBIAL CONTAMINATION IN A CLASS A PHARMACEUTICAL COMPOUNDING ENVIRONMENT
	3PC-053	NEW FORMULATIONS FOR THE TREATMENT OF ANTINEOPLASTIC AND RADIOTHERAPY-INDUCED MUCOSITES
	3PC-054	ADDED VALUE FROM AN INFORMATION AND COMMUNICATION TECHNOLOGY-ASSISTED INTERVENTION IN A TOTAL PARENTERAL UNIT OF A PAEDIATRIC HOSPITAL PHARMACY
	3PC-055	CYTOTOXIC AGENTS: SKIN TESTS FOR THE DIAGNOSIS OF DRUG HYPERSENSITIVITY
	3PC-056	PERFORMANCE ANALYSIS OF A FULLY AUTOMATED ONCOLOGY PHARMACY PRODUCTION: A 2018 UPDATE
	3PC-057	ECONOMIC IMPACT AFTER THE IMPLEMENTATION OF A RISK MATRIX IN THE PREPARATION OF CHEMOTHERAPY
	3PC-058	ROBOTIC COMPOUNDING: SAFETY AND PRODUCTIVITY ACHIEVEMENTS IN THE PREPARATION OF HAZARDOUS DRUGS
	3PC-059	USE OF EXTEMPORANEOUS ORAL SUSPENSIONS OF OXYBUTININ AND PRAZOSINE IN NEONATES
	3PC-060	HOT-MELT RAM EXTRUSION 3D PRINTING: A SMART METHOD FOR COMPOUNDING ORODISPERSIBLE FILMS IN HOSPITAL PHARMACIES
	3PC-061	OPTIMISATION OF INTRACAMERAL CEFUROXIME CONSUMPTION IN THE PREVENTION OF POSTOPERATIVE ENDOPHTALMITIS
	3PC-062	ABSTRACT WITHDRAWN
	3PC-063	GALENIC PREPARATION OF 40% DEXTROSE GEL: NEW APPROACH TO MANAGEMENT OF NEONATAL HYPOGLYCAEMIA
	3PC-064	FEEDBACK FROM LEAN MANAGEMENT IN A STERILISATION UNIT
	3PC-065	ORODISPERSIBLE FILMS – AN INTERESTING DOSAGE FORM!
	3PC-066	PT-SMELL TEST: A NOVEL HOSPITAL COMPOUNDING AND ITS CLINICAL VALIDATION TO DIAGNOSE OLFACTORY DYSFUNCTION
	3PC-067	ABSTRACT WITHDRAWN
	3PC-068	ABSTRACT WITHDRAWN

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-001	A REVISION OF PRESCRIBING PUMP INHIBITOR PRESCRIPTIONS IN INTERNAL MEDICINE AND ADDICTOLOGY DEPARTMENT
	4CPS-002	ANALYSIS AND IMPROVEMENT OF PROFESSIONNAL PRACTICES: PRESCRIPTION’S EVALUATION OF PROTON PUMP INHIBITORS IN ORAL ROUTES
	4CPS-003	AN EVALUATION OF GASTROINTESTINAL PROPHYLAXIS IN ELDERLY PATIENTS ON ASPIRIN THERAPY
	4CPS-004	PERTINENCE OF THE PRESCRIPTION OF STRESS ULCER PROPHYLAXIS IN INTENSIVE CARE MEDICINE
	4CPS-005	GLP-1 AGONIST LIRAGLUTIDE AS ADD-ON THERAPY IN TYPE 2 DIABETES
	4CPS-006	PHARMACIST-LED MEDICINE RECONCILIATION AT DIABETES OUTPATIENT CLINIC
	4CPS-007	COST MINIMISATION STUDY: SWITCH VIAL TO PEN IN GERIATRICS
	4CPS-008	IMPACT OF PHARMACEUTICAL INTERVIEW IN PATIENT ACCEPTANCE OF INSULIN GLARGINE’S BIOSIMILAR 100UI/ML
	4CPS-009	EVALUATION OF THE SAFETY OF INHIBITORS OF THE CO-TRANSPORTER 2 IN A UNIVERSITY CARE HOSPITAL
	4CPS-010	INSULIN PRESCRIPTION ANALYSIS IN A THIRD-LEVEL HOSPITAL
	4CPS-011	PREVALENCE AND RELATIONSHIP BETWEEN HYPOVITAMINOSIS D AND INSULIN RESISTANCE IN OBESE PATIENT CANDIDATES FOR BARIATRIC SURGERY
	4CPS-012	PREVALENCE OF NUTRITIONAL COMPLICATIONS ACCORDING TO THE REQUESTED HOSPITALISATION SERVICE OF TOTAL PARENTERAL NUTRITION
	4CPS-013	ORAL ANTICOAGULANT PRESCRIPTION PRACTICE AFTER AN ISCHAEMIC STROKE
	4CPS-014	ABSTRACT WITHDRAWN
	4CPS-015	EVALUATION OF ANTICOAGULANTS MISUSE IN PATIENTS ADMITTED FOR ISCHAEMIC STROKE IN A NEUROLOGY UNIT
	4CPS-016	ABSTRACT WITHDRAWN
	4CPS-017	EVALUATION OF PHARMACISTS' INPUT IN ANTICOAGULATION CLINIC REVIEWING DIRECT ORAL ANTICOAGULANTS INITIATED IN A SECONDARY CARE HOSPITAL IN LONDON
	4CPS-018	EVALUATION OF ANTIPLATELET AGENT PRESCRIBING IN PATIENTS ON DIRECT ORAL ANTICOAGULANT
	4CPS-019	MEDICATION USE EVALUATION OF EDOXABAN IN A TERTIARY HOSPITAL
	4CPS-020	ANTICOAGULATION THERAPY IN HAEMODIALYSIS - A CLINICAL PHARMACIST EXPERIENCE IN A PRIMARY CARE TEAM
	4CPS-021	ABSTRACT WITHDRAWN
	4CPS-022	HIGH INPUT IN PATIENT SAFETY - DOCUMENTATION OF CARDIOVASCULAR SYSTEM DRUGS
	4CPS-023	SACUBITRIL/VALSARTAN (ENTRESTO) IN REAL LIFE: AN OBSERVATIONAL STUDY IN A HOSPITAL CENTRE
	4CPS-024	EFFICACY, SAFETY AND ACCEPTANCE OF TREATMENT WITH ALIROCUMAB OR EVOLOCUMAB IN PATIENTS WITH DYSLIPIDAEMIA
	4CPS-025	LIPID MODIFICATION THERAPY FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE
	4CPS-026	ADHERENCE AND EFFECTIVENESS OF PCSK9 INHIBITORS IN ROUTINE CLINICAL PRACTICE
	4CPS-027	REAL-WORLD EFFECTIVENESS OF EVOLOCUMAB AND ALIROCUMAB AT 12 MONTHS OF TREATMENT
	4CPS-028	STATIN OVERUSE? EVALUATION OF STATIN INITIATION FOR PRIMARY PREVENTION DURING HOSPITALISATION BETWEEN TWO NEIGHBOURING COUNTRIES IN EUROPE IN HIGH-RISK PATIENTS
	4CPS-029	CLINICAL EXPERIENCE OF NEW LIPID-LOWERING THERAPIES: EVOLOCUMAB AND ALIROCUMAB
	4CPS-030	ANALYSIS OF ADAPTATION TO A PROTOCOL OF USE OF THE PCSK9 INHIBITORS
	4CPS-031	THE PRIMARY EFFICACY ENDPOINT FOR ALIROCUMAB, REDUCTIONS IN LOW-DENSITY LIPOPROTEIN CHOLESTEROL
	4CPS-032	SKIN PROTECTION AND PREVENTION OF CUTANEOUS MYCOSIS
	4CPS-033	THE USE OF ORAL APREMILAST FOR THE TREATMENT OF PLAQUE PSORIASIS
	4CPS-034	USE OF USTEKINUMAB IN REFRACTORY PATIENTS OF PSORIASIS
	4CPS-035	PERSISTENCE AND SAFETY OF APREMILAST IN PSORIASIS
	4CPS-036	APREMILAST ADHERENCE IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
	4CPS-037	THE IMPACT OF MULTIDISCIPLINARY COLLABORATION IN OPTIMISING THE PRESCRIPTION OF ANTIBIOTICS IN A PAEDIATRIC HOSPITAL
	4CPS-038	QUALITY OF LIFE OF PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS UNDERGOING OUT-PATIENT TREATMENT WITH DUPILUMAB
	4CPS-039	DUPILUMAB TREATMENT DISCONTINUATION DUE TO LIMITING ADVERSE EFFECTS: A CASE REPORT
	4CPS-040	OPTIMISING OF ANTIBIOTIC PROPHYLAXIS AT CARDIAC SURGERY CLINIC
	4CPS-041	IMPLEMENTATION OF AN EMPIRICAL ANTIBIOTIC TREATMENT GUIDE: IMPACT ON ANTIOBITIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT
	4CPS-042	SWITCH FROM CLARITHROMYCIN TO AZITHROMYCIN - ONE OPTION TO OPTIMISE MACROLIDE USE THROUGH CLINICAL PHARMACISTS
	4CPS-043	EXTENSIVELY PANDRUG-RESISTANT PSEUDOMONAS AERUGINOSA INFECTIONS: ANALYSIS AND OUTCOMES
	4CPS-044	IMPACT OF CLINICAL PHARMACIST-VANCOMYCIN MONITORING ON PATIENT SAFETY OUTCOME
	4CPS-045	VALUE OF THE CLINICAL PHARMACIST IN THE PHARMACOKINETIC MONITORING OF ANTIMICROBIALS: HEALTH OUTCOMES
	4CPS-046	PHARMACEUTICAL INTERVENTIONS IN ANTIMICROBIAL TREATMENT IN A 150-BED HOSPITAL
	4CPS-047	FEASIBILITY OF PHARMACY FOLLOW-UP OF ANTIBIOTIC RE-EVALUATION IN A UNIVERSITY HOSPITAL: DAY-2 OR/AND DAY-7?
	4CPS-048	QUALITY OF THE EMPIRIC ANTIBIOTIC TREATMENT IN COMMUNITY-ACQUIRED PNEUMONIA
	4CPS-049	CEFTOBIPROLE IN EMPIRICAL TREATMENT OF BONE AND JOINT INFECTIONS: SURVEY OF THE PRESCRIPTIONS, RESPECT OF THE PROTOCOL AND ECONOMIC EVALUATION OVER 6 MONTHS
	4CPS-050	ANALYSIS OF ANTIBIOTIC ADMINISTRATION IN SURGICAL PROPHYLAXIS
	4CPS-051	ABSTRACT WITHDRAWN
	4CPS-052	FROM THE SURVEILLANCE OF ANTIBIOTICS PRESCRIPTIONS TO LIMITATION OF MULTIDRUG RESISTANT BACTERIA STRAINS: THE ROLE OF THE HOSPITAL PHARMACY IN DEFINING A CARBAPENEM-SPARING-STRATEGY
	4CPS-053	STUDY ON DAPTOMYCIN USE AS A FIRST STEP TOWARDS AN ANTIMICROBIAL STEWARDSHIP PROGRAMME
	4CPS-054	USE OF ANTIMICROBIAL AGENTS IN THE EMERGENCY DEPARTMENT IN A THIRD-LEVEL HOSPITAL
	4CPS-055	EFFICACY AND SAFETY OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF MALARIA
	4CPS-056	MAPPING ANTIBIOTIC USE PATTERNS IN A SEPTIC ORTHOPAEDIC WARD
	4CPS-057	HOW WELL IS THE TARGET CONCENTRATION OF VANCOMYCIN ACHIEVED IN INTENSIVE CARE UNIT PATIENTS?
	4CPS-058	AVOID SIMULTANEUS PRESCRIPTION BETWEEN LINEZOLID AND VORICONAZOLE: PHARMACOKINETIC STUDY
	4CPS-059	EFFECTIVENESS OF MEROPENEM TREATMENT IN CRITICAL PATIENTS: PHARMACOKINETIC STUDY
	4CPS-060	PREVALENCE OF VANCOMYCIN-RELATED NEUTROPAENIA, THROMBOCYTOPAENIA AND ACUTE KIDNEY INJURY
	4CPS-061	EXTENDED INFUSION OF MEROPENEM IN A NEONATE WITH COMPLICATED KLEBSIELLA PNEUMONIAE MENINGITIS
	4CPS-062	IMPACT OF ANTIMICROBIAL STEWARDSHIP PROGRAMME ON CARBAPENEMS RESISTANCE AND CONSUMPTION IN A TERTIARY HOSPITAL: A BEFORE-AND-AFTER INTERVENTIONAL STUDY
	4CPS-063	IMPACT OF PHARMACEUTICAL CARE IN THE RATIONAL USE OF DAPTOMYCIN
	4CPS-064	EVALUATION OF BROAD-SPECTRUM BETA-LACTAM PRESCRIPTIONS (EXCEPTCARBAPENEMS) IN THE MILITARY HOSPITAL OF INSTRUCTION MOHAMMED V RABAT
	4CPS-065	CLINICAL IMPACT EVALUATION OF IMPLEMENTING ANTIBIOTHERAPY CONTROL OF MORE THAN 7 DAYS
	4CPS-066	ADHERENCE OF PATIENTS RECEIVING ANTIBIOTIC THERAPY AFTER HOSPITALISATION
	4CPS-067	EFFECTIVENESS AND SAFETY OF THE EARLY SWITCH FROM INTRAVENOUS TO ORAL ANTIBIOTICS TREATMENT IN THE PNEUMOLOGY WARD
	4CPS-068	IMPACT OF THE PHARMACEUTICAL RECOMMENDATIONS FOR THE IMPROVEMENT IN ANTIBIOTICS PRESCRIPTION
	4CPS-069	IMPACT OF IMPLEMENTING A GLOBAL COLLABORATIVE PHYSICIAN-PHARMACIST STRATEGY ON PROPHYLACTIC ANTIBIOTIC PRACTICES IN A UNIVERSITY HOSPITAL CENTRE
	4CPS-070	DOES ANTIBIOTIC CONSUMPTION PREDICT THE INCIDENCE DENSITY OF HEALTHCARE-ASSOCIATED INFECTIONS?
	4CPS-071	SHORTAGE OF DRUGS ERA: IMPACT OF PIPERACILIN/TAZOBACTAM SHORTAGE
	4CPS-072	ABSTRACT WITHDRAWN
	4CPS-073	FOLLOW-UP OF RECOMMENDATIONS ON DOSE ADJUSTMENT OF CEFTOLOZANE/TAZOBACTAM IN RENAL FAILURE
	4CPS-074	ROLE OF THE PHARMACIST IN THE EVALUATION OF THE PRESCRIPTIVE APPROPRIATENESS IN ANTIBIOTIC THERAPY AS A “SINGLE DOSE”
	4CPS-075	CREATION OF AN INNOVATIVE AND ATTRACTIVE TRAINING PROGRAMME FOR PRESCRIBERS TO PROMOTE THE CORRECT USE OF FLUOROQUINOLONES
	4CPS-076	ENCOURAGING THE RESPONSIBLE USE OF ANTIBIOTICS: AWARENESS AND UNDERSTANDING AMONG A UNIVERSITY STUDENT POPULATION OF A COMMUNITY PHARMACY PUBLIC HEALTH CAMPAIGN IN SCOTLAND
	4CPS-077	INHALED COLISTIN AS CHRONIC SUPPRESSOR THERAPY IN PATIENTS WITH BRONCHIECTASIAS WITH NON-CYSTIC FIBROSIS
	4CPS-078	ADEQUACY OF SYSTEMATIC ANTIFUNGAL AGENT PRESCRIPTIONS IN A TEACHING HOSPITAL
	4CPS-079	PATIENT WITH COMPLICATED FUNGAL ENDOCARDITIS : A CASE REPORT
	4CPS-080	APPROPRIATE USE OF ANTIFUNGALS: IMPACT OF AN ANTIFUNGAL STEWARDSHIP PROGRAMME ON THE CLINICAL OUTCOME OF CANDIDAEMIA IN A UNIVERSITY HOSPITAL
	4CPS-081	EVALUATION OF THE STANDARD DOSAGE REGIMEN OF VORICONAZOLE IN A PAEDIATRIC AND ADULT POPULATION THROUGH THERAPEUTIC DRUG MONITORING
	4CPS-082	NEPHROGENIC DIABETES INSIPIDUS INDUCED BY LIPOSOMAL AMPHOTERICIN B: A CASE REPORT
	4CPS-083	AGING WITH HIV: OPTIMISING PHARMACOTHERAPY BEYOND INTERACTIONS
	4CPS-084	EVOLUTION OF NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS USE SINCE 2010 IN A THIRD-LEVEL HOSPITAL
	4CPS-085	STEWARDSHIPS OF HEPATITIS C VIRUS PATIENTS IN PRISONS
	4CPS-086	A FULLY INTEGRATED CLINICAL TRIAL-LIKE SYSTEM TO MANAGE AND MONITOR PERSISTENCE IN PLANNED HEPATITIS C TREATMENT
	4CPS-087	EVOLUTION OVER TIME OF ANTIRETROVIRALS
	4CPS-088	EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C
	4CPS-089	RETREATMENT OF PATIENTS WITH HEPATITIS C VIRUS INFECTION AFTER VIROLOGICAL FAILURE TO DIRECT-ACTING ANTIVIRALS
	4CPS-090	HEALTH OUTCOMES USING DIRECT-ACTING ANTIVIRAL DRUGS FOR THE TREATMENT OF PATIENTS WITH HEPATITIS C VIRUS AND F0-F1 LIVER FIBROSIS STAGE
	4CPS-091	CURRENT STATE OF RETREATMENT OF HEPATITIS C INFECTION IN PATIENTS WHOM PRIOR THERAPY FAILED IN A HEPATITIS REFERRAL CENTRE
	4CPS-092	PREVALENCE OF POLYPHARMACY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION
	4CPS-093	PERSISTENCE OF AN ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN A TERTIARY LEVEL HOSPITAL
	4CPS-094	EFFECTIVENESS OF GLECAPREVIR/PIBRENTASVIR IN REAL-WORLD CLINICAL PRACTICE FOR CHRONIC HEPATITIS C INFECTION
	4CPS-095	RESCUE OF PATIENTS INFECTED WITH HEPATITIS C VIRUS NOT RESPONDING TO INTERFERON-FREE THERAPIES
	4CPS-096	ABSTRACT WITHDRAWN
	4CPS-097	COBICISTAT INTERACTIONS WITH CHRONIC TREATMENTS
	4CPS-098	INFLUENCE OF PHARMACOLOGICAL INTERACTIONS IN HEPATITIS C TREATMENT SELECTION IN OPIATE-DEPENDENT PATIENTS
	4CPS-099	PALIVIZUMAB OFF LABEL USE IN TERTIARY REFERRAL HOSPITAL
	4CPS-100	QUALITY OF INTRATECT: IN VITRO EVALUATION OF BIOLOGICAL ACTIVITIES
	4CPS-101	INTRAVENOUS IMMUNOGLOBULINS USE FOR CHILDREN'S NEUROLOGICAL AND NEURODEVELOPMENTAL DISORDERS
	4CPS-102	MEASUREMENT OF HEALTH OUTCOMES OF POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE COMBINATION IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
	4CPS-103	EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
	4CPS-104	CHEMOTHERAPY TREATMENT IN COLORECTAL CANCER PATIENTS OLDER THAN 70 YEARS AT A TERTIARY HOSPITAL
	4CPS-105	PRESCRIBED ANTINEOPLASTIC AGENTS IN PAEDIATRIC PATIENTS
	4CPS-106	MULTI-STATE MODEL TO ESTIMATE THE OPTIMAL DURATION OF FIRST-LINE CHEMOTHERAPY IN ADVANCED GASTRIC CANCER: DATA FROM THE NATIONAL REGISTRY AGAMENON
	4CPS-107	EFFECTIVENESS AND SAFETY STUDY OF NIVOLUMAB IN THE SECOND LINE OF ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
	4CPS-108	DABRAFENIB AND TRAMETINIB: COMBINATION THERAPY FOR METASTATIC MELANOMA
	4CPS-109	POTENTIAL DRUG-DRUG INTERACTIONS INVOLVING TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA TREATED AT A UNIVERSITY HOSPITAL
	4CPS-110	SAFETY AND EFFECTIVENESS OF OBINUTUZUMAB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: OUR EXPERIENCE
	4CPS-111	TREATMENT OF FOLLICULAR LYMPHOMA IN ROUTINE CLINICAL PRACTICE.
	4CPS-112	ASSESSMENT OF AGGRESSIVE CARE IN ONCOLOGY PATIENTS AT THE END OF LIFE IN CLINICAL PRACTICE
	4CPS-113	DRUG COST SAVING RESULTING FROM METASTATIC MELANOMA CLINICAL TRIALS
	4CPS-114	DOSING OF PLATINUM AND TAXANES IN OBESE PATIENTS: A SYSTEMATIC REVIEW
	4CPS-115	RITUXIMAB IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS
	4CPS-116	VEMURAFENIB-INDUCED STEVENS-JOHNSON SYNDROME IN A PATIENT WITH METASTATIC MELANOMA: A CASE REPORT
	4CPS-117	DOSE BANDING - OPTIMISING DOSES IN CETUXIMAB OR BEVACIZUMAB REGIMENS
	4CPS-118	EXPERIENCE OF DUAL TARGETING USE OF NEOADJUVANT HER2-POSITIVE BREAST CANCER
	4CPS-119	EXPERIENCE OF NAB-PACLITAXEL AND GEMCITABINE USE IN METASTATIC PANCREATIC CANCER
	4CPS-120	ERLOTINIB IN NON-SMALL-CELL LUNG CANCER WITHOUT EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATIONS
	4CPS-121	COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPY OF ANTINEUTROPHIL CYTOPLASM ANTIBODY-ASSOCIATED VASCULITIDES
	4CPS-122	EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE
	4CPS-123	EFFICACY AND SAFETY OF COBIMETINIB USED IN MONOTHERAPY FOR ERDHEIM-CHESTER DISEASE
	4CPS-124	SAFETY AND EFFECTIVENESS OF TRASTUZUMAB EMTANSIN IN LOCALLY ADVANCED OR METASTATIC HER2 POSITIVE BREAST CANCER
	4CPS-125	TOLERANCE TO CHEMORADIOTHERAPY TREATMENT: COMPARING CAPECITABINE WITH 5-FLUOROURACIL IN NEOADJUVANT THERAPY FOR STAGE II-III RECTAL CANCER
	4CPS-126	EFFECTIVENESS AND SAFETY OF NAB-PACLITAXEL IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS, IN A REAL-WORLD SETTING
	4CPS-127	DEVELOPMENT OF A STRATIFICATION MODEL FOR AMBULATORY ONCOLOGY PHARMACY PATIENTS
	4CPS-128	ADEQUACY OF NIVOLUMAB AND PEMBROLIZUMAB IN NON-SMALL-CELL LUNG CANCER
	4CPS-129	CHEMOTHERAPY NEAR THE END OF LIFE IN ONCO-HAEMATOLOGICAL ADULT PATIENTS
	4CPS-130	PALBOCICLIB COMBINED WITH HORMONAL THERAPY FOR METASTATIC BREAST CANCER TREATMENT
	4CPS-131	RUXOLITINIB AS SALVAGE THERAPY IN PAEDIATRIAC PATIENTS WITH STEROID-REFRACTORY GRAFT-VERSUS-HOST DISEASE
	4CPS-132	INTERACTIONS BETWEEN ALTERNATIVE THERAPIES AND PRODUCTS IN CLINICAL TRIAL IN ONCO-HAEMATOLOGY
	4CPS-133	DARATUMUMAB (DARZALEX) FOR THE TREATMENT OF MULTIPLE MYELOMA IN A THIRD-LEVEL HOSPITAL: VARIABILITY OF USE AND EFFECTIVENESS
	4CPS-134	HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH DISEASE-MODIFYING THERAPIES
	4CPS-135	TERIFLUNOMIDE AND DIMETHYLFUMARATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
	4CPS-136	ANALYSIS OF THE USE OF OMALIZUMAB IN ORAL TOLERANCE INDUCTION FOR HIGH-RISK FOOD ALLERGIES IN CHILDREN
	4CPS-137	NATALIZUMAB: A REVIEW OF ITS USE IN THE MANAGEMENT OF MULTIPLE SCLEROSIS, EXPERIENCE IN A UNIVERSITY HOSPITAL
	4CPS-138	BIOSIMILARS' UTILISATION UNDER HOSPITAL PHARMACY MANAGEMENT POLICY
	4CPS-139	THE PIRAMID STUDY: PATIENTS TREATED BY MYELOMA ORAL MEDICATION HAVE A BAD COMPLIANCE
	4CPS-140	HOW PHARMACISTS CAN IMPROVE PATIENTS' CARE MANAGEMENT IN SUBCUTANEOUS ANTIPSORIATIC BIOLOGIC THERAPY
	4CPS-141	ECONOMIC IMPACT OVER THE PAST 4 YEARS ASSOCIATED WITH BIOLOGICAL THERAPY OPTIMISATION IN RHEUMATIC DISEASES PATIENTS
	4CPS-142	ADJUVANT CHEMOTHERAPY AND RELAPSE-ASSOCIATED PROGNOSTIC FACTORS IN OPERABLE BREAST CANCER
	4CPS-143	EVALUATION OF KNOWLEDGE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED BY THE REFERENCE PRODUCT CONCERNING BIOSIMILARS: ROLE OF CLINICAL PHARMACISTS
	4CPS-144	ESTABLISHMENT OF A PHARMACEUTICAL STANDARDISED INTERVIEW CONCERNING BIOSIMILARS OF INFLIXIMAB IN THE DAYCARE CLINIC OF A GASTROENTEROLOGY DEPARTMENT FOR PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE
	4CPS-145	PHARMACOGENETICS AS A TOOL IN DOSE ADJUSTMENT OF IMMUNOSUPPRESSIVE DRUGS: A CASE REPORT
	4CPS-146	SUBLINGUAL AND ENTERIC TACROLIMUS WHOLE BLOOD LEVELS IN AN INTENSIVE CARE UNIT
	4CPS-147	CLINICAL EXPERIENCE OF OPTIMISING CO-ADMINISTRATION THERAPY OF LOW-DOSE ALLOPURINOL WITH LOW-DOSE THIOPURINES IN INFLAMMATORY BOWEL DISEASE PATIENTS ATTENDING A VIRTUAL PHARMACIST CLINIC
	4CPS-148	ANALYSIS OF INTRA-PATIENT VARIABILITY OF PLASMATIC LEVELS OF TACROLIMUS IN EARLY MAINTENANCE OF RENAL POST-TRANSPLANT
	4CPS-149	EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN THE DIFFERENT PERIODS OF THE KIDNEY POST-TRANSPLANT
	4CPS-150	EVALUATION OF INTRA-PATIENT VARIABILITY OF THE TACROLIMUS PLASMATIC LEVELS IN DIFFERENT PERIODS AFTER LIVER TRANSPLANT
	4CPS-151	INFLUENCE OF THE ROUTE AND PHARMACEUTICAL PREPARATION IN INTRA-PATIENT VARIABILITY OF TACROLIMUS SERUM LEVELS IN THE LIVER TRANSPLANT PATIENT
	4CPS-152	CHEMOTHERAPY PHARMACEUTICAL CONSULTATION: PHARMACEUTICAL INTERVENTIONS AFTER 18 MONTHS OF IMPLEMENTATION
	4CPS-153	COMPARATIVE ANALYSIS BETWEEN ORIGINATOR AND BIOSIMILAR INFLIXIMAB ACCORDING TO TROUGH LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
	4CPS-154	ABSTRACT WITHDRAWN
	4CPS-155	A NEW MULTIDISCIPLINARY MODEL WITH THE CLINICAL PHARMACIST FOR MEDICATION RECONCILIATION IN THE PATIENT WITH ADVANCED RENAL DISEASE
	4CPS-156	SAFETY PROFILE OF APREMILAST IN PSORIASIS AND PSORIATIC ARTHRITIS
	4CPS-157	TUMOUR NECROSIS FACTOR INHIBITORS: UTILITY OF PHARMACOKINETICS MONITORING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT
	4CPS-158	CLINICAL BENEFIT OF INFLIXIMAB MONITORING IN INFLAMMATORY BOWEL DISEASE
	4CPS-159	PERIOPERATIVE MANAGEMENT OF ANTIRHEUMATIC MEDICATION IN REAL PRACTICE: IS MISMANAGEMENT RELATED TO POST-SURGICAL COMPLICATIONS?
	4CPS-160	EFFICACY AND SAFETY OF ANAKINRA AND CANAKINUMAB FOR THE TREATMENT OF IL-36R ANTAGONIST DEFICIENCY
	4CPS-161	SCOPING REVIEW ON THE USE OF CANAKINUMAB AND ANAKINRA IN INTERLEUKIN-1 ANTAGONIST RECEPTOR DEFICIENCY
	4CPS-162	MEDICATION COUNSELLING BY CLINICAL PHARMACISTS IN NEWLY GRAFTED RENAL TRANSPLANT RECIPIENTS
	4CPS-163	BONE METASTASIS TREATMENT IN PROSTATE CANCER: EFFICACY AND SAFETY
	4CPS-164	ORAL KETAMINE IN UNMANAGEABLE CHRONIC PAIN: A CASE REPORT
	4CPS-165	LIDOCAINE 5% PLASTER: IS IT WORTH THE PAIN?
	4CPS-166	IS THERE STILL A PLACE FOR CHLORAL HYDRATE SYRUP IN HOSPITAL?
	4CPS-167	STUDY OF THE USE OF TAPENTADOL
	4CPS-168	POSTOPERATIVE PAIN MANAGEMENT AND PAIN REFERRED BY ADULT PATIENTS 24 HOURS AFTER SURGERY AND ONE MONTH AFTER DISCHARGE
	4CPS-169	COMPARATIVE ANALYSIS OF EFFECTIVENESS BETWEEN A PATIENT-CONTROLLED ANALGESIA MORPHINE DEVICE AND A SUBLINGUAL SUFENTANIL TABLET SYSTEM
	4CPS-170	ESTIMATING THE ECONOMIC IMPACT OF PHARMACIST-LED PRESCRIPTION ORDER VALIDATION OF OPIOID PRESCRIPTIONS IN A TERTIARY UNIVERSITY HOSPITAL
	4CPS-171	THE CHOICE OF ANTIEPILEPTIC DRUG TREATMENT AFTER STATUS EPILEPTICUS
	4CPS-172	IMPACT OF MEDICATION RECONCILIATION IN PATIENTS ON ADMISSION TO AN EXPERT CENTRE FOR PARKINSON'S DISEASE
	4CPS-173	8 YEARS' EVOLUTION OF ANTIPSYCHOTICS PRESCRIPTIONS IN A MENTAL HEALTH PUBLIC INSTITUTION
	4CPS-174	A NEW BREATH FOR CLOZAPINE …
	4CPS-175	OPTIMISATION OF ANTIPSYCHOTIC TREATMENT IN A PATIENT UNDERGOING DIALYSIS: A CASE REPORT
	4CPS-176	A SYSTEMATIC REVIEW OF META-ANALYSES OF THE EFFICACY OF ORAL ANTIPSYCHOTIC LURASIDONE FOR THE TREATMENT OF ADULT PATIENTS WITH SCHIZOPHRENIAA SYSTEMATIC REVIEW OF META-ANALYSES OF THE EFFICACY OF ORAL ANTIPSYCHOTIC LURASIDONE FOR THE TREATMENT OF ADULT PA
	4CPS-177	DEALING WITH IATROGENIC CARDIAC ARREST IN PSYCHIATRY, DO NOT OVERLOOK MONITORING!
	4CPS-178	ABSTRACT WITHDRAWN
	4CPS-179	USE OF SPECIFIC DRUGS FOR DEMENTIA IN PEOPLE AT THE END OF LIFE IN NURSING HOMES
	4CPS-180	THE PRACTICE OF USING DEXMEDETOMIDINE IN A PAEDIATRIC INTENSIVE CARE UNIT: RETROSPECTIVE CHART REVIEW
	4CPS-181	EFFECTIVENESS AND SAFETY OF OMALIZUMAB IN CHRONIC IDIOPATHIC URTICARIA
	4CPS-182	EXPERIENCE WITH OMALIZUMAB IN THE TREATMENT OF UNCONTROLLED PERSISTENT ASTHMA
	4CPS-183	COLLABORATION WITH THE OPHTHALMOLOGY SERVICE IN A PUBLIC RESIDENTIAL CARE HOME
	4CPS-184	OFF-LABEL USES OF BEVACIZUMAB IN OPHTHALMOLOGY IN A MOROCCAN UNIVERSITY HOSPITAL
	4CPS-185	THE EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY IN THE MANAGEMENT OF GAUCHER DISEASE
	4CPS-186	THERAPEUTIC DRUG MONITORING OF TYROSINE KINASE INHIBITORS: KEY TO PERSONALISED MEDICINE IN ONCOLOGY
	4CPS-187	EVALUATION OF EXIT PRESCRIPTIONS USING COMPUTERISED PROVIDER ORDER-ENTRY SYSTEM FOR OUTPATIENTS
	4CPS-188	GALENIC PREPARATIONS AND RARE DISEASES: GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY: EXPERIENCE IN A LOCAL HOSPITAL
	4CPS-189	ADEQUACY OF THE PRESCRIPTION OF PARENTERAL NUTRITION IN NEONATOLOGY
	4CPS-190	RITUXIMAB USE IN CHILDREN, A SINGLE HOSPITAL EXPERIENCE
	4CPS-191	EFFECTIVENESS AND SAFETY OF RADIUM-223 CHLORIDE IN BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
	4CPS-192	IDENTIFYING MEDICATION HISTORY ERRORS AT HOSPITAL ADMISSION USING THE LUND INTEGRATED MEDICINES MANAGEMENT MODEL
	4CPS-193	A THEORETICALLY BASED CROSS-SECTIONAL SURVEY ON THE BEHAVIOURS AND EXPERIENCES OF CLINICAL PHARMACISTS CARING FOR CHRONIC KIDNEY DISEASE PATIENTS
	4CPS-194	CLINICAL IMPACT OF GENOMIC BIOMARKERS PREDICTORS OF RESPONSE AND THE THERAPEUTIC STRATEGY IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL
	4CPS-195	PHARMACIST INTERVENTIONS: THE SUCCESS OF AN ANTIMICROBIAL STEWARDSHIP TEAM
	4CPS-196	ABSTRACT WITHDRAWN
	4CPS-197	DETERMINING THE NECESSARY COMPONENTS OF A PHARMACEUTICAL CARE COMPLEXITY SCREENING TOOL: AN e-DELPHI STUDY
	4CPS-198	CLINICAL EXPERIENCE WITH DALBAVANCIN IN A TERTIARY HOSPITAL
	4CPS-199	ASSESSMENT OF MEDICATION RECONCILIATION IN CHRONIC COMPLEX PATIENTS
	4CPS-200	USE OF PROHEMOSTATIC DRUGS IN MASSIVE HAEMORRHAGE EPISODES
	4CPS-201	ACCULTURATION OF PRESCRIBERS TO RECOMMENDATIONS ON THE MANAGEMENT OF CLOSTRIDIUM DIFFICILE INFECTIONS TWO YEARS' AFTER AN ANTIMICROBIAL STEWARDSHIP PROGRAMME IN A UNIVERSITY HOSPITAL
	4CPS-202	ANTICHOLINERGICAL RISK IN CHRONIC COMPLEX PATIENTS
	4CPS-203	PHARMACOECONOMIC ANALYSIS OF THE MANAGEMENT OF GAUCHER DISEASE IN A PAEDIATRICS HOSPITAL
	4CPS-204	MEDICATION RECONCILIATION AND PHARMACOTHERAPEUTIC REVIEW IN AN ORTHOGERIATRIC UNIT OF A CENTRAL HOSPITAL
	4CPS-205	ENOXAPARIN DOSE ADJUSTMENT IN THE ELDERLY - THE INTERVENTION OF THE CLINICAL PHARMACIST
	4CPS-206	IMPACT OF PHARMACEUTICAL INTERVENTIONS IN PARENTERAL NUTRITION
	4CPS-207	SCREENING FOR PAINFUL DIABETIC NEUROPATHY
	4CPS-208	CHOOSING THE RIGHT WOUND DRESSING FOR THE RIGHT PRESSURE ULCER: THE DEVELOPMENT OF A COLOUR-BASED CHART HELPING HEALTHCARE PROVIDERS
	4CPS-209	OUTCOMES RESEARCH ON NEW TYROSINE KINASE INHIBITORS FOR NON-SMALL CELL LUNG CANCER
	4CPS-210	PATIENTS IN CLINICAL TRIALS AND THEIR TREATMENT: DID THE PRESCRIPTION SUPPORT A FIRST-LINE INFORMATION TOOL?
	4CPS-211	IMPACT OF THE ELECTRONIC PRESCRIPTION IN AN EMERGENCY DEPARTMENT
	4CPS-212	PRESCRIPTION AND ADMINISTRATION OF ORAL MEDICATION THROUGH THE JEJUNOSTOMY AND THE NASOGASTRIC TUBE IN AN INTENSIVE CARE UNIT: IMPACT OF GOOD PRACTICES GUIDELINES ON CLINICAL PRACTICE
	4CPS-213	ABSTRACT WITHDRAWN
	4CPS-214	ASSESSMENT OF THE MEDICATION ERROR RATE PRE-PRESCRIPTION DURING THE MEDICATION RECONCILIATION PROCESS
	4CPS-215	ACCESS TO ‘FONDO AIFA 5%’ AS AN INSTRUMENT SUPPORTING THE SUSTAINABILITY IN A SHARED CLINICAL MANAGEMENT OF RARE AND DIFFICULT-TO-TREAT DISEASES
	4CPS-216	PRESCRIPTION OF FALL-RISK-INCREASING DRUGS IN PATIENTS SUFFERING A FALL WITH MAJOR LESIONS DURING ADMISSION AT AN INTERMEDIATE CARE CENTRE
	4CPS-217	ASSESSING MEDICATION ADHERENCE AND CONDITION-RELATED KNOWLEDGE OF HEART FAILURE PATIENTS
	4CPS-218	ASSESSMENT OF CLINICAL PHARMACIST INTERVENTIONS IN AN INTENSIVE CARE UNIT
	4CPS-219	ANALYSIS OF PHARMACEUTICAL INTERVENTIONS IN AN EMERGENCY DEPARTMENT
	4CPS-220	THERAPEUTIC DRUG MONITORING: ARE WE GETTING IT RIGHT AND OPTIMISING THERAPY?
	4CPS-221	IMPACT OF HOSPITAL-CITY COMMUNICATION BASED ON THE MULTIPROFESSIONAL AND COLLABORATIVE DEVELOPMENT OF THE DISCHARGE LETTER ON THE CONTINUITY OF PATIENTS' MEDICATION MANAGEMENT-CITY STUDY
	4CPS-222	IMPACT OF THE ESTABLISHMENT OF THE ASSISTED ELECTRONIC PRESCRIPTION ON THE IMPROVEMENT OF THE UNIT-DOSE DRUG DISPENSATION SYSTEM
	4CPS-223	ANTICOAGULANT THERAPY IN CHRONIC COMPLEX PATIENTS WITH ATRIAL FIBRILLATION
	4CPS-224	EVALUATION OF SYSTEMIC ANTIBIOTICS AND ANTIFUNGAL USE IN AN INTENSIVE PAEDIATRIC CARE UNIT : A FIVE-YEARS STUDY IN A FRENCH UNIVERSITY HOSPITAL
	4CPS-225	THE ROLE OF CLINICAL PHARMACISTS MONITORING REGARDING THE EFFECTIVENESS AND TOLERANCE OF EXPENSIVE DRUGS PRESCRIBED OFF-LABEL
	4CPS-226	ADHERENCE TO TREATMENT IN OLDER ADULTS ADMITTED TO AN ACUTE GERIATRIC UNIT AND ASSOCIATED FACTORS
	4CPS-227	EVALUATION OF ADHERENCE TO INHALED MEDICATIONS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
	4CPS-228	AN EVALUATION OF A PHARMACIST-MANAGED PAEDIATRIC TOXICOLOGY CONSULTATION SERVICE
	4CPS-229	CLINICAL MANAGEMENT OF MALIGNANT MESOTHELIOMA IN AN ASBESTOS-ENDEMIC AREA
	4CPS-230	ABSTRACT WITHDRAWN
	4CPS-231	ABSTRACT WITHDRAWN
	4CPS-232	REORGANISATION IN HOSPITAL OUTPATIENT DRUG DELIVERY: ANY PROGRESS?
	4CPS-233	ANALYSIS OF DRUG PRESCRIPTIONS OF INCOMPATIBLE DRUGS THROUGH DRUG UTILISATION REVIEW
	4CPS-234	PHARMACIST INTERVENTIONS IN NEONATAL INTENSIVE CARE UNIT AND ASSOCIATED COST AVOIDANCE AND COST SAVINGS
	4CPS-235	PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS AS AN EARLY-ONSET ADVERSE EFFECT IN ADULT PATIENTS
	4CPS-236	THE IMPACT OF A WARD-BASED PHARMACY TECHNICIAN SERVICE
	4CPS-237	STUDY OF PATIENT SATISFACTION WITH PHARMACEUTICAL INTERVIEW IN AN OUTPATIENT ONCOLOGY MEDICAL UNIT
	4CPS-238	MEDICATION AND CONFUSION IN ACUTE HOSPITAL OLDER PATIENTS
	4CPS-239	A COMPARISON OF CLINICAL PHARMACY ACTIVITY BETWEEN TWO METHODS OF CLINICAL PHARMACY SERVICE DELIVERY IN AN ACUTE PSYCHIATRIC HOSPITAL
	4CPS-240	A QUALITATIVE STUDY ON HOW CLINICAL PHARMACISTS PREFORM MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT
	4CPS-241	DDI-PREDICTOR: A NOVEL CLINICAL PHARMACY DECISION-MAKING TOOL FOR DOSE ADAPTATION?
	4CPS-242	REGULATORY VALIDATION OF PRESCRIPTIONS AT A TEACHING HOSPITAL
	4CPS-243	EFFECTIVENESS AND USE OF OFF-LABEL TREATMENTS IN A GENERAL HOSPITAL
	4CPS-244	TIME TO PERFORM MEDICATION RECONCILIATION AT ADMISSION IN A NEUROLOGY UNIT: COMPARISON BETWEEN PROACTIVE AND RETROACTIVE PROCESSES
	4CPS-245	EVALUATION OF THE DEGREE OF ADHERENCE TO THE INTRAVENOUS TREATMENT OF AMBULATORY PATIENTS
	4CPS-246	PALATABILITY ASSESSMENT OF ORAL MEDICATION
	4CPS-247	LOCAL ASSESSMENT OF THE IMPACT OF PHARMACIST-LED MEDICATION RECONCILIATION ON HOSPITALISED ELDERLY PATIENTS
	4CPS-248	ANTIMICROBIAL POINT PREVALENCE SURVEY
	4CPS-249	IMPLEMENTATION OF AN INTEGRATED SOFTWARE FOR CLINICAL TRIALS MANAGEMENT AND AUTOMATED PREPARATION OF INVESTIGATIONAL DRUGS IN A HOSPITAL PHARMACY
	4CPS-250	INFLUENCE OF TIME AND STORAGE CONDITIONS IN THE STABILITY OF NEONATAL TOTAL PARENTERAL NUTRITION ADMIXTURES
	4CPS-251	IMPACT OF A MULTIDISCIPLINARY TEAM IN REDUCING POLYPHARMACY AND TREATMENT COMPLEXITY IN HOME CARE PATIENTS
	4CPS-252	ABSTRACT WITHDRAWN
	4CPS-253	COMMUNITY PHARMACY-BASED eGFR SCREENING FOR EARLY DETECTION OF CHRONIC KIDNEY DISEASE IN HIGH-RISK PATIENTS
	4CPS-254	BIOSIMILAR RITUXIMAB - A YEAR BEYOND
	4CPS-255	THE EFFECT OF AN ENHANCING MEDICATION ADHERENCE PROGRAMME FOR A TYPE 2 DIABETES MELLITUS NETWORK
	4CPS-256	LINEZOLID USAGE AND COST ANALYSISAFTER A HOSPITAL TRANSFER
	4CPS-257	DETERMINING FACTORS AFFECTING PATIENTS’ CLARITY ON DISPENSED MEDICATION INSTRUCTIONS: A CASE STUDY AT COPPERBELT UNIVERSITY HEALTH FACILITY IN KITWE, ZAMBIA
	4CPS-258	IMPACT OF A TEAM OF CLINICAL PHARMACISTS IN A PAEDIATRIC SURGERY UNIT: RESULTS AFTER 6 MONTHS
	4CPS-259	EVALUATION OF PATIENTS', DOCTORS' AND COMMUNITY PHARMACISTS' SATISFACTION CONCERNING PHARMACEUTICAL CONSULTATIONS FOR PATIENTS RECEIVING ORAL ANTI-CANCER DRUGS
	4CPS-260	PRE-ANAESTHESIA BEST POSSIBLE MEDICATION HISTORY FOR ORTHOPAEDIC SURGERY-PROGRAMMED PATIENTS
	4CPS-261	ANALYSIS OF THE METHODOLOGY TO COMMUNICATE POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN INPATIENTS TO AN INTERNAL MEDICINE SERVICE OF A THIRD-LEVEL HOSPITAL
	4CPS-262	PLACE OF CLINICAL PHARMACIST IN THE MANAGEMENT OF PATIENTS UNDERGOING BARIATRIC SURGERY
	4CPS-263	ANALYSIS OF CLINICAL PHARMACIST INTERVENTIONS CARRIED OUT IN AN INTENSIVE CARE UNIT
	4CPS-264	ANALYSIS OF THE DISCREPANCIES FOUND IN THE RECONCILIATION OF CONCOMITANT MEDICATION IN A COHORT OF ELDERLY PATIENTS INFECTED WITH HIV
	4CPS-265	EFFECT OF DEDICATED PHARMACIST INTERVENTION IN NEUROCRITICAL CARE UNIT: BEFORE AND AFTER PARTICIPATING IN MULTIDISCIPLINARY ROUNDS
	4CPS-266	Clone of ANALYSIS OF AN EPIDEMIOLOGICAL MODEL FOR THE TREATMENT OF HEPATITIS C VIRUS IN CO-INFECTED HIV/HCV DRUG ADDICTIONS VIA PARENTERAL
	4CPS-266	ANALYSIS OF AN EPIDEMIOLOGICAL MODEL FOR THE TREATMENT OF HEPATITIS C VIRUS IN CO-INFECTED HIV/HCV DRUG ADDICTIONS VIA PARENTERAL
	4CPS-267	LACK OF HEPATITIS C VIRUS UPTAKE IN HIV/HCV CO-INFECTED PATIENTS
	4CPS-268	EVALUATION OF THE SATISFACTION OF THE IMPLEMENTATION OF A PHARMACEUTICAL LETTER OF HOSPITAL DISCHARGE TRANSMITTED TO PATIENTS AND COMMUNITY HEALTH PROFESSIONALS
	4CPS-269	ARE PATIENTS AND HEALTHCARE PROFESSIONALS WILLING TO EXCHANGE ON THE PRICE OF TREATMENTS TO CHOOSE A BIOSIMILAR? EXPERIENCE BASED ON THE DELPHI METHOD
	4CPS-270	A SIMULATION PILOT STUDY OF HEALTH OPTIMISATION FOR PATIENTS WITH BIPOLAR DISORDERS: AN EMERGING ROLE FOR CLINICAL PHARMACISTS AS DECISION COACHES
	4CPS-271	DEVELOPMENT OF PHARMACIST MEDICATION REVIEW IN PAEDIATRIC DISCHARGE PROCESS
	4CPS-272	ANALYSIS OF ADVERSE REACTION REPORTS BEFORE AND AFTER THE USE OF EQUIVALENT IMATINIB IN A TERTIARY HOSPITAL
	4CPS-273	PHARMACY INTERVENTION AND DRUG PRESCRIPTION REGULATIONS IN A TERTIARY HOSPITAL
	4CPS-274	ABSTRACT WITHDRAWN
	4CPS-275	A SYSTEMATIC REVIEW OF PHARMACIST INPUT IN THE SCREENING, MANAGEMENT AND PREVENTION OF METABOLIC SYNDROME
	4CPS-276	ANTIMICROBIAL STEWARDSHIP PROGRAMME IMPLEMENTATION IN THE GULF COOPERATION COUNCIL STATES: A SYSTEMATIC REVIEW
	4CPS-277	ABSTRACT WITHDRAWN
	4CPS-278	ABSTRACT WITHDRAWN
	4CPS-279	THE EFFECT OF CONTINUATION OF HOME MEDICATION BY HOSPITALISED PATIENTS ON MEDICATION WASTE AND PATIENT SATISFACTION, A MULTICENTRE, QUASI-EXPERIMENTAL STUDY WITH A PRE-POST DESIGN
	4CPS-280	DOES PLATELET-RICH PLASMA COMPOSITION MATTER IN HIP OSTEOARTHRITIS?
	4CPS-281	A COMPARATIVE STUDY OF THE SATISFACTION OF CLIENTS WITH THE SERVICES OF AN OUTPATIENT PHARMACY IN A TERTIARY HOSPITAL
	4CPS-282	ABSTRACT WITHDRAWN
	4CPS-283	ABSTRACT WITHDRAWN
	4CPS-284	BINARY LOGISTIC REGRESSION ANALYSIS TO EVALUATE THE INFLUENCE OF DIFFERENT BASAL FACTORS ON THE EFFECTIVENESS OF LEDIPASVIR/SOFOSBUVIR

Section 5: Patient Safety and Quality Assurance
PDF document	Poster number	Poster Title
	5PSQ-001	EFFICACY OF OBETICHOLIC ACID IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID
	5PSQ-002	IATROGENIC HYPOGLYCAEMIA: FREQUENCY AND IMPACT ON QUALITY OF LIFE AMONG TYPE 2 DIABETES MELLITUS PATIENTS
	5PSQ-003	A QUALITATIVE ANALYSIS OF BARRIERS TO MEDICATION ADHERENCE IN UNCONTROLLED DIABETES – FOCUS ON INSULIN AND SUGGESTIONS FOR PRACTICE IMPROVEMENTS
	5PSQ-004	OBSERVATIONAL STUDY OF THE EVOLUTION OF BLOOD GLUCOSE LEVELS AFTER THE CHANGE TO INSULIN DEGLUDEC
	5PSQ-005	SAFETY AND EFFICACY OF FAST-ACTING INSULIN ADDED TO TOTAL PARENTERAL NUTRITION
	5PSQ-006	USE OF SUBSTITUTE ENZYMATIC TREATMENT AND SUBSTRATE REDUCTION IN GAUCHER DISEASE
	5PSQ-007	SEBELIPASE ALFA AS ENZYME REPLACEMENT THERAPY IN THREE PAEDRIATRIC PATIENTS
	5PSQ-008	CYP2C19 SNP´S INFLUENCE ON CLOPIDOGREL RESPONSE IN PERIPHERAL ARTERY DISEASE PATIENTS
	5PSQ-009	CYP2C19 SNP´S INFLUENCE ON CLOPIDOGREL RESPONSE IN CEREBROVASCULAR DISEASE PATIENTS: FINAL RESULTS
	5PSQ-010	MANIPULATION OF WARFARIN TABLETS IN PAEDIATRIC CARE: DO WE GIVE THE RIGHT DOSE?
	5PSQ-011	VENOUS THROMBOEMBOLIC EVENTS AND TOTAL HIP OR KNEE ARTHROPLASTY: INCIDENCE AND ASSOCIATED FACTORS
	5PSQ-012	IMPACT OF THERAPEUTIC PATIENT EDUCATION IN THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER
	5PSQ-013	PRESCRIPTIONS OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS ADMITTED
	5PSQ-014	NOVEL ORAL ANTICOAGULANTS VS VITAMIN K ANTAGONISTS: A COST ANALYSIS
	5PSQ-015	DRUG INTERACTION BETWEEN NOACs AND ITRACONAZOLE: AN ITALIAN DISTRICT ANALYSIS
	5PSQ-016	UNFAVOURABLE OUTCOMES OF BLOOD TRANSFUSIONS IN HOSPITALISED ANAEMIC PATIENTS
	5PSQ-017	IMPLEMENTATION AND MONITORING OF A PROTOCOL FOR THE USE OF INTRAVENOUS IRON
	5PSQ-018	IMPLEMENTATION OF PARENTERAL NUTRITION PRESCRIBING SOFTWARE IN A NEONATAL INTENSIVE CARE UNIT
	5PSQ-019	SWITCHING FROM INDIVIDUALISED NUTRITION TO STANDARDISED OR COMMERCIALISED NUTRITION IN NEWBORNS: ARE THERE ANY POSSIBILITIES?
	5PSQ-020	SAFETY EVALUATION OF INJECTABLE POTASSIUM CHLORIDE PRESCRIPTIONS IN HOSPITAL
	5PSQ-021	PHARMACOGENETIC TESTING FOR PERSONALISATION OF STATIN THERAPY
	5PSQ-022	AN EVALUATION OF THE PHARMACIST INTERVENTION IN INTRAVENOUS MIXTURES' STABILITY
	5PSQ-023	ADEQUATE DIGOXIN DOSAGE IN PATIENTS WITH DIGITALIS TOXICITY
	5PSQ-024	MEDICATION ERRORS - A CAUSE FOR MAJOR CARDIOVASCULAR EVENTS IN AN EMERGENCY DEPARTMENT
	5PSQ-025	PULMONARY ARTERIAL HYPERTENSION DRUGS: EPIDEMIOLOGICAL ANALYSIS CONCERNING AN ITALIAN DISTRICT
	5PSQ-026	IMPACT OF A SAFETY ALERT WITH VALSARTAN IN A HEALTH MANAGEMENT AREA
	5PSQ-027	EFFECTIVENESS AND SAFETY OF TOLVAPTAN AND UREA FOR THE TREATMENT OF SEVERE SYMPTOMATIC HYPONATRAEMIA: A CASE SERIES
	5PSQ-028	THE GOVERNANCE OF PCSK9-INHIBITORS FOR THE TREATMENT OF PRIMARY HYPERCHOLESTEROLAEMIA: APPROPRIATENESS ANALYSIS
	5PSQ-029	EFFECTIVENESS AND SAFETY OF EVOLOCUMAB IN REAL CLINICAL PRACTICE
	5PSQ-030	DO WE KNOW WHICH ANTIBIOTICS SHOULD BE AVOIDED IN OUR PATIENTS? ANTIBIOTIC ALLERGY SURVEY AMONG HOSPITALISED PATIENTS
	5PSQ-031	A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS
	5PSQ-032	ADMINISTRATION PROTOCOL FOR PENICILLIN G IN A PATIENT WITH A SEVERE REACTION TO BETALACTAMS AND ABDOMINAL ACTINOMYCOSIS
	5PSQ-033	EFFECTIVENESS OF COMPUTERISED DECISION SUPPORT SYSTEM-BASED INTERVENTION IN ANTIMICROBIAL USE: THE HIGEA PROJECT
	5PSQ-034	LINEZOLID AND SEROTONIN SYNDROME
	5PSQ-035	ANALYSIS OF THE MEDICATION TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA TREATED IN THE COMMUNITY AND HAVING RESULTED IN HOSPITALISATION
	5PSQ-036	POLYPHARMACY AND DEPRESCRIBING IN HIV-INFECTED ELDERLY POPULATION
	5PSQ-037	ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS POSTEXPOSURE PROPHYLAXIS IN A THIRD-LEVEL HOSPITAL
	5PSQ-038	SAFETY AND EFFECTIVENESS OF HIV POST-EXPOSURE PROPHYLAXIS
	5PSQ-039	GLECAPREVIR/PIBRENTASVIR ASSOCIATION FOR CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS IN HEALTH
	5PSQ-040	REAL-LIFE DIRECT-ACTING ANTIVIRALS EFFECTIVENESS COMPARATIVE STUDY IN HIV-HEPATITIS C VIRUS COINFECTED PATIENTS
	5PSQ-041	EFFICACY AND SAFETY OF CIDOFOVIR IN THE TREATMENT OF LARYNGEAL PAPILLOMATOSIS: CASE REPORTS
	5PSQ-042	MODIFICATION ON FASTING LIPID AND RENAL PARAMETERS IN PATIENTS SWITCHING FROM TENOFOVIR DISOPROXIL TO TENOFOVIR ALAFENAMIDE
	5PSQ-043	COMORBIDITIES, POLYPHARMACY AND ADHERENCE IN GERIATRIC HIV PATIENTS
	5PSQ-044	ASEPTIC MENINGITIS INDUCED BY INTRAVENOUS IMMUNOGLOBULIN
	5PSQ-045	SAFETY PROFILE OF SUNITINIB IN REAL CLINICAL PRACTICE
	5PSQ-046	EFFICACY AND SAFETY OF PANITUMUMAB IN METASTATIC COLORECTAL CANCER TREATMENT
	5PSQ-047	NIVOLUMAB FLAT DOSE, CLINICAL-ETHICAL AND ECONOMIC IMPLICATIONS
	5PSQ-048	REAL-WORLD SAFETY AND TOLERABILITY OF THE RECENTLY COMMERZIALISED PALBOCICLIB
	5PSQ-049	ATEZOLIZUMAB: EFFICACY AND SAFETY IN ADVANCED NON-SMALL CELL LUNG CANCER
	5PSQ-050	TOXICITY WITH 5-FLUOROURACIL AND IRINOTECAN: INTEREST OF GENOTYPING IN PATIENT CARE
	5PSQ-051	ANALYSIS OF CARDIOVASCULAR EVENTS ASSOCIATED WITH CARFILZOMIB IN PATIENTS WITH MULTIPLE REFRACTORY MYELOMA
	5PSQ-052	THE ERROR ROOM: A FUN TRAINING TOOL FOR THE PHARMACEUTICAL CHEMOTHERAPY UNIT
	5PSQ-053	ADAPTATION OF PROPHYLAXIS AGAINST VARICELLA-ZOSTER VIRUS IN PATIENTS WITH MULTIPLE MYELOMA
	5PSQ-054	NIVOLUMAB IN LUNG CANCER: FROM WEIGHT-BASED TO FLAT DOSING
	5PSQ-055	DOES PALBOCICLIB MEAN NEUTROPAENIA?
	5PSQ-056	SAFETY BETWEEN THE USE OF COMMERCIAL AND GENERIC IMATINIB: IS THE EXCIPIENT RELEVANT?
	5PSQ-057	OLAPARIB AND NIRAPARIB SAFETY PROFILE IN THE CLINICAL PRACTICE OF A TERTIARY-LEVEL HOSPITAL
	5PSQ-058	MEASURING ADHERENCE TO EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES FOR PATIENTS TREATED WITH TRASTUZUMAB
	5PSQ-059	CYCLIN DEPENDENT KINASES 4/6 INHIBITORS: NEW OPTIONS IN HR+ HER2- BREAST CANCER
	5PSQ-060	IMMUNOTHERAPY AND TOXICITY: EXPERIENCE IN A THIRD-LEVEL HOSPITAL
	5PSQ-061	DETERMINATION OF GENETIC POLYMORPHISMS OF THE DIHYDROPYRIMIDINE DEHYDROGENASE GENE IN REAL CLINICAL PRACTICE: POSOLOGICAL INDIVIDUALISATION
	5PSQ-062	RALTITREXED AS AN END-OF-LIFE TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER
	5PSQ-063	MORE RISK OF NEUTROPAENIA IN OBESE PATIENTS TREATED WITH PACLITAXEL?
	5PSQ-064	INTENSIVE MONITORING OF AFATINIB – CASE REPORT
	5PSQ-065	MANIC SYMPTOMATOLOGY INDUCED BY ALECTINIB: A CASE REPORT
	5PSQ-066	THE OTHER SIDE OF IMMUNOTHERAPY: SAFETY AND TOXICITY MANAGEMENT IN CLINICAL PRACTICE
	5PSQ-067	DETECTION OF ADVERSE NEUROPSYCHIATRIC REACTIONS ASSOCIATED WITH ABIRATERONE AND ENZALUTAMIDE TREATMENTS IN THE HOSPITAL
	5PSQ-068	ADHERENCE TO DISEASE-MODIFYING THERAPIES IN SPANISH PATIENTS WITH MULTIPLE SCLEROSIS
	5PSQ-069	ABSTRACT WITHDRAWN
	5PSQ-070	INFLUENCE OF PATHOLOGY IN INJECTION PAIN REDUCTION WITH A NEW FORMULATION OF ORIGINAL ADALIMUMAB
	5PSQ-071	EVALUATION OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
	5PSQ-072	ACUTE PROMYELOCYTIC LEUKAEMIA AFTER INFLIXIMAB THERAPY IN A CROHN'S DISEASE PATIENT: A CASE REPORT AND A REVIEW OF THE LITERATURE
	5PSQ-073	MUCORMYCOSIS INDUCED BY INAPPROPIATE USE OF ORAL CORTICOIDS – A CASE REPORT
	5PSQ-074	CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER AND SECONDARY AMYLOIDOSIS: A CASE REPORT
	5PSQ-075	INTRODUCTION OF BIOSIMILAR ETANERCEPT: AN ITALIAN DISTRICT ANALYSIS
	5PSQ-076	SWITCHING BIOLOGIC TREATMENTS: EXPERIENCE OF A REGIONAL HOSPITAL
	5PSQ-077	COST-EFFECTIVENESS OF BIOSIMILAR ETANERCEPT IN CLINICAL PRACTICE USE
	5PSQ-078	MORPHINE OVERDOSE FROM ERROR INFUSION RATE WITH INTRAVENOUS PUMP: FEEDBACK EXPERIENCE AND ACTION PLAN
	5PSQ-079	THE USE OF FENTANYL SUBLINGUAL TABLETS IN A HOSPITAL
	5PSQ-080	A STUDY ON RISK FACTORS ELICITING OPIOID ADVERSE REACTIONS IN ELDERLY MALES
	5PSQ-081	Δ-9-TETRAHYDROCANNABINOL(SATIVEX) FOR THE TREATMENT OF MULTIPLE SCLEROSIS SPASTICITY: EVALUATION OF EFFECTIVENESS AND SAFETY
	5PSQ-082	ABSTRACT WITHDRAWN
	5PSQ-083	DEVELOPMENT AND VALIDATION OF QUALITY INDICATORS FOR BENZODIAZEPINE USE IN GENERAL AND MENTAL HEALTH HOSPITALS: SHORTCOMINGS OF AVAILABLE REIMBURSEMENT DATA
	5PSQ-084	RISK OF QT INTERVAL PROLONGATION IN OLDER PATIENTS
	5PSQ-085	METABOLIC DISORDERS IN PATIENTS TREATED WITH SECOND-GENERATION ANTIPSYCHOTICS: AN OPPORTUNITY FOR PHARMACEUTICAL INTERVENTION
	5PSQ-086	PREVALENCE OF ASPIRATION PNEUMONIA FOLLOWING ANTIPSYCHOTICS: A LARGE POPULATION STUDY
	5PSQ-087	INAPPROPIATE USE OF HYDROXYCINE
	5PSQ-088	DEVELOPMENT OF ALZHEIMER'S DISEASE AND EXPOSITION TO BENZODIAZEPINES: A COHORT STUDY IN A HEALTH REGION OF CATALONIA BETWEEN 2002 AND 2015
	5PSQ-089	PREVALENCE OF PRESCRIPTION OF ANTIPSYCHOTIC POLYPHARMACY IN A PSYCHIATRIC HOSPITAL
	5PSQ-090	ANTICHOLINERGIC DRUGS AND ACETYLCHOLINESTERASE INHIBITORS: A NON-RECOMMENDED COMBINATION
	5PSQ-091	ASTHMA IN THE MOROCCAN POPULATION
	5PSQ-092	PROFILE AND COMPLEXITY LEVEL OF CLINICAL TRIALS IN THE PHARMACY SERVICE
	5PSQ-093	CHARACTERISATION OF PRE-FILLED SYRINGE USE IN AN ACUTE CARE SETTING: COSTS AND ADVANTAGES
	5PSQ-094	USE OF EXCIPIENTS IN ORAL LIQUID COMMERCIAL MEDICINES IN A CHILDREN'S HOSPITAL
	5PSQ-095	ABSTRACT WITHDRAWN
	5PSQ-096	KEY STAKEHOLDERS, PERSPECTIVES ON MEDICATION SAFETY PRACTICES AND ERROR REPORTING IN QATAR - AN EXPLORATORY SEQUENTIAL MIXED-METHOD STUDY
	5PSQ-097	TRIPLE WHAMMY INTERACTION: IMPROVING PATIENTS´ SAFETY
	5PSQ-098	USING A CUSTOMISED MEDICATION VERIFICATION TOOL ON ADMISSION TO HOSPITAL IN PSYCHIATRIC PATIENTS TO REDUCE CLINICALLY RELEVANT MEDICATION DISCREPANCIES
	5PSQ-099	IMPACT OF ROBOTICS ON PATIENT SAFETY AND PRODUCTIVITY
	5PSQ-100	PUBLIC PERCEPTIONS AND CONCERNS INCLUDING MEDICATION AWARENESS IN LIFESTYLE HEALTH CAMPAIGNS
	5PSQ-101	LESS-CHRON FOR DEPRESCRIBING IN NURSING HOME RESIDENTS
	5PSQ-102	ANTIMICROBIAL TREATMENT INADEQUACY IN AN EMERGENCY DEPARTMENT
	5PSQ-103	PHARMACOLOGICAL STUDY OF HIV PATIENTS ENTERED INTO THE HOSPITAL
	5PSQ-104	INVESTIGATING ERROR REPORTING RATES BY ALL PHARMACY STAFF IN THE PHARMACY DEPARTMENT OF A GENERAL HOSPITAL
	5PSQ-105	EFFECTIVENESS AND TOXICITY PROFILE ANALYSIS OF ANTIFIBROTIC AGENTS IN IDIOPATHIC PULMONARY FIBROSIS
	5PSQ-106	FOCUSING AUDITS ON PATIENT SAFETY
	5PSQ-107	ASPIRIN AND NOVEL ORAL ANTICOAGULANTS: REPORTING OF ADVERSE DRUG REACTIONS
	5PSQ-108	PROCEDURE FOR PAEDIATRIC EMERGENCY AND RESULTS OF A SURVEY ON USE
	5PSQ-109	ABSTRACT WITHDRAWN
	5PSQ-110	COMPUTERISED PHYSICIAN ORDER ENTRY SYSTEMS AND RELATED CLINICAL DECISION SUPPORT TOOLS IN INPATIENT CARE – BARRIERS OF COST-EFFECTIVENESS
	5PSQ-111	EVALUATION OF THE FORM'S QUALITY OF MEDICAL PRESCRIPTIONS FROM PUBLIC HOSPITALS AND PRIVATE CLINICS
	5PSQ-112	RISK ASSESSMENT OF ELEMENTAL IMPURTIES FOR MANUFACTURING THE DRUG SUBSTANCE (ICH Q3D)
	5PSQ-113	HOW TO SECURE MEDICATION SELF-MANAGEMENT IN HOSPITALISED POSTPARTUM WOMEN?
	5PSQ-114	EVALUATION OF PHARMACEUTICAL INTERVENTIONS PERFORMED ON MEDICATION ERRORS DETECTED IN THE PRESCRIPTION
	5PSQ-115	"PATIENT EXPERIENCE" FOR IMPROVING PATIENT CLINICAL PATHWAYS IN AN ONCOLOGY DAY HOSPITAL
	5PSQ-116	ANALYSIS AND EVALUATION OF A RENAL FUNCTION-BASED DOSAGE ADJUSTMENT SYSTEM AT A UNIVERSITY HOSPITAL
	5PSQ-117	PREVENTING MEDICATION ERRORS REGARDING HIGH-ALERT MEDICATION
	5PSQ-118	SURVEILLANCE AND MONITORING OF PATIENT FALLS IN A HOSPITAL SETTING BY THE HOSPITAL PHARMACIST: FOCUS ON PATIENT-RELATED RISK FACTORS AND DRUG THERAPY
	5PSQ-119	A PRELIMINARY SURVEY ON DAILY DRUG INTAKE IN OLDER PATIENTS IN COMPLIANCE WITH EAHP POLICY STATEMENT ON AN AGEING SOCIETY
	5PSQ-120	APPLICATION OF INTERNATIONAL GERIATRIC CRITERIA ACCORDING TO EAHP POLICY STATEMENT ON AN AGEING SOCIETY
	5PSQ-121	QUALITY ASSESSMENT WITHIN FRENCH FIRE AND RESCUE SERVICES PHARMACIES IN THE NORTH OF FRANCE: DEVELOPMENT AND EVALUATION OF A SELF-ASSESSMENT TOOL
	5PSQ-122	PERIPHERIC INTRAVENOUS PERFUSION IN ANAESTHESIA: SECURING MEDICAL TREATMENT IS ALSO ABOUT THE PROPER USE OF MEDICAL DEVICES
	5PSQ-123	FAILURE MODES, EFFECTS AND CRITICALITY ANALYSIS: APPLICATION TO A HOSPITAL PHARMACY
	5PSQ-124	ABSTRACT WITHDRAWN
	5PSQ-125	QUALITY AND RISK MANAGEMENT IN HOSPITALS : EVALUATION OF IMPLANTABLE MEDICAL DEVICES’ TRACEABILITY PROCESS
	5PSQ-126	MEDICATIONS AND FALLS IN THE ELDERLY: AN EPIDEMIOLOGICAL STUDY IN A FRENCH HOSPITAL
	5PSQ-127	DISPENSATION OF FINITE MEDICATION AT DISCHARGE IN THE COMPLEX CHRONIC PATIENT
	5PSQ-128	PHARMACOTHERAPEUTIC PROFILE AND RISK OF DRUG-RELATED PROBLEMS AND DRUG INTERACTIONS IN HIV+ PATIENTS OF A HEALTH AREA
	5PSQ-129	BALANCE AND CLASSIFICATION OF PHARMACEUTICAL INTERVENTIONS IN A GENERAL HOSPITAL OF SPECIALTIES: THE PERSONALISED HOSPITAL PHARMACY
	5PSQ-130	ANALYSIS OF RITUXIMAB OFF-LABEL USE
	5PSQ-131	PHARMACOVIGILANCE 2018: SURVEY ON THE PERCEPTION OF PHARMACOVIGILANCE IN THE HOSPITAL - TOOLS TO ENHANCE ADVERSE DRUG REACTIONS REPORTING
	5PSQ-132	ASSOCIATION BETWEEN ANTICHOLINERGIC BURDEN OF MEDICATIONS AND MORTALITY IN OLDER ADULTS: A SYSTEMATIC REVIEW
	5PSQ-133	DRUG-RELATED HOSPITAL ADMISSIONS IN AN ACUTE GERIATRIC UNIT AND ASSOCIATED FACTORS
	5PSQ-134	ANALYSIS OF MEDICATION DISCREPANCIES AS PART OF THE CLINICAL PHARMACY MEDICATION RECONCILIATION PROCESS
	5PSQ-135	SAFETY RELATED TO PSYCHOGERIATRIC PATIENTS. ONE-YEAR PROSPECTIVE STUDY
	5PSQ-136	A PHARMACEUTICAL CARE PROGRAMME IN PATIENTS UNDERGOING CARDIAC SURGERY
	5PSQ-137	WHEN IS A DRUG INTERACTION NOT A DRUG INTERACTION? COMPARISON OF DRUG-DRUG INTERACTIONS-CHECKING DATABASES BETWEEN THE UK AND USA
	5PSQ-138	REVIEW OF MEDICATION ERRORS IN A PAEDIATRIC HOSPITAL BASED ON AN INSTITUTIONAL REPORTING SYSTEM
	5PSQ-139	ORTHOPAEDIC IMPLANT RESUPPLY CHAIN: BETTER, FASTER, STRONGER!
	5PSQ-140	THE COMMUNICATION PROCESS BETWEEN PHARMACY AND OTHER DEPARTMENTS AND WARDS IN AN ACUTE HOSPITAL
	5PSQ-141	POLYPHARMACY AND TRANSCATHETER AORTIC VALVE IMPLANTATION
	5PSQ-142	RISK FACTORS FOR HYPONATRAEMIA IN ELDERLY PATIENTS, BEYOND PHARMACOLOGICAL ADVERSE EFFECTS
	5PSQ-143	PREVALENCE OF POTENTIALLY INAPPROPRIATE PRESCRIPTIONS IN INSTITUTIONALISED AND NON-INSTITUTIONALISED ELDERLY PATIENTS
	5PSQ-144	MEDICATION RECONCILIATION PROGRAMME PERFORMED IN A GENERAL AND DIGESTIVE SURGERY SERVICE
	5PSQ-145	SEVERITY OF MEDICATION RECONCILIATION ERRORS IN ELDERLY PATIENTS PRODUCED IN THE EMERGENCY DEPARTMENT
	5PSQ-146	DRUGS INTERACTION ANALYSIS OF PRESCRIPTIONS OF A TEACHING HOSPITAL: FREQUENCY AND GRAVITY
	5PSQ-147	THE VALSARTAN SAGA: PHARMACISTS' COMPETENCE TO RESOLVE THE THERAPEUTIC CHALLENGE
	5PSQ-148	PHARMACOVIGILANCE AND CLINICAL PHARMACY APPLIED TO MEDICAL DEVICES: SHOULD CANCER PATIENTS BE INFORMED ABOUT THEIR MEDICAL DEVICES?
	5PSQ-149	SELF-MEDICATION IN CANCER PATIENTS: SURVEY CONDUCTED IN THE PHARMACY DEPARTMENT OF A UNIVERSITY HOSPITAL
	5PSQ-150	TRADITIONAL MISUSE OF CAMPHOR POWDER: CONCERNING TWO CASES OF PAEDIATRIC POISONING
	5PSQ-151	ARE PROPOFOL EMULSIONS STABLE WHEN INTRAVENOUSLY CO-ADMINISTERED WITH REMIFENTANIL?
	5PSQ-152	DO WE KNOW THE CONTENT OF HARMFUL EXCIPIENTS IN MEDICINES THAT NEONATES RECEIVE?
	5PSQ-153	DETECTION OF POTENTIALLY INAPPROPRIATE PRESCRIBING IN AN INSTITUTIONALISED POPULATION
	5PSQ-154	INCIDENT REPORTS VERSUS DIRECT OBSERVATION TO IDENTIFY MEDICATION ERRORS AND RISK FACTORS IN HOSPITALISED NEWBORNS
	5PSQ-155	THE EFFECT OF GERIATRIC STEWARDSHIP ON DRUG-RELATED PROBLEMS AFTER DISCHARGE
	5PSQ-156	RISK ASSESSMENT AND MANAGEMENT TO IMPROVE THERMO-SENSITIVE DRUGS SAFETY
	5PSQ-157	IMPACT OF ANTICHOLINERGIC BURDEN, QUANTIFIED BY ANTICHOLINERGIC RISK SCALES, ON COGNITIVE AND FUNCTIONAL STATUS AND FALLS IN PATIENTS WITH MULTIMORBIDITY: A PRELIMINARY STUDY
	5PSQ-158	INTEREST IN MEDICATION RECONCILIATION AND ESTABLISHMENT OF A PRIORITISATION SCORE IN A VASCULAR SURGERY DEPARTMENT
	5PSQ-159	KEY POINTS IN IMPROVING THE RECONCILIATION PROCESS IN AN EMERGENCY DEPARTMENT
	5PSQ-160	MEDICATION RECONCILIATION IN THE EMERGENCY DEPARTMENT IN ELDERLY PATIENTS
	5PSQ-161	SECURING STORAGE OF HIGH-RISK MEDICINES IN A CARE UNIT: WHERE ARE WE NOW?
	5PSQ-162	ABSTRACT WITHDRAWN
	5PSQ-163	MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT
	5PSQ-164	DRUG-DRUG INTERACTIONS IN PATIENTS WITH CARDIOVASCULAR DISEASES
	5PSQ-165	QUALITY CONTROL OF INFUSIONS IN PATIENT-SPECIFIC PREPARATIONS FOR ONCOLOGICAL TREATMENT

Section 6: Education and Research
PDF document	Poster number	Poster Title
	6ER-001	HIGH VERSUS LOW DOSE OF URSODEOXYCHOLIC ACID FOR THE MANAGEMENT OF INTRAHEPATIC CHOLESTASIS OF PREGNANCY: A COHORT RETROSPECTIVE STUDY OF MATERNAL AND NEONATAL OUTCOMES
	6ER-002	EFFICACY OF A FIXED-RATIO COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
	6ER-003	COST OF VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS WITH LUNG AND PROSTATE CANCE: COSTECAT STUDY
	6ER-005	USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC HEART FAILURE
	6ER-006	EFFECTS OF STATINS USE ON CLINICAL OUTCOMES IN PATIENTS ADMITTED WITH COMMUNITY-ACQUIRED PNEUMONIA
	6ER-007	OFF-LABEL USE OF DALBAVANCIN IN GRAM-POSITIVE INFECTIONS: EFFECTIVENESS, SAFETY AND COST IN CLINICAL PRACTICE
	6ER-008	PERSISTENCE AND REASONS FOR SWITCHING THE INITIAL ANTIRETROVIRAL TREATMENT IN A COHORT OF NAÏVE HIV-INFECTED PATIENTS
	6ER-009	PATIENT SATISFACTION AND KNOWLEDGE AFTER SWITCHING FROM EVIPLERA TO ODEFSEY
	6ER-010	PUBLIC KNOWLEDGE AND PERCEPTION TOWARDS VACCINES IN ITALY
	6ER-011	MODELLING THE IMPACT OF DISCOUNTS ON THE REAL-LIFE COST-EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN SPAIN
	6ER-012	EFFICACY AND SAFETY ANALYSIS OF ALEMTUZUMAB IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
	6ER-013	A PILOT RANDOMISED DOUBLE-BLINDED PLACEBO-CONTROLLED TRIAL OF PROPHYLACTIC SILDENAFIL IN PRETERM INFANTS AT RISK OF BRONCHOPULMONARY DYSPLASIA
	6ER-014	PLATELET-RICH PLASMA: WHAT ARE WE REALLY ADMINISTERING TO OUR PATIENTS?
	6ER-015	IMPACT ON PAIN MANAGEMENT AFTER A SINGLE VISCOSUPPLEMENTATION INTRAARTICULAR INJECTION IN PATIENTS WITH HIP OSTEOARTHRITIS WHO FAILED CONVENTIONAL TREATMENT
	6ER-016	CLINICAL TRIALS: THERAPEUTIC OPPORTUNITIES, ECONOMIC IMPACT AND SAVINGS FOR THE NATIONAL HEALTH SYSTEM
	6ER-017	ABSTRACT WITHDRAWN
	6ER-018	DEVELOPMENT AND PERFORMANCE EVALUATION OF THE MEDICINES OPTIMISATION ASSESSMENT TOO: A PROGNOSTIC MODEL TO TARGET HOSPITAL PHARMACISTS' INPUT TO PREVENT MEDICATION-RELATED PROBLEMS
	6ER-019	INTRODUCING YOUNG HOSPITAL PHARMACISTS TO SCIENTIFIC RESEARCH: AN EDUCATIONAL PROJECT SUPPORTED BY A NATIONAL SOCIETY FOR CLINICAL PHARMACY
	6ER-020	SOCIAL AUTHORITIES CONCERNING #HOSPITALPHARMACY ON TWITTER
	6ER-021	WHY SUCH A LOW PARTICIPATION OF PHARMACISTS IN THE PATIENT EDUCATION PROGRAMMS IN OUR HOSPITAL?
	6ER-022	WHAT IS PHARMACOVIGILANCE FOR YOU? A SURVEY OF 153 PHARMACISTS
	6ER-023	ESTABLISHMENT OF GROUP WORK: WHAT IS THE EFFECT ON THE STATE OF KNOWLEDGE AND PERCEPTION OF PHARMACOVIGILANCE AMONG OUR FUTURE MOROCCAN PHARMACISTS?
	6ER-024	ASPIRIN COMPARED TO ENOXAPARIN OR RIVAROXABAN FOR THE PREVENTION OF VTE FOLLOWING HIP AND KNEE REPLACEMENT – A RETROSPECTIVE COHORT STUDY IN IRELAND
	6ER-025	IMPACT OF THE NEW EUROPEAN REGULATION ON CLINICAL TRIALS IN THE ACTIVITY AND DYNAMICS OF RESEARCH ETHICS COMMITTEES FROM CATALONIA
	6ER-026	PERCEPTION OF A PEER-TO-PEER MENTORING EXPERIENCE WITH EUROPEAN PHARMACY STUDENTS IN A STUDENT-RUN FREE CLINIC
	6ER-027	ABSTRACT WITHDRAWN
	6ER-028	PERCEPTION OF HOSPITAL PHARMACISTS TOWARDS PHARMACOGENETIC TESTING

23rd Congress of the EAHP

Section 1: Introductory Statements and Governance
PDF document	Poster number	Poster Title
	1ISG-002	EFFECTIVENESS OF ANGIOTENSIN RECEPTOR BLOCKER IN HOSPITALISED PATIENT
	1ISG-003	COST SAVING IN ANTIRETROVIRAL THERAPY THROUGH BREAKING FIXED-DOSE COMBINATION AND SWITCH TO GENERIC FORMULATIONS
	1ISG-005	A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB VERSUS DOCETAXEL FOR ADVANCED NONSQUAMOUS NON-SMALL-CELL LUNG CANCER IN SECOND LINE IN A HEALTHCARE SETTING
	1ISG-006	CONTAMINATION OF THE BLISTER PACKS BY POMALIDOMIDE AFTER USE IN CLINICAL SITUATION
	1ISG-007	BIOSIMILAR OF INFLIXIMAB: DOES THE PENETRATION RATE MEET EXPECTATIONS? APPRAISAL IN A CENTRAL PURCHASING OFFICE
	1ISG-008	ECONOMIC IMPACT OF THE USE OF BIOSIMILAR INFLIXIMAB IN A SECOND-LEVEL HOSPITAL
	1ISG-009	ECONOMIC IMPACT OF AFLIBERCEPT OPTIMISATION FOR THE TREATMENT OF EYE-RELATED CONDITIONS
	1ISG-011	DEVELOPMENT OF A PREDICTIVE MODEL FOR ESTIMATING FUTURE DRUG EXPENSES
	1ISG-012	THE ROLE OF THE PHARMACIST IN CHOOSING THE CENTRAL VENOUS ACCESS DEVICE FOR THE PREVENTION OF COMPLICATIONS: AN EXAMPLE OF BUDGET IMPACT ANALYSIS
	1ISG-013	ECONOMIC IMPACT OF ORPHAN DRUGS USED IN PAEDIATRIC PATIENTS ATTENDING HOSPITAL OUTPATIENT PHARMACY AND DAY HOSPITAL
	1ISG-014	ISO 9001 CERTIFICATION: CUSTOMER FOCUS
	1ISG-015	MULTIPLE SCLEROSIS COMMITTEE: INCLUDING A PHARMACIST AS PART OF THE MULTIDISCIPLINARY TEAM
	1ISG-016	EVALUATION OF SUBSTITUTION AND SWITCH TO ETANERCEPT BIOSIMILAR AND RELATED COST SAVINGS
	1ISG-017	ANALYSIS OF PRESCRIBING QUALITY INDEX (PQI) IN HOSPITAL CARE AND STRATEGIES FOR IMPROVEMENT
	1ISG-018	EVALUATION OF THE ECONOMIC SUSTAINABILITY OF A ROBOTIC SYSTEM FOR CHEMOTHERAPY COMPOUNDING
	1ISG-020	MARKET ACCESS IN THE EU, DO WE HAVE ENOUGH EVIDENCE?
	1ISG-021	PROCEDURAL KITS WITH MEDICAL DEVICES FOR EYE SURGERY: OPTIMISATION STRATEGY

Section 2: Selection, Procurement and Distribution
PDF document	Poster number	Poster Title
	2SPD-002	ECONOMIC ASPECTS OF THE USE OF FLUIDS IN SEPSIS
	2SPD-003	MAGNETIC DOUBLE PIGTAIL STENT: AN ECONOMICALLY INTERESTING INNOVATIVE DEVICE?
	2SPD-004	ANALYSIS OF PIPERACILLIN/TAZOBACTAM USE DURING ITS WORLDWIDE SHORTAGE
	2SPD-007	COMPARATIVE EFFECTIVENESS AND SAFETY OF EVEROLIMUS AND AXITINIB AS SECOND-LINE THERAPY IN METASTATIC RENAL CELL CARCINOMA
	2SPD-009	IMPLEMENTATION OF A SPECIFIC CIRCUIT OF HAZARDOUS DRUGS IN A PHARMACY DEPARTMENT
	2SPD-010	ASSESSMENT OF PERTUZUMAB USE FOR HER2- POSITIVE BREAST CANCER TREATMENT
	2SPD-011	LEAD-TIME FOR DELIVERY OF CHEMOTHERAPIES AT DAY HOSPITAL: DIFFICULTIES OF A CHEMOTHERAPY COMPOUNDING UNIT WITH TWO DAY HOSPITALS ON TWO SITES
	2SPD-012	BUDGETARY IMPACT OF ULTRA-RARE DISEASES IN A THIRD-LEVEL HOSPITAL
	2SPD-015	ANALYSIS OF EXPENDITURE ON ORPHAN DRUGS ACCORDING TO THE DIAGNOSIS
	2SPD-016	IMPLANTABLE MEDICAL DEVICES MANAGEMENT: A CHALLENGE
	2SPD-017	THE REVIEW AND CLASSIFICATION OF THE MOST COMMONLY USED SURGICAL SUTURES
	2SPD-018	DETERMINATION OF TRENDS OF PRESCRIPTION AND USE OF OFF-LABEL DRUGS IN PAEDIATRIC UNITS AT A HIGH COMPLEXITY HOSPITAL
	2SPD-022	EVALUATION OF THE IMPLEMENTATION OF A CENTRALISED FLOOR STOCK: WHAT CONCLUSIONS CAN BE DRAWN?
	2SPD-023	IMPROVEMENTS IN WARD PHARMACY MANAGEMENT BY PHARMACEUTICAL STAFF
	2SPD-024	UNIT DOSE SYSTEM EVALUATION
	2SPD-025	PRACTICAL CLASSIFICATION OF MEDICAL DEVICES BASED ON ANATOMICAL SYSTEMS AND CREATION OF AN ELECTRONIC GUIDE FOR USERS IN A TEACHING HOSPITAL
	2SPD-026	MEDICINES’ SHORTAGE AND HOSPITAL PHARMACISTS’ STRATEGIES
	2SPD-027	CENTRALISED PURCHASING AS A STRATEGIC LINE FOR THE RATIONALISATION OF PHARMACEUTICAL EXPENDITURE IN A REGIONAL HEALTH SERVICE
	2SPD-028	COMPARATIVE STUDY OF TWO METHODS OF UNITDOSE PACKAGING: ETICONFORM® AND EURAF®
	2SPD-029	IMPACT OF THE IMPLEMENTATION OF THE FALSIFIED MEDICINES DIRECTIVE ON A HEALTHCARE INSTITUTION
	2SPD-030	DRUG SHORTAGE IMPACT ON PATIENT CARE: AN INCREASING HEALTHCARE PROBLEM
	2SPD-031	ECONOMIC ANALYSIS OF THE PHARMACEUTICAL SUPPLY TO A SOCIO-SANITARY CENTRE FROM THE HOSPITAL PHARMACY SERVICE

Section 3: Production and Compounding
PDF document	Poster number	Poster Title
	3PC-002	STABILITY OF MIXTURES OF ONDANSETRON AND HALOPERIDOL STORED IN INFUSORS AT DIFFERENT TEMPERATURES
	3PC-003	PAEDIATRIC PARENTERAL NUTRITION ON WEEKENDS: WHO PREPARES? SURVEY OF COUNTRY’S HOSPITALS
	3PC-004	AUTOMATION OF PARENTERAL NUTRITION ELABORATION IN A HOSPITAL PHARMACY SERVICE
	3PC-005	A NEW PACKAGING OF HYPERTONIC SOLUTION TO OVERCOME AN UNAVAILABLE FORMULATION IN FRANCE
	3PC-008	FORMULATION AND STABILITY STUDY OF THE EXTEMPORANEOUS ORAL SOLUTIONS OF CARDIOLOGIC DRUGS FOR PERSONALISED THERAPY OF NEWBORNS
	3PC-009	PHYSICOCHEMICAL STABILITY OF INTRAVENOUS INJECTION OF A GENERIC PRODUCT OF FUROSEMIDE PREPARED IN POLYPROPYLENE SYRINGES
	3PC-011	HPLC METHOD DEVELOPMENT AND VALIDATION TO DETERMINATE RESORCINOL FOR QUALITY CONTROL IN PHARMACEUTICAL FORMULATIONS
	3PC-012	STABILITY OF CEFUROXIME 80 MG/ML SOLUTION IN READY-TO-ADMINISTER POLYPROPYLENE SYRINGES
	3PC-014	STABILITY STUDY OF GENTAMICIN LOCK THERAPY WITH HEPARIN OR CITRATE AS ANTICOAGULANT
	3PC-015	MEDIA-FILL SIMULATION TESTS OF INFUSION BAGS PREPARED IN SERIES BY THE COMPOUNDING ROBOT APOTECACHEMO
	3PC-017	TIME SAVINGS AND IMPROVED QUALITY ASSURANCE OF INTRAVENOUS CYTOSTATICS WITH SEMIAUTOMATED DOSE-BANDING
	3PC-018	THE ADVANTAGE OF AUTOMATION IN THE PREPARATION OF CHEMOTHERAPY DRUGS FOR THE INTERCEPTION OF ERRORS
	3PC-024	APPLICATION OF A MATRIX RISK TO AN APPROPRIATE COMPOUNDING PROCESS OF AFLIBERCEPT AND RANIBIZUMAB INTRAVITREAL INJECTIONS
	3PC-026	PHYSICOCHEMICAL STABILITY OF ROCURONIUM BROMIDE INJECTION SOLUTION 10 MG/ML AS BULK SOLUTION AND IN 10 ML READY-TO-ADMINISTER SYRINGES
	3PC-027	AMIFAMPRIDINE AND PYRIDOSTIGMINE HARD CAPSULES FOR TREATMENT OF CONGENITAL MYASTHENIC SYNDROMES: A CASE REPORT
	3PC-029	CALCULATION OF ANNUAL ECONOMIC IMPACT OF MANUFACTURING AVASTIN® SYRINGES IN THE AGERELATED MACULAR DEGENERATION TREATMENT IN OUR HOSPITAL
	3PC-032	DETERMINATION OF SENSITIVITY THRESHOLD FOR STERILITY ASSAY OF THE BINARY PARENTERAL NUTRITION BAGS BY DIRECT SEEDING
	3PC-033	IN VITRO PHYSICOCHEMICAL INTERACTIONS STUDY BETWEEN IRON AND ANTICANCER DRUGS ADMINISTRATED IN HOSPITAL
	3PC-034	SCREENING FOR PHYSICOCHEMICAL INCOMPATIBILITIES OF CYTOTOXIC DRUGS AFTER RECONSTITUTION: THE CASE OF METHOTREXATE
	3PC-035	SO, HAPPY? AUTOMATED NOMINATIVE DISPENSATION: SATISFACTION SURVEY OF THE NURSING STAFF
	3PC-036	SMALL-SCALE COMPOUNDING USING A POWDER DISPENSING TOOL FOR INDIVIDUALISED SOLID DOSAGE FORM DRUG DELIVERY
	3PC-037	CLEANING VALIDATION OF SOLUTION PRODUCTION IN A HOSPITAL PHARMACY
	3PC-038	IFOSFAMIDE-INDUCED ENCEPHALOPATHY: QUALITY CONTROL OF INTRAVENOUS SOLUTION OF METHYLENE BLUE FORMULATED AND PREPARED IN PHARMACY USING A DISPOSABLE CLOSED SYSTEM TRANSFER DEVICE – A CASE REPORT
	3PC-039	CENTRALISED NON-HAZARDOUS INTRAVENOUS COMPOUNDING: IMPROVEMENT OF CLINICAL PRACTICE

Section 4: Clinical Pharmacy Services
PDF document	Poster number	Poster Title
	4CPS-004	RELEVANCE OF PROTON PUMP INHIBITOR (PPI) TREATMENTS IN 2017 IN TWO GERIATRIC DEPARTMENTS: IMPACT OF A FIRST STUDY IN 2014 ON PRESCRIBING PRACTICES
	4CPS-007	INTERDISCIPLINARY TEAM IN THE FOLLOW-UP OF A PATIENT WITH TEDUGLUTIDA
	4CPS-009	EFFICACY, SAFETY AND ECONOMIC IMPACT OF VEDOLIZUMAB IN ULCERATIVE COLITIS AND CROHN’S DISEASE
	4CPS-010	ANALYSIS OF USE OF PROTON PUMP INHIBITORS IN PATIENTS BEFORE HOSPITAL ADMISSION AND AT HOSPITAL DISCHARGE
	4CPS-011	THE PHARMACIST’S ROLE IN THE MANAGEMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
	4CPS-012	PHARMACOTHERAPEUTICAL PROFILE BEFORE AND AFTER LIVER TRANSPLANTATION
	4CPS-013	DISCONTINUATION OF SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS DUE TO RECURRENT GENITOURINARY INFECTIONS
	4CPS-014	FOLLOW-UP TO RECOMMENDATIONS ABOUT RENAL FUNCTION MONITORING IN ELDERLY PATIENTS TREATED WITH SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS
	4CPS-015	PHARMACEUTICAL INTERVENTIONS IN PATIENTS TREATED WITH DIRECT-ACTING ORAL ANTICOAGULANTS ADMITTED IN INTERNAL MEDICINE
	4CPS-017	MISUSE OF NOVEL ORAL ANTICOAGULANTS IN HOSPITAL SETTINGS
	4CPS-019	EVALUATION OF VENOUS THROMBOEMBOLIC EVENT PROPHYLAXIS IN HOSPITALISED CANCER PATIENTS: A SINGLE-CENTRED RETROSPECTIVE STUDY
	4CPS-020	USE AND EFFECTIVENESS OF CARBOXYMALTOSE IRON AND ISOMALTOSIDE IRON
	4CPS-021	TREATMENT OF PREOPERATIVE ANAEMIA WITH FERRIC CARBOXYMALTOSE
	4CPS-022	PREVALENCE OF POTASSIUM, PHOSPHORUS AND CALCIUM IMBALANCE IN VERY-LOW-BIRTHWEIGHTPRETERM INFANTS RECEIVING PARENTERAL NUTRITION FROM THE FIRST DAY OF LIFE
	4CPS-023	IMPACT OF DRUG AND THERAPEUTIC COMMITTEE INTERVENTION ON RATIONALISATION OF ALBUMIN USE IN CANCER PATIENTS ADMITTED TO SURGERY WARDS OF A TERTIARY CARE TEACHING HOSPITAL
	4CPS-024	HUMAN NORMAL IMMUNOGLOBULIN REQUIREMENTS IN PAEDIATRIC PATIENTS WITH PRIMARY IMMUNODEFICIENCY, FOCUSING ON THE ADMINISTRATION ROUTE SWITCHING
	4CPS-025	SUITABILITY OF SACUBITRIL VALSARTAN PRESCRIPTIONS IN A HEALTH MANAGEMENT AREA
	4CPS-026	THE SACUBITRIL-VALSARTAN ASSOCIATION: FROM THEORY TO PRACTICE
	4CPS-027	HOSPITAL PHARMACIST INTERVENTIONS IN AN ACCREDITED CARDIOLOGY DEPARTMENT
	4CPS-028	EDUCATING CARDIAC REHABILITATION PATIENTS ON THEIR MEDICINES
	4CPS-029	ADHERENCE TO MEDICATION AND SALT RESTRICTION AND BLOOD PRESSURE CONTROL AMONG HYPERTENSIVE PATIENTS
	4CPS-030	EVALUATION OF PHARMACIST-LED CARDIOVASCULAR SERVICES WITHIN PRIMARY CARE, PROVIDED BY CARDIOVASCULAR PHARMACISTS
	4CPS-032	STUDY OF THE CHARACTERISTICS OF PATIENTS TREATED WITH TOLVAPTAN
	4CPS-033	EFFECTIVENESS OF THERAPEUTIC INTERCHANGE PROGRAMMES FOR ANGIOTENSIN RECEPTOR BLOCKERS IN THE HOSPITAL SETTING
	4CPS-034	EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODIES AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN 9 (PCSK9 INHIBITORS) FOR THE TREATMENT OF HYPERCHOLESTEROLAEMIA
	4CPS-035	EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODY PCSK9 INHIBITORS
	4CPS-036	STATINS AND THE ELDERLY: IS THEIR USE APPROPRIATE?
	4CPS-037	ANALYSIS OF USAGE PROFILE, EFFECTIVENESS AND SAFETY OF ALIROCUMAB IN A TERTIARY HOSPITAL
	4CPS-038	INITIAL EXPERIENCE WITH THE USE OF PCSK9- INHIBITORS IN THE REAL-WORLD CLINICAL PRACTICE
	4CPS-039	ALLANTOIN 6% CREAM IN EPIDERMOLYSIS BULLOSA: A CASE REPORT
	4CPS-040	COST-COMPARISON OF SECUKINUMAB AND USTEKINUMAB FOR TREATMENT OF PSORIASIS
	4CPS-041	DRUG SURVIVAL OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PSORIASIS
	4CPS-042	APREMILAST IN PSORIATIC ARTHRITIS AND PSORIASIS: A CASE REPORT
	4CPS-043	EVALUATION OF NON-FORMULARY DRUGS PRESCRIPTION AND ACCEPTANCE OF AN ALTERNATIVE DRUG
	4CPS-044	G